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Intracellular recordings were made from pyramidal neurones in the CA1 region of the
rat hippocampus to investigate aspects of cholinergic synaptic transmission in the
mammalian brain. In the presence of ionotropic glutamate and y-aminobutyric acid
(GABA) receptor antagonists, single shock stimulation of the septohippocampal
cholinergic input, in stratum oriens, evoked a slow excitatory postsynaptic potential
(EPSP) which was associated with an increase in input resistance. Stimulation at
intensities sub-threshold for evoking a slow EPSP caused a reduction of spike
frequency adaptation (SFA). Pharmacological analysis of these responses revealed
that they were mediated by muscarinic acetylcholine receptors (mAChRs).
Having established a protocol for evoking reproducible mAChR-mediated EPSPs
(EPSPms) and mAChR-mediated inhibition of SFA, experiments were conducted to
investigate the modulation of these responses by other neurotransmitter receptors. In
this respect, activation of adenosine receptors by the broad spectrum adenosine
receptor agonist 2-chloroadenosine (CADO) reversibly inhibited mAChR-mediated
synaptic responses in a concentration dependent manner. The pharmacological
profile of this effect established that it was mediated by adenosine A, receptors. The
adenosine A, receptor antagonist 8-cyclopentyl-l,3-dipropylxanthine (DPCPX) alone
facilitated cholinergic synaptic responses, demonstrating that these receptors are
activated tonically in vitro. In support of this, 5-iodotubercidin, an adenosine kinase
inhibitor which inhibits the uptake of adenosine, also caused a DPCPX-sensitive
inhibition of EPSPMs.
To assess whether CADO was acting pre- or post-synaptically to inhibit EPSPMs, the
concentration-response relationship for this effect was compared with relationships
for known pre- and post-synaptic effects of CADO. The concentration-response
relationship for the inhibition of EPSPMs most closely resembled that for the
presynaptic depression of glutamate receptor-mediated EPSPs, providing indirect
evidence in favor of a presynaptic locus for the inhibition of EPSPMs by CADO.
That CADO was acting presynaptically was confirmed by the observation that
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postsynaptic depolarization and inhibition of SFA evoked by carbachol (CCh) were
not significantly affected by CADO at concentrations that significantly depressed
cholinergic synaptic responses.
The effect ofGABAb receptor activation on mAChR-mediated synaptic responses
was also investigated. The selective GABAb receptor agonist baclofen (5 pM)
inhibited EPSPMs. However, at a concentration as high as 20 pM, baclofen had no
consistent effect on the mAChR-mediated inhibition of SFA. The GABA uptake
inhibitor NNC 05-0711 also inhibited EPSPMs. The selective GABAb receptor
antagonist CGP 55845A reversed the effects of both baclofen and NNC 05-0711. In
addition, CGP 55845A, when applied alone, facilitated EPSPMs. These data suggest
that endogenously released GABA, acting at GABAb receptors, inhibits EPSPMs and
that this effect is enhanced by inhibition ofGABA uptake.
In conclusion, it is possible to evoke isolated mAChR-mediated synaptic responses
with a single stimulus in the CA1 region of the rat hippocampus. Adenosine A,
receptors are present on cholinergic terminals in this region and act to inhibit these
responses by an unknown mechanism. GABAb receptor activation also inhibits
cholinergic synaptic transmission although the mechanism and site of action of this
effect is unclear. Finally, endogenous adenosine and GABA, acting at adenosine A,
and GABAb receptors respectively, inhibit cholinergic synaptic transmission in vitro.
This modulation provides a potentially important mechanism for the control of
neuronal excitability in the hippocampus in vivo.
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The ability of the mammalian central nervous system (CNS) to function effectively
as an information processor relies on the organization of neurones into circuits and
networks. For these circuits to function, neurones must be able to communicate
through the process of synaptic transmission. Synaptic transmission refers to the
transmission of information across synapses through the release of neurotransmitters
to act at postsynaptic receptors (see Shepherd & Koch, 1990). Acetylcholine (ACh)
was the first compound to be identified as a neurotransmitter, initially at peripheral
synapses (Dale, 1934) and subsequently in the CNS (Eccles et al. 1954; Eccles et al.
1956). The process of synaptic transmission itself can be modulated by receptor
systems other than that which principally mediates synaptic transmission. Such
neuromodulation can occur pre- and post-synaptically providing precise control of
synaptic transmission and, as such, may be particularly important in controlling the
transfer of information in neuronal circuits.
Although it is possible to mimic the effects of neurotransmitters pharmacologically,
the only method by which to investigate the complete process of synaptic
transmission is to study evoked synaptic responses mediated by endogenously
released neurotransmitter. With respect to (acetyl)cholinergic synaptic transmission,
synaptic responses may be evoked in hippocampal slices by electrical stimulation of
the septohippocampal cholinergic input (Cole & Nicoll, 1983; 1984). The present
study has utilized in vitro electrophysiological recording techniques to
i) establish an effective method with which to evoke and investigate the modulation
of cholinergic synaptic responses and,
ii) investigate the influence of adenosine and GABA receptor activation on
cholinergic synaptic transmission in the CA1 region of the rat hippocampus.
This chapter will serve as a general introduction to the major receptor systems and
neurotransmitters dealt with in this thesis. Neurotransmitters ACh, glutamate and
GABA, and the neuromodulator adenosine will be discussed in terms of their
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receptor pharmacology and functional effects in the CNS. Where appropriate,
aspects of neurotransmitter function will be discussed with particular reference to the
hippocampus to maintain brevity and relevance to this study. In addition, the major
functional and anatomical aspects of the hippocampus and relevant neuronal
pathways will be introduced.
1.1. ACETYLCHOLINE
1.1.1. Historical perspectives
During the early part of this century, a study of the action of an active component of
adrenal extracts found that a derivative of choline reduced blood pressure in rabbits
(Hunt & Taveau, 1906). This derivative was subsequently found to be ACh,
providing the first evidence of a pharmacological action of ACh. Subsequently, a
chance discovery by H. H. Dale (1914) led him to distinguish the nicotinic and
muscarinic actions of ACh (Dale, 1914). However, it was a further seven years
before the first firm evidence of chemical transmission by ACh was published by
Loewi (Loewi, 1921). Loewi (1921) described the action of a substance released
following vagal stimulation on isolated heart. This substance was later identified as
ACh (Loewi & Navratil, 1926). During the 1930's these advances were further
developed by Dale and coworkers when they published a series of papers proposing
that ACh was a chemical transmitter in both the parasympathetic and sympathetic
nervous systems (Dale, 1934; Dale et al. 1936).
Around this time, a neurotransmitter role for ACh in the CNS was postulated by Dale
(1938) among others (Feldberg, 1945). This hypothesis was based on
i) the presence of ACh and acetylcholinesterase (AChE: an endogenous
enzyme which breaks down extracellular ACh) in the CNS,
ii) the synthesis and release of ACh in the CNS, and
iii) the central effects of ACh and physostigmine (eserine) an inhibitor of
AChE (Feldberg, 1945).
2
That cholinergic synapses existed in the CNS was not reported however until the
1950's, when Eccles and coworkers (1954; 1956) demonstrated the existence of a
synapse operated by ACh between motor-axon collaterals and nicotinic ACh
receptors (nAChRs) on Renshaw cells in the spinal cord. Since then classification of
muscarinic ACh receptors (mAChRs) and nAChRs has been developed using
pharmacological and molecular cloning techniques (Brann et al. 1993). As such,
there are now multiple subtypes of both neuronal nAChRs and mAChRs (Hulme et
al. 1990; Nicoll et al. 1992; Lindstrom et al. 1995a).
1.1.2. The Receptors and Their Pharmacology
The basic classification of ACh receptors is still based on Dale's original description
of the nicotinic and muscarinic actions of ACh (Dale, 1914). The receptors that
mediate muscarinic and nicotinic responses have entirely different structures and
functions. Nicotinic ACh receptors are ligand (ACh) gated ion channel (ionotropic)
receptors whereas muscarinic ACh receptors are guanine nucleotide binding (G)-
protein coupled (metabotropic) receptors.
1.1.2.1. Muscarinic Acetylcholine Receptors
The metabotropic mAChR belongs to the gene superfamily of G-protein coupled
receptors, which includes the ^-adrenergic receptor, the adenosine receptor and
rhodopsin (Hall, 1987). The structure of this group of receptor proteins is
characterized by an extracellular N-terminal region, seven hydrophobic
transmembrane spanning regions and an intracellular C-terminal region. Initial
classification of a response as being muscarinic was based on antagonism of that
response by atropine (Dale, 1914). Some 65 years later, further pharmacological
investigation ofmAChR-mediated effects led to the identification of two subtypes of
muscarinic receptor (termed M, and M2) based on the relative sensitivity of responses
to pirenzipine (Hammer et al. 1980). The structural difference between these
receptors has since been confirmed with the molecular cloning of both receptors
(termed ml and m2) (Kubo et al. 1986; Kubo et al. 1986). Three additional subtypes
ofmuscarinic receptor have been identified by homology cloning. These have been
termed m3, m4 and m5 (Bonner et al. 1987; Bonner et al. 1988).
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Clear pharmacological classification ofmAChR subtypes has been difficult to
achieve. In this respect, compounds have been developed which exhibit limited
selectivity for individual mAChRs, typically in the order of 10-fold selectivity for
one subtype over another. Thus, pirenzipine, has been found to be relatively
selective for the M, mAChR, and AFDX 116 to be relatively selective for M2
mAChRs (Giachetti et al. 1986). In addition, the compound AGV-dimethyl-4-
piperidinyl diphenylacetate (4-DAMP) is relatively selective for M, and M3 mAChRs
(Doods et al. 1987). Quantitative pharmacological investigations using these
antagonists can be used to narrow down the identity of the subtype of mAChR but
can prove inadequate to conclusively identify the exact subtype (Pitler & Alger,
1990; Mitchelson, 1988). As such, it is difficult to unequivocally identify mAChR
subtypes due to the lack of specificity of the available antagonists and, in particular,
the lack of potent and selective antagonists for M4 and M5 mAChRs. Indeed, in the
hippocampus, there is some controversy regarding the subtype(s) ofmAChRs which
mediate the variety ofmAChR-mediated effects evoked by either AChR agonists
such as carbachol (CCh) and methacholine or by synaptically released ACh (Cole &
Nicoll, 1984b; Benson et al. 1988; Dutar & Nicoll, 1988a; Pitler & Alger, 1990). A
summary of the most subtype-specific mAChR antagonists presently available is
provided in Table 1.1. Since few of these antagonists exhibit greater than 10-fold
selectivity for one subtype over other mAChR subtypes, it is clear that more selective
mAChR agonists and antagonists will be required to specifically inhibit the action of
particular mAChRs.
The lack ofmAChR subtype-specific ligands has also limited the amount of
information, regarding the distribution of mAChR subtypes in the brain, that can be
gained from binding and autoradiographic studies (Cortes & Palacios, 1986;
Waelbroeck et al. 1990; Zubieta & Frey, 1993; Levey et al. 1994). However, such
studies, in conjunction with in situ hybridization and immunocytochemical studies,
have helped to provided information regarding the specific localization ofmAChR
subtypes in many areas of the CNS, including the hippocampus (Table 1.2; Buckley
et al. 1988; Weiner & Brann, 1989; Levey et al. 1995).
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Table 1.1. mAChR subtypes: Pharmacology and transduction mechanisms.
mAChR m1 m2 m3 m4 m5
(molecular
subtype)
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f (Brann et al. 1993); $(Levey et at. 1995).
All five subtypes of mAChR protein and mRNA have been localized in the
hippocampus as well as the cortex, striatum, olfactory tubercle, thalamus and basal
forebrain (Brann et al. 1993; Table 1.2.). In terms of the amount of expression of
mAChR mRNA in the hippocampus as a whole, the rank order is
ml>m2/m4>m3/m5 (Table 1.1). mAChR protein and mRNA have differential
cellular distributions in different areas of the hippocampus, withml and m3 mAChR
protein expression prominent in pyramidal neurones and m2 and m4 in non-
pyramidal neurones and fiber pathways (Levey et al. 1995; Table 1.1). In addition,
m2 mAChR proteins are expressed presynaptically in cholinergic axons presumably
of the septo-hippocampal pathway (Levey et al. 1995; see also section 1.6.2). The
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localization ofm2 mRNA in the medial septum is consistent with this observation
(Buckley et al. 1988; Rouse et al. 1997).
With respect to mAChR transduction mechanisms, it is clear that each mAChR
subtype is coupled to G-proteins of either the G/G0 or Gq/Gn subtypes and, as such,
mAChRs modulate a variety of signal transduction mechanisms (Table 1.1). In
general, M,, M3 and M5 mAChRs are positively linked, via the Gq/Gn subtype ofG-
protein, to the phospholipase C (PLC)/inositol triphosphate (IP3) system and M2 and
M4 mAChRs negatively linked, via the G/G0 subtype of G-protein, to the AC/cyclic
adenosine 5' monophosphate (cAMP) system (Hulme et al. 1990; Felder, 1995).
Additional complexity to the functioning ofmAChRs is offered by the presence of an
allosteric binding site (Tucek & Proska, 1995). Neuromuscular blocking drugs such
as gallamine allosterically inhibit the action ofmAChR agonists at all five mAChR
receptors, particularly the M2 subtype (Ellis et al. 1991). In contrast, alcuronium can
augment, as well as inhibit, the binding ofmAChR ligands (Tucek et al. 1990).
1.1.2.2, Nicotinic Acetylcholine Receptors
In contrast to mAChRs, nAChRs belong to the gene superfamily of ion channel
receptors, which includes GABAa and glycine receptors. nAChRs, which are
activated by both ACh and nicotine, mediate synaptic transmission at both peripheral
and central synapses. Responses mediated by nAChRs may be distinguished
pharmacologically from mAChR-mediated responses using the competitive
antagonist curare (Dale, 1914). nAChRs can now be broadly divided into,
i) muscle nAChRs,
ii) neuronal nAChRs that bind a-bungarotoxin, and
iii) neuronal nAChRs that do not bind a-bungarotoxin (see Lindstrom et al.
1995b).
Biochemical and molecular cloning techniques have revealed that these ACh-gated
cation channels consist of a pentamer of homologous subunits, which assemble to
form a central ion channel (McCarthy et al. 1986; Hucho et al. 1996). In addition to
the subunits which form muscle and ganglionic nAChRs, eight neuronal a subunits
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and three neuronal p subunits have been cloned (Albuquerque et al. 1997). These
subunits form heterooligomeric complexes in which subunits combine with the
stoichiometry 2a, 3p or homooligomeric complexes of a7 or a9 subunits. Each
nAChR subunit composition exhibits different pharmacological and biophysical
properties (Deneris et al. 1991; Alkondon & Albuquerque, 1993; McGehee & Role,
1995; Albequerque et al. 1995a). As such, a -subunits a2-a6 form distinct channels
when expressed with different P-subunits in oocytes from Xenopus laevis. In
contrast either a7-, a8- or a9-subunits alone, when expressed in oocytes, form
homomers which support a-bungarotoxin-sensitive currents. Only a9 and, most
prominently a7 subunits are found in the rat, whereas a8 subunits are only found in
the chick (McGehee & Role, 1995). The rapidly desensitizing a7 nAChR is thought
to be of particular functional importance due to its high permeability to Ca++ and its
presence at presynaptic terminals.
The effective characterization of neuronal nAChRs has been restricted by the lack of
selective ligands for the large variety of nAChR subunit constructs found in the CNS.
In the hippocampus for example, nAChRs modulate at least three separate cationic
currents which are termed types I—III (Alkondon & Albuquerque, 1993; Albuquerque
et al. 1995a; Albuquerque et al. 1997). These currents may be identified by different
channel kinetics and their sensitivity to nicotinic agonists and the nicotinic
antagonists methylcaconitine, P-erythroidine, a-bungarotoxin and mecamylamine
(Albuquerque et al. 1995b; Albuquerque et al. 1997). In the hippocampus a7
nAChRs are thought to underlie type 1A currents which are mediated predominantly
by Ca++ (Albuquerque et al. 1995b). In addition to direct excitatory effects, nAChRs
have also been shown to presynaptically modulate the release of neurotransmitters
(e.g. glutamate and ACh) and glutamate synaptic transmission in several areas of the
brain, including the hippocampus (e.g. Araujo et al. 1988; Gray et al. 1997,
Wonnacott, 1997). The pharmacology, structure and function of nAChRs has been
comprehensively reviewed (Sargent, 1993; Albuquerque et al. 1995b; Lindstrom et
al. 1995a/b; McGehee & Role, 1995; Lindstrom et al. 1996; Wonnacott, 1997).
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1.1.3. The NeurotransmitterRole ofAcetylcholine
Both nAChRs and mAChRs have been shown to be synaptically activated in a
number of well-defined cholinergic pathways in the mammalian brain (Eccles et al.
1954; Cole & Nicoll, 1983; Nicoll et al. 1992). The most well characterized of these
is the septo-hippocampal cholinergic pathway, which innervates pyramidal neurones
in the hippocampus (Dutar et al. 1995; Nicoll, 1985; See Section 1.6.2). Stimulation
of this pathway, using high frequency stimulation, can evoke slow mAChR-mediated
excitatory responses in CA1 pyramidal neurones (Cole & Nicoll, 1983, 1984a).
1.1.4. MuscarinicAcetylcholine Receptor-mediated Effects in the
CNS
In contrast to the limited effects of nAChR activation in the CNS, mAChR activation
can result in a variety of effects that are both excitatory and inhibitory (Brown et al.
1997). These effects include
i) inhibition/activation of certain K+ conductances,
ii) inhibition/activation of voltage-dependent Ca++ currents, and
iii) activation of non-selective cationic currents.
In the hippocampus, the most extensively studied of these effects is the inhibition of
K+ conductances.
1.1.4.1. Effects on potassium channels
Synaptic activation ofmAChRs in the hippocampus evokes a slow depolarization
associated with an increase in input resistance (Cole & Nicoll, 1983; 1984), effects
which are similar to those produced by application of CCh or ACh in, for example,
hippocampus and cortex (see Table 1.2; Dodd et al. 1981; Haas, 1982; Segal, 1982;
Cole & Nicoll, 1983, 1984a & 1984b). This depolarizing effect is due to an apparent
inward current (Halliwell & Adams, 1982; Madison et al. 1987; Benson et al. 1988)
which represents a decrease in a voltage-independent leak K+ current (Ik(leak))
(Benardo & Prince, 1982b; Madison et al. 1987; Benson et al. 1988).
In addition to inhibition of IK(LEAK), activation of mAChRs leads to the inhibition of a
8
voltage independent and Ca++ dependent K+ current (IK(Ca)) known as the small-K
current or IAHP in a variety of brain regions (see Table 1.2; Madison & Nicoll, 1984;
Constanti & Sim, 1987; Lancaster & Adams, 1986; Sah, 1996). The voltage- and
Ca++-dependent current (maxi-K current) Ic, however, is not affected by mAChR
activation (Madison et al. 1987). In hippocampal pyramidal neurones, both IAHP and
Ic are activated by calcium entry during the depolarizing phase of an action potential.
In this respect, the fast and slow afterhyperpolarizations (AHPs) which follow an
action potential are mediated by Ic and IAIIP, respectively. During maintained
depolarization of a neurone at firing threshold, the sAHPs which follow each
successive action potential summate due to the slow inactivation of IAHP (>1 s). This
summation of the IAHP results in a progressive increase in the duration between action
potentials, a phenomenon known as spike frequency adaptation (SFA). As such,
CCh has been shown to inhibit IAHP, resulting in an inhibition of the slow AHP and
hence inhibit SFA (Benardo & Prince, 1982a & 1982b; Cole & Nicoll, 1983;
Madison et al. 1987; Dutar & Nicoll, 1988a). In addition, the cholinergic effects of
CCh and ACh can be mimicked by stimulation of cholinergic afferents of the septo-
hippocampal pathway (see section 1.6.2) in area CA1 of the hippocampus (Cole &
Nicoll 1983, 1984; Nicoll, 1985). Thus, synaptically released ACh causes a
depolarization and increase in input resistance, and inhibits slow AHPs and SFA
(Cole & Nicoll, 1983, 1984b; Madison et al. 1987; Segal, 1988; Potier et al. 1992).
Other K+ currents have been shown to be modulated by mAChRs, including theM
current (IM), a voltage-dependent K+ current which does not inactivate with time. IM
was first described in bullfrog sympathetic neurones (Brown & Adams, 1980;
Brown, 1983) and subsequently in hippocampal neurones (Halliwell & Adams, 1982)
and was named M current because it is inhibited by muscarine, an mAChR agonist.
Consistent with this, CCh and other mAChR agonists have been shown to inhibit IM
in the hippocampus (Halliwell & Adams, 1982; Brown, 1983; Madison et al. 1987;
Benson et al. 1988; Dutar & Nicoll, 1988a; Halliwell, 1990), olfactory cortex
(Constanti & Sim, 1987) and superior cervical ganglion (SCG; Marrion et al. 1989).
Madison and co-workers (1987), showed that the concentration of CCh required to
inhibit IM was more than 10-fold higher than that required to inhibit IAHP (Madison et
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al. 1987), a similar observation has been made in the olfactory cortex (Constanti &
Sim, 1987). Consistent with this, inhibition of IM by synaptically released ACh in the
hippocampus was not as readily achieved as inhibition of IAHP or activation of the
slow current underlying the slow EPSP (Madison et al. 1987). As such, it was
concluded that inhibition of IM did not contribute to the slow EPSP evoked by
synaptically released ACh. In bullfrog sympathetic ganglion cells however, IM is
more readily inhibited than IAHP by mAChR activation (Pennefather et al. 1985).
Other examples ofmAChR-mediated modulation of K+ conductances include the
inhibition of the fast transient voltage-dependent A current (IA) which normally
enhances spike repolarization and slows discharge rate (Nakajima et al. 1986). In
neostriatal neurones mAChR activation also inhibits IA, which at hyperpolarized
potentials tends to reduce action potential firing frequency, whereas at depolarized
potentials mAChR activation inactivates IA completely increasing neuronal
excitability (Akins et al. 1990).
Conversely, mAChR activation in the hippocampus has also been shown to activate
K+ conductances such as the delayed rectifier K+ current (IK) (Zhang et al. 1992). In
other brain areas, such as the thalamus, mAChRs have also been shown to cause a
hyperpolarization associated with a conductance increase mediated by K+ ions (e.g.
McCormick & Prince, 1985). Finally, the anomalous inward rectifying current (IQ),
which is mediated by both K+ and Na+ ions, is also activated by mAChRs in the
hippocampus (Colino & Eialliwell, 1993).
1.1.4.2. Effects on calcium and nonselective cationic currents
Evidence for the effects of mAChR activation on Ca++ currents in the hippocampus is
more limited. mAChR-mediated decreases in Ca'' currents have been reported in
CA3 neurones in slice cultures (Gahwiler & Dreifuss 1982; Gahwiler & Brown
1987) and in the cortex and neostriatal neurones (Misgeld et al. 1986). mAChR
activation has been shown to inhibit high voltage-activated Ca++ currents in rat
embryonic hippocampal neurones (Toselli & Taglietti, 1995) and in excised
membranes of hippocampal neurones (Toselli & Taglietti, 1994). In the superior
cervical ganglion (SCG) and basal forebrain neurones mAChR-activation inhibits
10
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N-type Ca++ channels (Plummer et al. 1991). However one study also suggests an
inhibition of L-type channels in the SCG (Mathie et al. 1992), an effect also reported
in the cerebral cortex (Boess et al. 1990).
A considerable amount ofwork has been carried out using neuroblastoma hybrid
cells, transfected with cloned mAChR cDNA, to identify the mAChR subtypes
mediating modulation of Ca++ currents (Brown et al. 1993). Using this approach m2
and m4 mAChRs but not ml and m3 mAChRs have been found to inhibit a Ca++
current designated the "N" current (Higashida et al. 1990). This classification is
somewhat misleading, as the kinetics differ from the classic N-type current.
However, it is likely that this "N" current corresponds to Ca++ current(s) responsible
for modulating transmitter release, i.e. N-type Ca++ channels. Inhibition of these
currents is the likely mechanism for mAChR-mediated inhibition of transmitter
release at presynaptic terminals (Wu & Saggau, 1997).
In contrast, Fraser & MacVicar (1991) have shown that mAChR stimulation activates
a low-threshold transient (T-type) Ca++ current in hippocampal CA1 interneurones in
the laculosum-moleculare region. The same group have also demonstrated a
mAChR-mediated activation of a novel regenerating current, which underlies a
plateau potential, that involves the interplay between a high-voltage-activated Ca++
conductance and a Ca++ activated nonselective cation conductance (Fraser &
MacVicar, 1996).
mAChR-mediated depolarization through the activation of nonselective cationic
conductances has also been described in CA1 and CA3 neurones in hippocampal
slices and slice cultures, respectively (Colino & Halliwell, 1993; Caeser et al. 1993;
Guerineau et al. 1995), as well as in cortical layer V pyramidal neurones (Haj-
Dahmane & Andrade, 1996).
1.1.4.3. Functional consequences ofmAChR activation
In the hippocampus, mAChR activation has been shown to inhibit glutamate and
GABA release at synapses in the CA1 (Hounsgaard, 1978; Valentino & Dingledine,
1981; Dutar & Nicoll, 1988a; Cohen et al. 1991) and CA3 regions (Williams &
Johnston, 1988). Transmitter release may be inhibited by
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i) activation of K+ conductances,
ii) a direct inhibition of the calcium-dependent release machinery, or
iii) the inhibition of Ca++ currents.
A recent paper, however, has suggested that mAChR-mediated presynaptic inhibition
in area CA1 is mainly mediated by the inhibition of voltage-dependent Ca++ channels
(Quian & Saggau, 1997).
Cholinergic action may also affect synaptic efficacy through modulation of synaptic
plasticity, e.g. long term potentiation (LTP). In this respect activation of mAChRs
enhances induction of LTP (Blitzer et al. 1990) and even induces a form of long term
plasticity known as LTPm (Auerbach & Segal, 1996). The role ofmAChRs in
memory has been reviewed in some detail (Krnjevic, 1993; Aigner, 1995; Segal &
Auerbach, 1997).
Application of cholinergic agonists such as CCh can induce more complex effects
such as theta (9) rhythm-like activity (Konopacki et al. 1987; Bland et al. 1988). 9-
like activity consists ofmembrane potential oscillations and rhythmic spike
discharges at a frequency of 4-10 Hz and is thought to be functionally important in
learning and memory. As such, disruption of the 9-rhythm in the rat impairs
performance in spatial memory tasks (Winson, 1978). Related to this phenomenon is
the mAChR-activated rhythmical slow activity (RSA), which has been recorded in
CA3 hippocampal pyramidal neurones and consists of periodic bursts of 4-8 Hz
oscillatory depolarizations (MacVicar & Tse, 1989; Traub et al. 1992).
In addition to the effects on the oscillatory behavior of hippocampal neurones,
mAChR activation, using high concentrations of CCh, alters the action potential
waveform by a Ca++ dependent mechanism (Figenschou et al. 1996). Clearly,
therefore, the ability ofmAChR activation to alter synaptic efficacy, oscillatory
behavior and action potential waveform in the hippocampus indicates the importance
ofmAChR-mediated effects in network function in the hippocampus.
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1.2. THE PURINES ADENOSINE AND ADENOSINE TRIPHOSPHATE
The purine nucleotide adenosine 5'-triphosphate (ATP) and nucleoside adenosine are
unusual in that they are involved in cellular metabolic processes but also have actions
at cell surface receptors (Williams, 1987). The receptors at which adenosine and
ATP act are collectively known as purinoceptors (Burnstock, 1978). ATP, which
acts at P2 purinoceptors, is stored and released as a neurotransmitter in the peripheral
and central nervous system (Edwards & Gibb, 1993; Fredholm et al. 1994b). In
contrast, there is little evidence to suggest that adenosine, which acts at P,
purinoceptors, acts as a classical neurotransmitter, however many cells synthesize
and release adenosine (Stone et al. 1990). In addition, when ATP is released, it is
rapidly broken down to adenosine by ectonucleotidases (Meghji, 1990). As such,
adenosine is thought to act as a local hormone or neuromodulator and has many
neuromodulatory roles, in the nervous system (Dunwiddie, 1985; Snyder, 1985;
Daval et al. 1991). In the CNS, adenosine acts predominantly as an inhibitory
modulator in that its main actions are reduction in cell firing or excitability and
inhibition of transmitter release. A number of P2 receptors have been
pharmacologically identified and cloned, however the actions ofATP at this group of
receptors are not relevant to this study. P2 purinoceptors have been extensively
reviewed in numerous recent publications (Fredholm et al. 1994a; Dalziel &
Westfall, 1994; Kennedy & Leff, 1995; Fredholm et al. 1997).
1.2.1. Extracellular Actions of Adenosine- AnHistorical
Perspective
Drury and Szent-Gyorgyi in 1929, were the first to recognize the importance of
adenosine as a physiologically active compound from studies on the mammalian
heart. However, the primary evidence of the existence of receptors for adenosine
came over 30 years later, with the observation that caffeine inhibited the action of
adenosine on the mammalian heart (De Gubareff& Sleator, 1965). A rational system
for the classification of purinoceptors was introduced in 1978, when Burnstock
proposed a basis for distinguishing two types of purinergic receptor, namely
adenosine (P,) receptors and ATP (P2) receptors (Burnstock, 1978). The following
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year, the ability of adenosine to both inhibit and stimulate adenylate cyclase (AC)
activity led to the subclassification of adenosine receptors into adenosine A, and A2
receptors (A,Rs and A2Rs respectively) (Sattin & Rail, 1970; Van Calker et al. 1979;
Londos et al. 1980). This classification system also relied on the agonist potency
ratios of adenosine and its related analogues. With the subsequent development of
more selective agonists and antagonists, it is now relatively easy to identify the
actions of each subtype of adenosine receptor using subtype specific agonists and
antagonists (Collis & Hourani, 1993; Dalziel & Westfall, 1994). More recently, the
use ofmolecular biological techniques has led to the proposal of a third subgroup of
adenosine receptors termed A3 receptors (Caruthers & Fozard, 1993; Collis &
Hourani, 1993). The current system of classification of adenosine receptors is
summarized in Table 1.3.
Table 1.3. Adenosine receptor subtypes: Pharmacology and transduction
mechanisms.
Subtype A, A2a A2b A3
Selective
agonists
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Abbreviations: APNEA: A6-2-(4-amino-3-iodophenyl)-ethyladenosine.
1.2.2. Adenosine Receptors
Adenosine receptors, like mAChRs are members of the G-protein coupled receptor
superfamily whose structures are characterized by seven transmembrane hydrophobic
domains (Olah & Stiles, 1992). Adenosine receptors can be found on a variety of
peripheral tissues and in the CNS and are located both pre- and post-synaptically
(Thompson et al. 1992). Historically, it was the observation that adenosine could
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modulate AC that led to the increased interest in the actions of adenosine at cell
surface receptors (Sattin & Rail, 1970). In addition to the modulation ofAC,
adenosine receptors may also couple to phospholipase C (PLC) and phospholipase A2
(PLA2), guanylyl cyclase and several K+ and Ca++ channels (Olsson & Pearson, 1990)
to mediate a variety of functions both in peripheral and neuronal tissues. Four main
adenosine receptor subtypes (A,, A2a, A2b and A3) have been proposed and are now
generally accepted on the basis of pharmacological profiles, second messenger
systems and receptor structure (Abbaracchio et al. 1993).
1.2.2.1. Adenosine Aj Receptors
A,Rs are negatively linked to AC and so inhibit the turnover of intracellular cAMP.
This observation, and the rank order of potency of adenosine and its analogues 7V6-
phenylisopropyladenosine (PIA) and 5' -A'-c thy 1 carboxam idcadenos ine (NECA), was
the basis for the initial classification ofA,Rs. Thus, the rank order of agonist
potency of these agonists at A,Rs was proposed to be PIA > adenosine > NECA
(Londos et al. 1980). At present there are a number of other analogues of adenosine
which are useful in the investigation of the effects of adenosine receptor activation.
2-chloroadenosine (CADO), is an analogue of adenosine which is resistant to the
actions of adenosine deaminase (which breaks down adenosine to inosine causing its
inactivation). As such, CADO is a useful tool where the breakdown of adenosine
will adversely affect its apparent potency. CADO is only slightly more selective for
A,Rs over A2Rs, however, a stereoisomer ofPIA, R-PIA, is relatively subtype
selective for A,Rs. The most useful tool for the investigation ofA,R-mediated
effects is the agonist 2-chloro-A/6-cyclopenty [adenosine (CCPA) which is a highly
selective agonist at these receptors (Lohse et al. 1988). In terms of classification of
AjRs using antagonists, early studies relied on antagonists such as 8-
phenyltheophyline (8-PT), which has antagonist activity at both A,Rs and A2Rs.
However, the development of xanthine derivatives such as the selective A,R
antagonist DPCPX has led to more reliable classification of A,R-mediated effects. In
this respect, DPCPX has a 700-fold selectivity for A,Rs over A2Rs (Lohse et al.
1987).
16
1.2.2.2. Adenosine A2 Receptors
Adenosine A2 receptors were initially separated from A,Rs on the basis of their
ability to stimulate, rather than inhibit, AC activity (Van Calker et al. 1979; Londos
et al. 1980). In addition, the rank order of agonist potency for A2 receptors was
proposed to be NECA > PIA > adenosine. More recently, however, A2Rs were
subdivided into two subtypes, namely a high affinity receptor (A2aR) and a low
affinity receptor (A2bR), both ofwhich are positively coupled to AC (Daly et al.
1983; Bruns et al. 1986; Ongini & Fredholm, 1996). Pharmacological classification
of A2aRs and A2bRs was made easier in 1989, when CGS 21680 was first described as
a potent and selective adenosine A2a receptor agonist with 140-fold selectivity over
A,Rs (Jarvis et al. 1989). More recently a potent and A2aR selective non-xanthine
antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl) [l,2,4]-triazolo[2,3-
a][l,3,4]triazin-5-yl aminojethyl) phenol) has also been developed (Poucher et al.
1995).
1.2.2.3. Adenosine A3 Receptors
The proposal of an A3 receptor subtype has arisen from the cloning and functional
characterization of a novel adenosine receptor from a cDNA sequence from the rat
striatum (Zhou et al. 1992). When stably expressed in Chinese hamster ovary cells
adenosine receptor agonists bound to this receptor with the potency order R-PIA =
NECA > S-PIA. This order of agonist potency does not correlate with that for either
A,Rs or A2Rs and, in addition, the receptor is resistant to blockade by certain
xanthine antagonists. However, many of the compounds used in the study of A3R-
mediated effects also have activity at A,Rs and, like A,Rs, A3Rs are negatively
coupled to AC (Zhou et al. 1992).
1.2.3. The NeuromodulatoryRole of Adenosine
Unlike ATP, which is released from purinergic nerves (Burnstock, 1972), there is
little evidence to support a neurotransmitter role for adenosine (Bruns, 1991).
Adenosine receptors, however, are widely distributed in the periphery and in the
CNS and adenosine is released from neurones (Bender et al. 1981; Jonzon &
Fredholm, 1985; Stone et al. 1990; Mitchell et al. 1993; Fredholm et al. 1994b). As
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such, adenosine is thought to have a neuromodulatory role in the CNS.
Adenosine has many actions, mainly inhibitory, in the CNS. The principle action of
adenosine is inhibition of transmitter release at a variety of excitatory and inhibitory
synapses (Dunwiddie, 1990). Adenosine also has direct postsynaptic effects, such as,
modulation of postsynaptic K+ or Ca++ conductances and inhibition of spontaneous
neuronal firing (see section 1.2.4). These actions alone provide strong evidence for a
neuromodulatory role for adenosine. In support of this, the excitatory action of
caffeine and xanthine adenosine receptor antagonists alone in neuronal systems both
in vitro and in vivo suggests that adenosine tonically activates adenosine receptors
(Greene et al. 1985; Bauman et al. 1992; Kaplan et al. 1993; Dunwiddie & Diao,
1994). This so called "purinergic inhibitory tone" (Harms et al. 1978) is enhanced
by the inhibition of adenosine breakdown or uptake (Jackisch et al. 1984; Pak et al.
1994; Dunwiddie & Diao, 1994).
Although the extracellular actions of adenosine are well established, the source of
extracellular adenosine is controversial. Adenosine is a major component of cellular
metabolic processes (Arch & Newsholme, 1978) and, as such, it is difficult to
pinpoint localized production of adenosine. Electrical stimulation and K+-induced
depolarization evokes adenosine release, however this process is thought to be carrier
mediated as opposed to an exocytotic process (Sweeney, 1996). Another major
source of adenosine is 5'-nucleosidase mediated breakdown ofATP. Extracellular
concentrations of adenosine are highly dependent on the metabolic state of the
surrounding neurones. As such, during hypoxia, concentrations of adenosine are
dramatically elevated (Hagberg et al. 1987; Rudolphi et al. 1992). In this respect,
due to its inhibitory role in the CNS and vasodilatory role in cardiac tissues,
adenosine is thought of as a neuro- or cardio-protective agent. A more general
description came from Newby (1984), who described adenosine as a "retaliatory
metabolite".
1.2.4. Adenosine Receptor-mediated Effects in the CNS
The effects of adenosine receptor activation in the CNS can be separated into three
general categories
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i) inhibition of spontaneous neuronal firing,
ii) modulation of K+ or Ca++ conductances, and
iii) presynaptic modulation of neurotransmitter release.
Each of these effects have been extensively characterized in the hippocampus.
1.2.4.1. The Effects of Adenosine on Spontaneous Neuronal Firing
Adenosine receptor activation has been shown to inhibit spontaneous neuronal firing
and epileptic bursting (Phillis et al. 1979; Dunwiddie, 1980; Lee et al. 1984;
Schubert & Lee, 1986). These effects are mediated by postsynaptic A,Rs, as they are
inhibited by A,R antagonists and can be observed in the absence of synaptically
released transmitters. As such, these effects are likely to be due to the activation of a
postsynaptic K+ conductances which result in hyperpolarization and enhancement of
Iahp (see section 1.2.4.2) thus reducing postsynaptic excitability.
1.2.4.2. The Effects of Adenosine on K+ and Ca++ Channels
In the hippocampus, adenosine receptor activation has been shown to activate an
voltage insensitive K+ conductance, which mediates a hyperpolarization associated
with a decrease in input resistance (Okada & Ozawa, 1980; Segal, 1982; Greene &
Haas, 1985). This effect is mediated by a pertussis toxin sensitive G-protein (Gj or
G0) but does not involve the second messenger cAMP (Trussel & Jackson 1987). In
addition, adenosine receptor activation also enhances IA1IP, which underlies the slow
afterhyperpolarisation (slow AHP) in hippocampal pyramidal neurones (Haas &
Greene 1984). One study has even reported that, in cultured hippocampal neurones,
activation of adenosine receptors activates a voltage-dependent CI" conductance
(Mager et al. 1990).
There is some evidence for adenosine receptor-mediated inhibition of Ca++ currents,
both pre- and post-synaptically, in the CNS. In the hippocampus, adenosine inhibits
regenerative Ca++-dependent action potentials (calcium spikes) although it is not clear
if this effect is direct or whether it is via activation of a K+ conductance which
subsequently inhibits a Ca++ conductance (Proctor & Dunwiddie 1983). In addition,
adenosine receptor activation has been shown to inhibit N-type Ca++ currents in
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hippocampal CA3 neurones (Mogul et al. 1993) and mouse motoneurones (Mynlieff
& Beam, 1994). In cultured DRG neurones, adenosine receptor activation is reported
to inhibit the duration of Ca++ spikes (Dolphin et al. 1986; Macdonald et al. 1986).
1.2.4.3. Modulation of Transmitter Release by Adenosine
As discussed already, adenosine is not thought to act as a neurotransmitter but as a
neuromodulator (see section 1.2.3). Inhibition of transmitter release is perhaps the
best-recognized neuromodulatory effect of adenosine receptor activation. The
earliest reports of an inhibition of ACh release came from studies at the
neuromuscular junction (Ginsborg & Hirst, 1972). In terms of neurochemical
release, activation of presynaptic adenosine receptors has been shown to inhibit the
release of excitatory and inhibitory neurotransmitters, such as, ACh, adrenaline,
dopamine, GABA, glutamate and serotonin (Harms et al. 1978; Harms et al. 1979;
Burke & Nadler, 1988). The inhibition ofGABA release, however, is not a
consistent finding in all brain regions as, for example, adenosine inhibits GABA
release in the cortex and striatum but not the hippocampus (Harms et al. 1979;
Hollins & Stone, 1980).
Although there is a substantial amount of evidence for the presynaptic modulation of
transmitter release, the mechanism for these effects is controversial. Three possible
hypotheses have been proposed on the basis of the known effects of adenosine:
i) adenosine activates a presynaptic K+ conductance, resulting in a reduction in
Ca++ influx, leading to a reduction in transmitter release,
ii) adenosine inhibits a presynaptic Ca++ conductance, also leading to a reduction
in transmitter release, or
iii) adenosine acts directly on the Ca++ sensitivity of the release process to inhibit
transmitter release (Silinsky, 1986)
With respect to the inhibition of presynaptic Ca++ conductances, adenosine has been
shown to inhibit presynaptic Ca++ flux measured using Ca++-imaging techniques in
the guinea pig hippocampus (Wu & Saggau, 1994) and chick ciliary ganglion (Yawo
& Chuhma, 1993). In the hippocampus this inhibition is thought to involve co-
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conotoxin GVIA-sensitive N-type and possibly Q-type Ca++ channels (Wu & Saggau,
1994). In other brain areas such as the rat brainstem, adenosine, acting at A,Rs, has
been shown to inhibit synaptic transmission predominantly via inhibition of an N-
type Ca++ channel (Umemiya & Berger, 1994). In contrast, there is some evidence
that activation of adenosine A2Rs potentiates P-type Ca++ currents in hippocampal
CA3 neurones and rat brainstem thereby facilitating synaptic transmission in the
brainstem (Mogul et al. 1993; Umemiya & Berger, 1994).
1.3. THE INHIBITORY AMINO ACID GABA
1.3.1. GABA - An Historical Perspective
Decarboxylation of L-glutamate at its a-carbon atom (a process that is intrinsic to the
natural breakdown of L-glutamate) yields the now widely accepted inhibitory
neurotransmitter, GABA. The inhibitory properties of this neutral amino acid were
first suggested by the demonstration that extracts of mammalian brain, containing
GABA (Florey, 1961; Dudel et al. 1963), inhibited the firing of the crayfish stretch
receptor in an identical manner to the purified compound (Kuffler & Edwards, 1958;
Kravitz et al. 1963a; Kravitz et al. 1963b). GABA has since satisfied all the criteria
required for its classification as a neurotransmitter (Kelly & Beart, 1975; Bowery &
Nistico, 1989; Sivilotti &Nistri, 1990; Florey, 1991). In particular, the inhibitory
role of GABA in the CNS was confirmed by the similarity of the CI" ion dependency
and reversal potentials of inhibitory postsynaptic potentials (IPSPs) and GABA-




Historically, it was thought that both pre- and post-synaptic actions ofGABA were
mediated via a single receptor which universally gated a CI" conductance (Coombs et
al. 1955; Krnjevic, 1974; Eccles et al. 1977; Allen et al. 1977; Sakmanneta/. 1983).
This receptor was selectively blocked by the plant alkaloid bicuculline (Curtis et al.
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1970a) and was later designated the GABAa receptor (Hill & Bowery, 1981). Since
then GABAa receptors have been described in nearly every region of the CNS where
classically they mediate a fast hyperpolarizing IPSP (Bormann, 1988; Stephenson &
Dolphin, 1989; Sivilotti & Nistri, 1990).
Investigation of presynaptic GABA-mediated inhibition in rat post-ganglionic
sympathetic nervous tissue using baclofen, the (3-p-chlorophenyl- analogue ofGABA
(Bowery, 1982), led to the discovery of a second type ofGABA receptor (Bowery et
al. 1980). This receptor was insensitive to bicuculline and was later termed the
GABAb receptor (Hill & Bowery, 1981). Unlike GABAa receptors, GABAb
receptors are coupled through G-proteins to both ionotropic and metabotropic
responses (Bormann, 1988; Bowery, 1989; Wojcik et al. 1990; Crawford & Young,
1990). These effects, like those mediated by GABAa receptors, occur at both pre-
and post-synaptic loci (Dutar & Nicoll, 1988b; Deisz & Zieglgansberger, 1990;
Waldmeier & Baumann, 1990; Dolphin et al. 1990). The regional distribution of
GABAa and GABAb receptors is extremely similar (Bowery et al. 1984; Young &
Chu, 1990). Nevertheless, the relative densities of both GABA receptor-subtypes
varies in different brain regions (e.g. in the cerebellum, GABAa receptors
predominate in the granule cell layer and GABAb receptors in the interpeduncular
nucleus (Hill & Bowery, 1981)).
A third GABA receptor has now been identified, the so-called GABAC receptor.
Like classical GABAa receptors, GABAC receptors are ligand-gated CI" channels but
unlike GABAa receptors they are insensitive to bicuculline and to allosteric
modulation by benzodiazepine and barbiturate site ligands. Although the GABAb
receptor agonist (-)-baclofen is inactive at GABAC receptors, cA-4-aminocrotonic
acid (CACA) selectively activates these receptors (Polenzani et al. 1991).
Structurally, GABAC receptors are thought to be composed of the molecularly
identifiable pi and p2 subunits, which are expressed significantly in the rat retina
(pi), hippocampus and cortex (p2; Enz et al. 1995). GABAC receptor-like effects
have been observed in the hippocampus (Strata & Cherubini, 1994), although there is
no firm evidence for their synaptic activation.
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1.3.2.2. GABAa Receptors
The GABAa receptor is closely related to the same ligand-gated channel superfamily
as nAChRs (Barnard et al. 1987; Schofield et al. 1987). Like many other receptors
in this superfamily, multiple isoforms of GABAa receptors are likely to exist in situ
(Schofield et al. 1987; Levitan et al. 1988; Olsen & Tobin, 1990; Tobin et al. 1991).
In this respect six a-, four p-, three y-, one 5- and one s-subunit have now been
identified using molecular cloning techniques. These subunits are thought to form
heterooligomeric receptors with the stoichiometry (a)2P(y)2 where the y-subunit can
be replaced by a 5- or e-subunit. (Sieghart, 1995).
The GABAa receptor is a multi-ligand binding complex (Simmonds, 1983; Bowery,
1984) which, in addition to the classical competitive agonist and antagonist binding
site, includes sites for barbiturates, benzodiazepines, neurosteroids and ethanol (for
review see Sieghart, 1995). Pharmacological activation ofGABAa receptors can be
achieved using 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) and muscimol
which are two of the most potent and selective GABAa receptor agonists
(Krogsgaard-Larsen et al. 1977). In addition, bicuculline or picrotoxin are often used
to competitively and non-competitively antagonize GABAa receptors, respectively
(Simmonds, 1980). Two different GABAa receptor-mediated responses have been
reported to occur following afferent stimulation within a single neurone type i.e.
"synaptic" (hyperpolarizing) and "extra-synaptic" (depolarizing) responses (Barker &
Ransom, 1978; Thalmann et al. 1981; Alger & Nicoll, 1982a).
1.3.2.3. GABAb Receptors.
In contrast to GABAa receptors, GABAb receptors belong to the G-protein linked
superfamily of receptors (Kuriyama & Ohmori, 1990) and have only recently been
cloned (Kaupmann et al. 1997). To date, the most widely used selective GABA0
receptor agonist is the (-)-isomer of baclofen (Bowery, 1982). 3-
aminopropylphosphinic acid (3-APA) has been reported to be approximately 10-20
times more potent than (-)-baclofen (Harrison et al. 1990), however, under certain
conditions, it may exhibit partial agonist properties (Bowery, 1989).
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The first competitive GABAb receptor antagonist to be developed was a phosphinic
acid derivative of baclofen, for which the colloquial name phaclofen was assigned
(Kerr et al. 1987; Kerr et al. 1989b). This antagonist has since been superseded by
sulphinic analogues, such as 2-hydroxy-saclofen, which have a 10-fold higher
antagonist potency (Kerr et al. 1988; Kerr et al. 1989a). These compounds are still
relatively weak and exhibit some loss of selectivity at the high (mM) concentrations
required to block GABAb receptor-mediated synaptic responses (Davies et al. 1990;
Mott & Lewis, 1991). The first potent (equipotent to 2-hydroxy-saclofen) and
selective GABAb receptor antagonist to be developed was the A-substituted
phosphinic analogue ofGABA, P-[3-aminopropyl]-R-(diethoxymethyl)phosphinic
acid, commonly referred to as CGP 35348 (Olpe et al. 1990). More recently,
however, the selective GABAb receptor antagonist CGP 55845A (3-A- [l-(5)-(3,4-
dichlorophenyl)ethyl] amino-2-(S)-hydroxypropyl-P-benzyl-phosphinic acid), has
been shown to be 500-1000 more potent than CGP 35348 (Davies et al. 1993;
Froestl et al. 1995). In addition, non-competitive antagonism ofGABAB receptor-
mediated responses also provides a powerful tool with which to probe GABAb
receptor function. This can be attained for certain GABAb receptor-mediated
responses by means of intracellular application of Cs+ (Randall et al. 1991; Yoon &
Rothman, 1991) or QX 314 (2-(triethylaminium)-A-(2,6-dimethylphenyl)acetamide)
(Nathan et al. 1990) which are thought to block the GABAb receptor-operated K+
conductance.
1.3.3. GABAb Receptor-mediated Effects in the CNS
The susceptibility of certain GABAb receptor-mediated effects to pertussis toxin
suggests that GABAb receptors are coupled to ion channels through the G, or G0 type
ofG-protein (Andrade et al. 1986; Thalmann, 1988; Bormann, 1988). Indeed, the
classic GABAb receptor-mediated late or slow IPSP, seen throughout the CNS, is
generated by the coupling of this type of G-protein to a "promiscuous" inwardly
rectifying K+ conductance that is thought to be shared by numerous other receptor
systems including serotonin 5-HTIA receptors (Andrade et al. 1986) and M2 mAChRs
(Christie & North, 1988). Similarly, GABAb receptor-mediated inhibition of
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voltage-dependent Ca++ currents and the consequent reduction in the Ca++-dependent
plateau phase of the action potential (Dunlap & Fischbach, 1981) can be accounted
for by direct inhibition of a Ca++ conductance by a pertussis toxin-sensitive Ga0-
protein (Deisz & Lux, 1985; Dolphin & Scott, 1987; Dolphin et al. 1989; Campbell
et al. 1993). This mechanism is thought to account for GABAb receptor-mediated
presynaptic inhibition of transmitter release and consequent depression of synaptic
transmission. However, presynaptic inhibition by GABAb receptors in the
hippocampus is not sensitive to pertussis toxin (Dutar & Nicoll, 1988b; Harrison,
1990). In addition, GABAb receptors do not affect the amplitude or transmission of
the presynaptic Na+-dependent action potential (Peng & Frank, 1989) but may
modulate presynaptic K+ conductances such as the fast activating IA (Saint et al.
1990).
In addition to these effects, GABAb receptors, through their activation of G-proteins,
can also invoke multiple intracellular biochemical effects, including inhibition of AC
and enhancement of IP, production (Karbon et al. 1990; Wojcik et al. 1990;
Crawford & Young, 1990). These complex intracellular effects are likely to explain
the indirect GABAb receptor-mediated promotion and/or inhibition of both cyclic
adenosine 5'-monophosphate (cAMP) and inositide formation induced by other
agents e.g. noradrenaline and histamine.
1.4. THE EXCITATORY AMINO ACIDS GLUTAMATE AND ASPARTATE
1.4.1. Excitatory Amino Acids - An Historical perspective
The increased neuronal activity and susceptibility to epileptic seizures that followed
in vivo CNS application of L-aspartate and L-glutamate first suggested that these
endogenous acidic amino acids fulfill an excitatory role in the CNS (Hayashi, 1952;
Hayashi, 1954). Indeed, intracellular recording subsequently revealed that they
strongly depolarized both excitatory and inhibitory neurones (Curtis et al. 1959;
Curtis et al. 1960; Curtis et al. 1961). The concept that specific receptors mediated
this depolarization was confirmed by the strict structural requirements for
compounds to evoke this response (Curtis & Watkins, 1960; Curtis & Watkins,
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1963). Indeed, quantitative structure-activity relationships for l-glutamate and l-
aspartate indicated that these amino acids acted at independent receptor sites
(McLennan et al. 1968; Duggan, 1974). In particular, C-fiber compound action
potentials were insensitive to l-aspartate but were readily suppressed by l-glutamate
(Davies et al. 1979b; Evans, 1980; Agrawal & Evans, 1986). Within a few years, it
was accepted that three pharmacologically distinct excitatory amino acid (EAA)
receptor subtypes existed. These three subtypes were defined by the agonists N-
methyl-d-aspartate (NMDA), kainate and quisqualate (Johnston et al. 1974;
McCulloch et al. 1974; Watkins & Evans, 1981). However, more recently, the
development ofmore selective pharmacological agents has led to the reclassification
ofEAA receptors into four broad subtypes (Watkins et al. 1991; Lodge & Johnson,
1991; Young & Fagg, 1991).
1.4.2. Excitatory Amino Acid Receptors
The most well studied of the EAA receptor subtypes are the so-called a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA; formerly known as quisqualate
receptors) and NMDA receptors. These ionotropic receptors are believed to mediate
the faster and slower components of dual component EPSPs evoked in the
hippocampus, respectively (Dale & Roberts, 1985; Bekkers & Stevens, 1989;
Headley & Grillner, 1991). Such EPSPs are characteristic of fast excitatory synaptic
transmission throughout the vertebrate CNS. An additional "non-NMDA" ionotropic
receptor subtype exists, namely the kainate receptor, which exhibits anomalous
regional distribution to AMPA receptors. This receptor subtype also mediates
synaptic transmission but only under conditions where repetitive afferent stimulation
is used (Vignes & Collingridge, 1997).
The final EAA receptor subtype is commonly referred to as the metabotropic class of
receptor ofwhich nine different molecular entities have so far been isolated. These
metabotropic glutamate receptors differ from the ionotropic receptor subtypes in that
they directly activate numerous intracellular biochemical cascades through their




Since the molecular cloning of the NMDA NR1 subunit was achieved in 1991
(Moriyoshi et al. 1991) a further four NR2 subunits in the rat (NR2A, NR2B, NR2C
and NR2D) have been cloned (Sucher et al. 1996). NR1 subunits can form
homomeric complexes whereas NR1 and NR2 subunits form heteromeric structures
of unknown stoichiometry (Sucher et al. 1996). As with nAChRs, different subunit
assemblies posses different pharmacological and biophysical properties.
NMDA ion channel receptors bind both glutamate and NMDA, although activation
requires glycine to bind as a co-agonist (Johnson & Ascher, 1987). One of the first
selective and competitive antagonists to be developed for any one of the excitatory
amino acid receptors was D-2-amino-5-phosphonopentanoate (D-AP5), which is
selective for the NMDA receptor (Davies et al. 1981; Evans et al. 1982).
Significantly, electrophysiological studies using this antagonist demonstrated that
NMDA receptors could be activated physiologically in the CNS (Herron et al. 1986;
Ascher & Nowak, 1987). In particular, in the CA1 region of the hippocampus, the
ease with which it is possible to evoke NMDA receptor-mediated responses
(Collingridge et al. 1988a; Collingridge et al. 1988b) correlates well with the
extraordinarily dense NMDA receptor binding observed in this brain region
(Monaghan & Cotman, 1985).
Non-competitive antagonism ofNMDA receptor-mediated responses was first shown
for Mg++ (Evans et al. 1977; Davies et al. 1979a; Mayer & Westbrook, 1987; Ascher
& Nowak, 1988). At physiological concentrations, this divalent cation blocks the
NMDA receptor-operated channel. In this respect, although this cation can enter the
NMDA receptor-operated channel, its large size prevents free passage through the
channel. Consequently, it prevents the normal passage ofNa+, K+ and Ca++, which
mediate the NMDA receptor-mediated synaptic current (Sucher et al. 1996). In
addition several pharmacological compounds, such as MK 801, have been developed
which, like Mg++, non-competitively antagonize NMDA receptors.
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1.4.2.2. AMPA Receptors.
The regional distribution ofAMPA receptors within the CNS closely correlates with
that ofNMDA receptors (Bekkers & Stevens, 1989; Young & Fagg, 1991) and
supports the concept that dual EPSPs in the brain are mediated by these two EAA
receptors. Somewhat unusually, the amino acid sequences and overall structural
characteristics of both these receptors differ from those of other ionotropic
superfamily receptors in that each subunit is proposed to have only three
transmembrane domains as opposed to the four proposed for the nAChR (McCarthy
et al. 1986; Barnard & Henley, 1991). Their pharmacological separation was first
achieved using D-AP5 to block NMDA receptor-mediated EPSPs (EPSPN)
(Collingridge et al. 1983). However, with the development of the quinoxalenedione
family ofnon-NMDA receptor antagonists, such as 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX) (Honore, et al. 1988; Blake et al. 1989), it has been possible to
convincingly isolate intact EPSPNs (Andreasen et al. 1988; Blake et al. 1988; Davies
& Collingridge, 1989). A more potent non-NMDA receptor antagonist is NBQX,
which has been shown to inhibit AMPA/kainate receptor-mediated EPSPs in the
hippocampal area CA1 (Randle et al. 1992). More recently, GYKI53655, which is
selective for AMPA over kainate receptors, has been described (Paternain et al.
1995).
1.4.2.3 Kainate Receptors
The kainate receptors have a structure which conforms more closely with classical
ion channel receptors such as the nAChR (Hollmann & Heinemann, 1994). Three
low affinity (GluR5-7) and two high affinity and pharmacologically distinct (KA1-
KA2) kainate receptors have been cloned. Kainate receptors are widely distributed
throughout the brain but are particularly abundant in area CA3 of the hippocampus
and in spinal cord C-fibers (Pook et al. 1993). The demonstration of functional
kainate receptors in the brain has been aided by the introduction of the highly
selective AMPA receptor antagonist GYKI 53655 (l-(4-aminophenyl)-3-
methylcarbamyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine),
allowing the investigation of pure kainate receptor mediated effects (Paternain et al.
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1995). In addition, development ofmore selective ligands ATPA ((7?S)-2-amino-3-
(3-hydroxy-5-fe/7-butylisoxazol-4-yl)propanoic acid), a GluR5 agonist and
LY294486 ((3SR, 4aRS, 6SR, 8aRS)-6-((((lH-tetrazol-5-yl)methyl)oxy)methyl)-
l,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid), aGluR5 antagonist
has aided in the pharmacological classification of kainate receptor-mediated effects.
As such, GluR5 has been implicated in the inhibition ofGABA release (Clarke et al.
1997). However the GluR subtype mediating the kainate-induced inhibition of
glutamate release from hippocampal synaptosomes has not been elucidated
(Chittajallu et al. 1996). Activation of these populations of kainate receptors by
endogenous glutamate has not yet been verified, although recently it was shown that
postsynaptic kainate receptors in CA3 pyramidal neurones can be activated during
periods of repetitive stimulation (Castillo et al. 1997; Vignes & Collingridge, 1997).
The resultant synaptic potential possesses kinetics somewhat slower than AMPA and
NMDA receptor-mediated synaptic currents has recently been demonstrated.
1.4.2.4. Metabotropic Glutamate Receptors.
Metabotropic glutamate receptors (mGluRs), like mAChRs, are G-protein linked
receptors and classically act via activation ofPLC (group I) and inhibition ofAC
(group II and III) (Pin & Duvoisin, 1995) although a distinct phospholipase D (PLD)-
linked mGluR has recently been described in the hippocampus (Pellegrini-
Giampietro et al. 1996). Molecular cloning has revealed eight subtypes of mGluRs
(mGluR,.8) which are divided into three groups, based on agonist pharmacology and
the signal transduction mechanisms to which they couple (Pin & Duvoisin, 1995).
The major differences between the three groups are summarized in Table 1.4. 1 -
aminocyclopentane-lS^R-dicarboxylic acid ((1S,3R)-ACPD) is a group I and group
II mGluR agonist while L-2-amino-4-phosphonobutanoate (L-AP4) is a selective
agonist at group III mGluRs (Dubner & Ruda, 1992; Thomsen et al. 1992; Roberts,
1995). The phenylglycine derivative (+)-a-methyl-4-carboxyphenylglycine ((+)-
MCPG) is a competitive antagonist for group I and group II mGluRs (Jane et al.
1993; Watkins & Collingridge, 1994; Roberts, 1995; Sekiyama et al. 1996).
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Table 1.4. mGluR subtypes: Pharmacology and transduction mechanisms.
Group I II III




tplc (ip3/dag) 4AC (cAMP) 4AC (cAMP)
Agonists (S)-DHPG DCG IV L-AP4








In the hippocampus, mGluR activation, like mAChR activation has been shown to
inhibit IAHP and IM (Charpak et al. 1990; Guerineau et al. 1994). In addition, mGluR
activation in the hippocampus can inhibit IK(LEAK) which leads to an increase in input
resistance that accompanies a depolarization. This mechanism is believed to be
responsible for mGluR-mediated EPSPs, which are evoked following mossy fiber
stimulation (Charpak & Gahwiler, 1991). It has also been demonstrated, using
ACPD, that inhibition of IK(LEAK) in this manner can subsequently lead to the
activation of a non-specific cation conductance (Guerineau et al. 1995). As such,
many of the effects mediated by mGluRs are remarkably similar to those mediated by
mAChRs. In addition, in area CA1 of the hippocampus, mGluRs inhibit the release
of both GABA and glutamate (Gereau & Conn, 1995). The inhibition of glutamate
release has been proposed to involve the activation of 4-AP-sensitive K+ channels
and/or via inhibition of co-conotoxin-sensitive N-type Ca++ channels (Sladeczek et al.
1993; Swartz et al. 1993), although a detailed study of the mechanism of inhibition
ofGABA release has yet to be reported.
1.5. THE HIPPOCAMPUS
1.5.1. General
The hippocampus has proved the most popular brain region in which to study
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neuronal processes, especially those related to learning and memory processes.
Anatomically, this brain organ consists of an area of cortex rolled into the floor of the
inferior horn of the lateral ventricle. The hippocampal formation is a highly
organized structure which consists of four major regions designated Ammon's horn,
dentate gyrus, entorhinal cortex and subicular complex (Fig. 1.1; Ramon y Cajal,
1891). Within each of these regions there are extensive local (Andersen et al. 1971;
Amaral & Witter, 1989; Witter, 1989) as well as distant circuit interactions which
process synaptic inputs received from extensive areas of the brain e.g. the septum and
diagonal band, raphe nucleus, hypothalamus, thalamus and locus coeruleus (Swanson
et al. 1982). Ammon's horn is itself subdivided into regions cornu Ammon (CA) 1-4
(Lorente de No, 1934), with the CA1 and CA3 regions forming the greater part of the
hippocampus proper (Fig. 1.1). Within these regions, the cell bodies and dendrites of
pyramidal neurones are organized into discrete laminae (Andersen et al. 1971) which
can be easily distinguished in hippocampal slices prepared from transverse sections
of the brain (Fig. 1.2,4; See section 1.5.2). An extremely simplified view of the
transverse connectivity between the main areas of the hippocampus is outlined by the
so-called trisynaptic circuit (Andersen et al. 1971) which receives its major input
from layers II and III of the entorhinal cortex and consists of successive activation of:
i) dentate gyrus granule cells through the lateral and medial perforant paths from
the entorhinal cortex (McNaughton, 1980),
ii) CA3 pyramidal neurones via innervation from dentate granule cells through the
mossy fiber pathway (Blackstad & Kjaerheim, 1961) and,
iii) CA1 pyramidal neurones via input from the axons of the CA3 pyramidal
neurones through the Schaffer collateral-commissural pathway (see Fig 1.2A;
Andersen et al. 1971; Swanson et al. 1978).
1.5.2. The Hippocampal Slice Preparation
The parallel organization of these excitatory pathways approximately transverse to
the longitudinal axis of the hippocampus allows clear visibility and considerable
conservation of the trisynaptic circuit following transverse slicing (Fig. 1.24;










Figure 1.1. Location and General Structure of the Rat Brain and Hippocampus.
A, shows a 20 pm saggital section of rat brain in which cells are stained with Cresyl violet. The main
structures within the brain are marked. CA,: hippocampal area CA,; DG: dentate gyrus; Sub:
subiculum; LV: lateral ventricle; SomS: somatosensory cortex; Oc: occipital Area (Cortex); VB,:
lateral ventrobasal nuclear complex. Ba, shows a schematic representation of the rat brain and the
position of the hippocampus within it. Bb, is a schematic representation of the transverse
hippocampal slice in which the main areas (area CA1, area CA3, dentate gyrus, subiculum and















Synaptic Circuitry in the Rat Hippocampal Slice.
A, shows a schematic representation of the hippocampal slice in which the major excitatory pathways
which comprise the trisynaptic circuit are marked. The direction of synaptic connectivity between
pathways is represented by the arrows (perforant path —> mossy fibers —> Schaffer collateral-
commissural fibers). Note the clear differentiation between laminae (s. oriens, s. pyramidali and s.
radiatum). Ba, shows the placement of field stimulation and intracellular recording electrodes in the
hippocampal slice to evoke the synaptic response shown in Bb. Bb, shows the synaptic response
evoked by a single field stimulus applied to s. oriens. The point of afferent stimulation is marked by
the filled triangle. Note that the stimulus evoked a depolarizing response (EPSP, mediated
predominantly by AMPA receptors), followed by an hyperpolarizing response (IPSP, mediated by
GABAa and GABAb receptors). Note that the NMDA receptor-mediated response is masked by the
inhibitory response. C, shows a simplified schematic diagram of the synaptic circuitry involved in
evoking the response shown in Bb, emphasizing the difference between recurrent and feed-forward
inhibition. Pyramidal neurones are represented by filled triangles and interneurones by shaded
circles. Fiber pathways are represented by solid lines and presynaptic terminals as forks. Note that all
synapses are excitatory (mediated by glutamate) except those of interneurones which are inhibitory
(mediated by GABA). Note that stimulation of the Schaffer collateral-commissural fiber pathway
which extends from the CA3 will evoke direct excitatory responses and inhibitory responses (via
inhibitory interneurones) in CA1 pyramidal neurones.
33
The advantages of the in vitro transverse hippocampal slice preparation are many-
fold, including ease and stability of electrophysiological recording from identified
neurones (Schwartzkroin, 1975; Schwartzkroin, 1977; Knowles & Schwartzkroin,
1981) and the ability to precisely control the temperature and composition of the
extracellular medium (Andersen, 1981). Nevertheless, extrapolation to the in vivo
situation at best may only be a close approximation due to, amongst other
constraints, the substantial transection of synaptic connections between laminae as
well as those to and from other brain areas. Despite this obvious limitation, the
maintenance of the trisynaptic circuit and of other extrinsic inputs, in the face of
gross severance of other convergent synaptic inputs, provides a preparation in which
it is easy to monosynaptically activate synaptic inputs to specific target neurones
(Yamamoto & Mcllwain, 1966; Davies et al. 1990; Malinow, 1991). In this respect,
the study of CA1 pyramidal neurone synaptic input has allowed the acquisition of
substantial knowledge of synaptic transmission in the hippocampus.
1.6. SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS
1.6.1. Synaptic Transmission in the schaffer-collateral commisural
PATHWAY
Amino acids are thought to be the principal mediators of synaptic responses evoked
in CA1 pyramidal neurones following synchronous activation of Schaffer collateral-
commissural afferents. During low frequency synaptic transmission (<0.1 Hz) the
evoked response, like that seen at numerous other synapses in the CNS, comprises a
fast EPSP followed by a biphasic IPSP (Kandel et al. 1961; Nicoll & Alger, 1981;
Alger & Nicoll, 1982b; Fig. 1.2.6). This fast EPSP is thought to be mediated by
AMPA receptors (Davies & Collingridge, 1989; Andreasen et al. 1989) whilst the
biphasic IPSP is mediated by GABAa (IPSPa) (Schwartzkroin & Prince, 1980; Alger
& Nicoll, 1982a) and GABAb (IPSPb) receptors (Dutar & Nicoll, 1988c; Soltesz et
al. 1988; Lambert et al. 1989), respectively. Pharmacological isolation of these
responses also reveals an NMDA receptor-mediated EPSP (EPSPN) which is masked
predominantly by the IPSPA (Andreasen et al. 1989).
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1.6.1.1. CA1 pyramidal neurone excitatory synaptic input
The fast excitatory input to CA1 pyramidal neurones originates from CA3 pyramidal
neurones (Sayer et al. 1990; Malinow, 1991). Ipsilateral collaterals from these
neurones synapse with CA1 pyramidal neurone apical dendrites in .v. radiatum
(Blackstad, 1956; Hjorth-Simonsen, 1973; Laurberg, 1979; Laurberg & Sorensen,
1981). These fibers form en passage excitatory synapses with CA1 pyramidal cells
(Fig. 1.2C; Lorente de No, 1934; Andersen et al. 1966; Andersen & Lomo, 1966).
Under a variety of conditions, e.g. reduced synaptic inhibition (Wigstrom et al. 1986;
Dingledine et al. 1986), stimulation of Schaffer collateral-commissural afferents in s.
radiatum activates both EPSPNs and EPSPAs. It is likely, therefore, that the release
of a single neurotransmitter (L-glutamate) from Schaffer collateral-commissural
terminals accounts for both these synaptic potentials.
1.6.1.2. CA1 pyramidal neurone inhibitory synaptic input.
Historically, it was believed that inhibitory synaptic input to CA1 pyramidal
neurones was mediated solely through classical recurrent (feedback) inhibitory
circuits (Fig. 1.2C; Kandel et al. 1961; Andersen et al. 1964; Dingledine &
Langmoen, 1980; Knowles & Schwartzkroin, 1981). Subsequently, it was realized
that there is an additional feedforward inhibitory circuit that contributes to synaptic
inhibition (Fig. 1.2C; Alger & Nicoll, 1982b; Schwartzkroin & Knowles, 1983;
Buzski, 1984). In both types of inhibition, AMPA and NMDA receptor activation
provide the major synaptic drive of the inhibitory interneurones that mediate the final
GABAergic input to the CA1 pyramidal neurones (Davies & Collingridge, 1989;
Andreasen et al. 1989; Saheta/. 1990).
Both recurrent and feedforward GABAergic interneurones evoke a classic fast
hyperpolarizing IPSPA. This was initially characterized by its sensitivity to
bicuculline and to both intra- and extra-cellular CI" ion concentrations (Kandel et al.
1961; Andersen et al. 1964; Allen et al. 1977; Eccles et al. 1977; Dingledine &
Langmoen, 1980; Dingledine & Gjerstad, 1980).
The notion that GABA was the neurotransmitter mediating this IPSP was confirmed
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by:
i) the similarity between the properties of this IPSP and those of the
hyperpolarization induced by iontophoretic application ofGABA to the soma
of CA1 pyramidal neurones (Curtis et al. 1970b; Andersen et al. 1980; Alger &
Nicoll, 1982a),
ii) the presynaptic location ofGABA in hippocampal interneurones (Anderson et
al. 1986; Gamrani et al. 1986; Woodson et al. 1989), and
iii) the Ca++-dependent release ofGABA from the hippocampal CA1 region
(Skrede & Malthe-Sorenssen, 1981; Spencer et al. 1981; Corradetti et al.
1983).
Feedforward inhibitory circuits additionally activate a GABAb receptor-mediated
slow IPSPB (Nicoll & Alger, 1981; Newberry & Nicoll, 1984a), which was originally
characterized by its similarity to (-)-baclofen-induced hyperpolarizations (i.e. both
exhibited similar I-V relationships and dependency on extracellular K+) (Newberry &
Nicoll, 1984b; Newberry & Nicoll, 1985). This was subsequently confirmed by the
inhibition of IPSPBs by selective GABAb receptor antagonists (Lambert et al. 1989;
Olpe et al. 1990).
1.6.2. The Septohippocampal Input
As well as such intrinsic synaptic inputs, CA1 pyramidal neurones in the
hippocampus receive a number of extrinsic synaptic inputs from diverse areas of the
brain. One of the best-characterized extrinsic synaptic inputs is the
septohippocampal input (Dutar et al. 1995). This comprises a heterogeneous
population of afferents that mediate their effects through the release of numerous
neurotransmitters including ACh, GABA and a variety of neuropeptides (Decker &
McGaugh, 1991; Dutar et al. 1995). Cholinergic neurones in the medial septum and
nucleus of the diagonal band of Broca are the main groups of neurones to innervate
the hippocampal formation (Fig. 1.3). Of the heterogeneous inputs, the cholinergic
aspect of the septohippocampal input to the hippocampus has probably received most
attention due to its involvement in mnemonic processing (Cole & Nicoll, 1983;
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Figure 1.3. The Main Cholinergic Pathways in the Rat Brain.
This figure shows a schematic representation of the rat brain in saggital section. The main cholinergic
projections represented by the solid arrows. OB: olfactory bulb; OT: olfactory tubercle; MS: medial
septum; BMN: basal magnocellular nuclei. Note the septohippocampal cholinergic pathway runs
between the medial septum and the hippocampus.
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Decker & McGaugh, 1991; Dutar et al. 1995). In this respect, this pathway and the
cholinergic system are thought to be involved in the control and generation of the
hippocampal 9-rhythm (see section 1.1.4.3). Stimulation of this input has been
shown to activate a slow EPSP and to reduce SFA via mAChR-mediated inhibition
of K+ conductances (Cole & Nicoll, 1983; Cole & Nicoll, 1984a; Madison et al.
1987; Segal, 1988; Pitler & Alger, 1990).
1.7. AIMS
The initial aim of this project was to establish an experimental protocol with which to
evoke isolated cholinergic synaptic responses in CA1 pyramidal neurones of the rat
hippocampus. This was to be achieved using the established method of stimulation
of the s. oriens to evoke the release of ACh from septohippocampal cholinergic
afferents in area CA1 (Cole & Nicoll, 1983 & 1984). Ionotropic glutamate and
GABA receptor antagonists were to be used to block all "fast" amino acid-mediated
synaptic transmission. Once isolated the intention was to develop a protocol to
evoke consistent cholinergic synaptic responses with the simplest of stimulation
paradigms. Subsequently, a basic characterization of cholinergic synaptic responses
would be required to establish the cholinergic nature of the responses. Having
achieved this, experiments would be conducted to investigate possible mechanisms
for the modulation of this system.
A common mechanism of control of synaptic inputs within the brain is via activation
of different receptors to those that mediate the postsynaptic response, e.g. activation
of autoreceptors, or presynaptic heteroreceptors (Thompson et al. 1993). The
primary aim of this study, therefore, was to investigate the possibility that a
neurotransmitter/neuromodulator other than ACh may restrict the activation of the
mAChR-mediated slow EPSP. Initially adenosine was chosen, because this classic
neuromodulator plays an important role in controlling the excitability of neuronal
networks by inhibiting other excitatory synaptic inputs in the hippocampus, e.g.
glutamate (Thompson et al. 1992; Thompson et al. 1993). Modulation of cholinergic






All experiments were performed using standard intra- and extra-cellular
electrophysiological techniques. Synaptic recordings were made from the CA1
region of transverse coronal rat hippocampal slices obtained from 2-5 week old
female Cobb-Wistar rats.
2.1.2. Preparation of hippocampal slices
The rats were cervically dislocated and subsequently decapitated in accordance with
UK Home Office guidelines. The brain was removed rapidly and placed
immediately in ice cold (0-4°C) artificial cerebrospinal fluid (ACSF). The brain
minus the cerebellum was hemisected and an agar block fixed to the base of the brain
using superglue. The brain was then fixed to a polypropylene block for the
subsequent cutting of 400 pm thick transverse coronal slices using a vibroslicer
(Campden Instruments, Loughborough, UK). Throughout the slicing procedure the
brain and slices were held in a chamber containing ice cold, ACSF. The slices were
then transferred to a glass Petri dish containing ACSF at room temperature (18-24
°C). The hippocampus was cut away from the rest of the brain slice and the CA3
region cut away to eliminate changes in network function that can occur due to
epileptiform bursting in area CA3 when picrotoxin is applied to the slice (see Fig.
3.1). Following an incubation period of at least half an hour the resultant CA3-
ectomized slices were placed in the recording chamber on a nylon mesh at the
interface of a warmed (32 ± 2 °C), perfusing (1-3 ml min~l) ACSF and an oxygen-
enriched (95% 02, 5% C02; BOC Medical Gasses, UK), humidified atmosphere (Fig.
2.1). The slices were then allowed to equilibrate in this environment for
approximately 1-2 h before any electrophysiological recording was attempted.
Surplus slices contained in the Petri dishes remained viable for several hours. If
required, these slices could be transferred to the recording chamber at a later time.
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The standard perfusion medium comprised (in mM): NaCl, 124; KC1, 3; NaHC03,
26; NaH^PO/p 1.25; CaCl2, 2; MgS04, 1; D-glucose, 10; and was bubbled with 95%
02, 5% C02 to maintain a pH of 7.4-7.5. ACSF was made up using distilled water
filtered (10-18 M£2 Cm"1) using the Millipore Milli-Q filter system (Millipore;
Molsheim, France) and all chemicals were analaR grade (BDH Chemicals Ltd.,
Poole, UK).
2.2. RECORDING SET-UP
The recording chamber and the micromanipulators were mounted on magnetic stands
(Narishige, Japan) supported on a steel plate on an anti-vibration table (Ealing, MA,
USA). A steel Faraday cage, grounded through the amplifier (Axoclamp-2B, Axon
Instruments, CA, USA), was placed around the recording system in order to isolate it
from extraneous electrical noise. All electrical equipment that was fitted with earth
leads was secured in a rack and earthed through the mains.
The recording chamber was a modified version of an interface electrophysiological
recording chamber designed by (Spencer et al. 1976) (Fig. 2.1). It consisted of an
outer water bath with a centrally mounted platform on which the tri-compartmental
recording chamber was secured. The outer water bath was partially filled with
distilled water and was bubbled with a 95% 02, 5% C02 mixture. The height of the
covering lid was adjusted to allow the oxygen-enriched humidified atmosphere to
flow over the slices.
ACSF was pumped, by means of a peristaltic pump (Watson-Marlow, England), to a
gravity-feed syringe. This fed a constant flow (1-3 ml min"1) of ACSF into the first
well of the recording chamber. The ACSF then flowed around the circumference of
this well and through a small inlet into the recording chamber proper. Here, it flowed
underneath the nylon mesh and was removed through a separate outlet by suction
through a syringe needle connected to a water-powered suction pump (Brownall,
England). By adjusting the height of the gravity feed and the magnitude of the outlet
suction, the level ofACSF in the recording chamber was maintained so that it was in
contact with the mesh but did not cover the slices. A heated patch connected to a




Figure 2.1. The interface recording chamber.
This figure shows a schematic representation of the recording chamber as viewed from above (A) and
from the side (B). ACSF, perfused with 95 % 02/ 5 % C02 and maintained at 32 °C, was passed
through tubing immersed in the temperature controlled external water bath and into the interface
chamber. The level of ACSF in the interface chamber was maintained just above the level of the
nylon mesh which supported the hippocampal slice. Waste ACSF was drawn off by suction through a
hypodermic needle. The humidified atmosphere was maintained by passing 95 % 02/ 5 % CO,
though distilled water maintained at 32 °C (by a heated plate) to create a fine mist. The reference
electrode was grounded through the Axoclamp 2B.
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base of the water bath (Fig 2.1) to maintain the temperature at 32 ± 2 °C.
The slices in the recording chamber were epi-illuminated with a fiber optics system
(Nachet, France). All stimulating and recording electrodes were mounted on
micromanipulators (Narishige, Japan) which allowed movement in the x, y and z
axes. An additional single axis fine movement hydraulic manipulator (Narishige,
Japan) was used for the recording electrode to allow increased sensitivity when
advancing the electrode for the impalement of neurones. To enable the positioning
of electrodes in the slice, the slice was viewed using an overhead dissecting
microscope (M3C, Leica, England). Recording microelectrodes were placed, at an
angle of approximately 45° to the vertical, in either stratum oriens (CA1 pyramidal
basal-dendritic layer) or stratum radiatum (CA1 pyramidal cell apical dendritic layer).
2.3. RECORDING TECHNIQUES
2.3.1. Recording electrodes
Microelectrodes were pulled from thick walled (internal diameter: 0.69 mm; outer
diameter: 1.2 mm) borosillicate glass capillaries with an inner filament (120F-10,
Clark Electromedical Instruments, England), on a horizontal Flaming-Brown P-97
micropipette puller (Sutter Instruments Co., USA). Intracellular microelectrodes
were back-filled with 2 M potassium methylsulphate (ICN Biomedicals Inc., USA)
and had resistances ranging 60-120 MQ. Extracellular microelectrodes with
resistances ranging 1-5 MQ were back-filled with 4 M sodium chloride.
Recording microelectrodes were then mounted in electrode holders (Clark
Electrochemical Instruments, England) filled with 4 M sodium chloride, in contact
with a silver chloride coated silver wire. The holders were inserted into unity gain
head stages (current gain x 0.1 or x 1.0: Axon Instruments, CA, USA) and connected
to an Axoclamp-2B amplifier through the microelectrode 1 (ME1) port for use in
"bridge balance" or "discontinuous current clamp" (DCC) modes. A silver-silver
chloride bath reference electrode, submerged in the recording chamber, was also
connected to the head stage and grounded through the Axoclamp amplifier.
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2.3.2. IntracellularRecording
Impalement ofCA1 pyramidal neurones was achieved by manually advancing the
recording microelectrode through the slice using the hydraulic vertical axis
manipulator, and intermittently applying a 1-2 ms "buzz" on the Axoclamp-2B.
"Buzzing" momentarily increases the capacitance neutralization of the electrode and
causes the headstage to oscillate at high frequency. This procedure aids penetration
of cells when the electrode is opposed to the cell membrane although the mechanism
by which this occurs is unclear. Cell impalement was routinely performed in normal
ACSF and only after a stable recording was obtained for at least 10 min were drugs
administered.
The membrane potential (Vm) of the neurone (as measured by the Axoclamp 2B
amplifier) was measured as the potential difference between the microelectrode and
the bath reference electrode. Prior to searching for cells, when the microelectrode
had been positioned extracellularly in the slice, Vm was set to zero. Immediately
following the end of each experiment this reading was checked again and any
correction in the recorded membrane potential made.
2.3.3. Current Injection
Before searching for cells the resistance of the microelectrode was measured in
bridge balance mode. This was done by balancing out the unwanted potential drop
across the microelectrode resistance through a differential amplifier incorporated in
the Axoclamp 2B amplifier (Fig. 2.2). The mode of recording was then switched to
discontinuous current clamp mode which allowed rapid switching (frequency 3-5
kHz) between current injection and voltage recording. Thus, current was injected
during the first 30 % of the cycle and the resulting potential across the
microelectrode resistance due to charging continually monitored on an oscilloscope
(Fig. 2.2). The capacitance neutralization was increased so that when the cell Vm was
sampled, just prior to the next current injection, the potential across the
microelectrode tip had fully decayed (Fig 2.2). Low resistance microelectrodes (60-
90 MQ) allowed the most accurate recording of membrane potential during current
injection.
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Figure 2.2. Bridge balance and DCC recording.
A, is a schematic diagram of the voltage responses (V) to hyperpolarizing current steps (I) with
varying degrees of bridge balance applied. Note that when the resistance of the electrode is properly
balanced ("just right") there is no voltage error at the start of the current step but a capacitance
transient can be seen at this point. B, shows plots of the potentials (V) which develop across the
resistance of the electrode during injection of depolarizing current pulses (I) (switching frequency 3
kHz). Current is injected during the first part of the cycle and membrane potential is "sampled" at the
points indicated by the arrows. The dashed line represents the ideal capacitance compensation ("just
right"), while solid lines represent the voltage change when capacitance is over- or under¬
compensated. Note that during current injection the electrode capacitance "charges" and then
"discharges". The membrane potential is sampled just before the next current injection. As such,
errors (indicated by the arrows) can be introduced if the capacitance is under- or over-compensated
(indicated by the solid lines). C, shows an intracellular voltage (V) response from a CA1 pyramidal
neurone in response to a hyperpolarizing (negative) current step recorded in discontinuous current
clamp (DCC) mode. Note that the electrode capacitance has been completely compensated, such that
no capacitance transient is observed. Figures A and B are adapted from Halliwell & Whittaker (1987).
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2.3.4. Amplification and filtering
Synaptic potentials recorded through the ME1 port on the Axoclamp-2B amplifier
were amplified 10 fold by an in-built gain. In DCC mode the amplifier set the
sample rate (3-5 kHz switching frequency). Signals above 1-3 kHz were filtered,
using a low-pass filter, which did not noticeably affect the waveform of the synaptic
potentials. Secondary amplification of synaptic responses was provided by variable
gain DC amplifiers (Neurolog, Digitimer, England). The output signals were then
digitally filtered through a Digidata 1200 interface (Axon Instruments Ltd.)
connected to a Dell Dimension P75t IBM personal computer (PC) (Dell, Texas,
USA) (Fig. 2.3). Any further filtering was carried out during off-line analysis with
Clampfit software (Axon Instruments Ltd.).
2.3.5. Data display and storage
Digitized data were captured and simultaneously viewed using pClamp6 software
(Axon Instruments Ltd.) on the PC. Digitized records were stored on the hard disk of
the PC for off-line analysis using Clampfit software (Axon Instruments Ltd.). The
potential across the microelectrode in discontinuous current clamp mode was
monitored on an analogue oscilloscope (Phillips, Holland). A continuous chart
record or digital tape (DAT) record of the membrane potential of the cell was
captured by a chart recorder (Gould, Ilford, Essex, UK) or DAT recorder (DTR1404,
Biologic Scientific Instruments, Claix, France). This provided a means to assess the
passive stability of the cell throughout each experiment.
2.3.6. Extracellular recording
Extracellular field potential recordings from the apical dendritic layer were made
with respect to the reference electrode (Fig. 2.4). Data were displayed and stored in a
similar manner to that used for intracellular recording. In experiments investigating
the effect of drugs on the slope of the field EPSP, the test field EPSP size was
adjusted to approximately 50 % ofmaximum.
2.4. STIMULATION
The septo-hippocampal cholinergic input or the Schaffer collateral-commissural fiber
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Figure 2.3. The recording set-up.
This figure shows a flow diagram of the experimental apparatus used for electrophysiological
recording. The direction of information transfer is represented by the direction of the arrows. The
dashed line represents the Faraday cage which surrounds the recording chamber and screens the
recording system from extraneous electrical noise. The stimulating electrode is represented by the
parallel lines attached to the stimulator and the recording electrode is represented by the open triangle
connected to the headstage. Data were displayed on the oscilloscope and VDU and stored on DAT
tape and on the hard drive of the PC. Abbreviations are, A-D converter: analogue to digital converter;
DAT recorder: digital data recorder; PC: personal computer; VDU: visual display unit.
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Figure 2.4. Electrode positioning for generation of synaptic responses in the rat
hippocampal slice.
Figures A-C, show the placement of stimulating (S) and recording (/?) electrodes in the hippocampal
slice (left hand panels) and the responses obtained using intracellular (A and B) and extracellular
recording (C) (right hand panels). A, shows the placement of a stimulating electrode in s. oriens (S) to
evoke a fast EPSP followed by an IPSP (mediated by glutamate and GABA respectively) measured
using an intracellular recording electrode (R) from a CA1 pyramidal neurone (Vm = -64 mV; see
section 1.6.1). A similar response can be obtained on stimulation of Schaffer collateral-commissural
fibers in s. radiatum (see Fig. 3.1). B, also shows placement of a electrodes in the same configuration
as in A, to evoke a slow mAChR-mediated EPSP (EPSPM; see chapter 3). C, shows placement of a
stimulating electrode (5) in .v. radiatum to evoke a field EPSP which is mediated by glutamate,
recorded using an extracellular field electrode (R) placed in the dendritic field ,v. radiatum.
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input to CA1 pyramidal neurones were orthodromically stimulated using bipolar
stimulating electrode(s) which were placed on the surface of the slice in stratum
radiatum and oriens respectively. The stimulating electrodes consisted of two 50 pm
diameter Formvar insulated nickel-chromium (80 %: 20 %) wires (Advent Research
Materials Ltd., England) twisted together and cut at the end to provide a focal
stimulation. Stimuli were produced by constant voltage or constant current isolated
stimulator boxes (Digitimer, England) in turn stimulated by a 5 V pulse produced by
the PC and relayed via the Digidata 1200. In every series of experiments stimuli
comprised square-wave pulses (20-200 ps; 0.1-30 V or 0.1-10 mA) delivered
homosynaptically at a fixed intensity every 15 s for ionotropic glutamate and GABA
receptor-mediated responses and every 5-10 min for mAChR-mediated responses.
2.5. SLICE AND CELL SELECTION CRITERIA
For both intra- and extra-cellular recordings slices were chosen that evoked only a
single population spike to a low frequency stimulus (0.033 Hz) in standard ACSF.
This was taken as an indicator for healthy synaptic inhibition. For intracellular
recordings the input resistance of the cell was greater than 30 MQ measured as
described in section 2.6 below. Action potentials overshot 0 mV and the cells
exhibited some degree of SFA (an accommodation of action potential firing when a
positive current step e.g. + 0.3-0.5 nA, 300ms was applied to the cell). In all
experiments care was taken that both the recorded response and the passive
membrane properties of intracellularly recorded neurones were stable for a period of
10-15 min before any physiological or pharmacological protocol was employed.
2.6. EXPERIMENTAL DESIGN
During the period between stimuli the input resistance and the extent of SFA of each
neurone were measured routinely using 300-600 ms long negative and positive
current steps (± 0.1-0.4 nA), respectively. In all experiments in which EPSPMs (Fig.
2.4), or sub-threshold stimulation induced reductions in SFA, were evoked, baseline
recordings comprised either successive EPSPs which had peak amplitudes that
differed by no more than 15 %, or reductions in SFA, that were consistent over 20-
30 min, respectively. In all experiments where the effects of drugs on Vm were
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assessed, stable baseline recordings, where the Vm and input resistance of the cell
varied no more than 1 mV and 10 % respectively over a period of 10-30 min, were
obtained prior to application of the drug.
In other experiments where it was required to compare the EPSPs evoked in the
presence and absence of a drug at the same Vm, DC was injected through the
electrode to compensate for any drug-induced changes in membrane potential.
2.7. ANALYSIS OF DATA
Analysis of intracellularly recorded responses usually comprised the measurement of
the peak amplitude or the slope of the rising phase of the recorded response
(extracellular field-EPSPs). The synaptic responses analyzed were averages of four
successive responses in the case of ionotropic glutamate and GABA receptor-
mediated responses or single responses in the case ofmAChR-mediated responses.
Average responses were used to reduce noise and mean the effects of biological
variation.
The data-handling software package Sigmaplot (Version 2.01; Jandel Scientific,
USA) was run on an IBM PC (Dell) and was used to generate single plots and plots
ofmeans. Pooled data are presented as means ± standard error of the mean (S.E.M.)
and statistical significance was assessed using a paired or unpaired Students /-test
performed on raw data with P < 0.05 being taken as indicating statistical
significance, n values refer to the number of times a particular experiment was
performed, each in a different slice taken from a different rat.
Where concentration-response data has been illustrated and curve fitting used, data
(Y) were fitted to the logistic expression: Y=M(X^/[X^ + K^]); where Xis the
concentration ofCADO, M the maximum effect, K is the IC50 or EC50 value and the
power P determines the slope of the curve.
2.8. BIOCYTIN STAINING
When depolarising current pulses were employed, intracellular diffusion of biocytin
from the electrode resulted in adequate filling of the recorded neurones. Following
recording, slices were sandwiched between two Millipore filters and fixed in 2.5 %
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paraformaldehyde, 1.25 % glutaraldehyde and 15 % (v/v) picric acid in 0.1 M
phosphate buffer (PB; pH 7.4), usually overnight. After fixation, the tissue was
rinsed in phosphate buffer and infiltrated with 10 % and then 20 % sucrose solution.
To increase the penetration of the reagents, slices were snap-frozen in liquid nitrogen
and thawed in phosphate buffer. Slices were then embedded in 10 % gelatine which
was placed in the same fixation solution for approximately one hour or until the
block was sufficiently hard for cutting. Taking care to keep the block flat, slices
were re-sectioned on a vibratome at 50-60 pm thickness. After three 10 min washes
in phosphate buffer and two 10 min washes in Tris-buffered saline (TBS; 0.05 M, pH
7.4), the sections were incubated overnight at 4 °C with 1 % avidin-biotinylated
horseradish preoxidase complex (ABC, Vector laboratories). Excess ABC was
removed by three 20 min washes in TBS and two 20 min washes in Tris-buffer (pH
7.6). Sections were then developed for 10-15 min in Tris-buffer with 0.05 % 3,3'-
diaminobenzidine tetrahydrochloride (DAB) and 0.01 % hydrogen peroxide. After
excess DAB was removed with further washes in tris-buffer (1x15 minutes) and
phosphate buffer (2x10 minutes), sections were postfixed for 1 hour with 1 %
osmium tetroxide in phosphate buffer. Following one 10 min rinse in phosphate
buffer followed by three 10 min washes in distilled water, slices were block-stained
for 40 min in a filtered 1 % aqueous solution of uranyl acetate. Sections were then
washed in distilled water (2x10 min) before being dehydrated between coverslips in
an ascending series of ethanol solutions (50 %, 70 %, 95 %, 100 % x 2; 10 minutes in
each). From the second absolute alcohol step, sections were transferred to propylene
oxide (2 x 10-minutes). Material was then infiltrated overnight in Durcupan resin
(Fluka) before being mounted onto glass slides and transferred to an oven (56 °C, 48
h) to allow the resin to resin polymerise.
2.9. DRUGS
Drugs were stored frozen in stock aliquots (100 pi to 5 ml) of 100 to 10000 times
final concentration and dissolved in ACSF, deionised water, 25 mM NaOFl or
ethanol. All drugs were added to the control ACSF and administered by bath
perfusion for at least 15 min to allow their full equilibration within the slice.
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Adenosine, atropine, baclofen, diphenylmethanone, 8-bromoadenosine 3,5-cyclic
monophosphate (8-Br cAMP), 2-chloroadenosine (CADO), carbachol (CCh), 2-
chloro-A^-cyclopentyladenosine (CCPA), nitrendipine, physostigmine, picrotoxin
and 7?(-)A6-(2-phenylisopropyl) adenosine (R-PIA) were purchased from Sigma
(Poole, UK). 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX), dipyridamole (DPY),
6-nitro-7-sulphamoylbenzo[/]quinoxaline-2,3-dione (NBQX) were purchased from
Tocris Cookson Ltd. (Bristol, UK). D-2-Amino-5-phosphonopentanoate (AP5), 2-p-
(2-carboxyethyl)phenethylamino-5'-A-ethylcarboxamidoadenosine (CGS 21680), 8-
cyclopentyl-l,3-dipropylxanthine (DPCPX), 5-iodotubercidin (5-IT), (+)-a-methyl-
4-carboxyphenylglycine ((+)-MCPG) and nitrendipine were purchased from
Research Biochemicals International (MA, USA).
D-(JE)-2-Amino-4-methyl-5-phosphono-3-pentanoic acid (CGP 40116), /?-[3-
aminopropyl]-/?-diethoxymethylphosphinic acid (CGP 35348) and [l-(S)-3,4-
dichlorophenyl)ethyl]amino-2-(S)-hydroxypropyl-p-benzyl-phosphonic acid (CGP
55845A) were gifts from Ciba-Geigy Ltd. (now Novartis; Basle, Switzerland).
Diphenylmethanone, 0-[2-(3-carboxy-1,2,5,6-tetrahydro-1 -pyridinyl)ethyl]oxime
hydrochloride (NNC 05-0711) was a gift from Novo Nordisk, Denmark. 11 -2[[2-
[(diethylamino)methyl]-l-piperidinyl]acetyl]-5,l l,-dihydro-6H-pyrido[2,3b]




ACTIVATION OF MUSCARINIC RECEPTOR-MEDIATED
SYNAPTIC RESPONSES IN THE RAT HIPPOCAMPUS IN VITRO
3.1. INTRODUCTION
As reported in the chapter 1, CA1 pyramidal neurones in the hippocampus receive an
extrinsic synaptic input from the medial septum known as the septohippocampal
input (Dutar et al. 1995). High frequency stimulation of this input, in addition to
activating multiple glutamatergic and GABAergic synaptic responses, has been
shown to activate a slow excitatory postsynaptic potential (slow EPSP) and to reduce
SFA via mAChR-mediated inhibition of IK(LEAK) and IAHP respectively (Cole & Nicoll,
1983; Cole & Nicoll, 1984a; Madison et al. 1987; Segal, 1988; Pitler & Alger, 1990).
The prolonged excitation produced by synaptic activation ofmAChRs on CA1
pyramidal neurones, if left unregulated, could be detrimental to these cells and may
result in epileptogenesis (Lothman et al. 1991; Wasterlain et al. 1993). In addition,
the ability of ACh to modulate postsynaptic action potential firing properties may
underlie cholinergic effects on learning and memory function (Cole & Nicoll, 1984a;
Figenschou et al. 1996). As such, understanding of such responses may be of some
importance with regard to diseases where memory and cholinergic systems are
affected such as Alzheimer's disease (Giacobini, 1990; Fibiger, 1991; Thai, 1996).
The initial aim of this chapter was to extend the scope of previous studies by
developing a simple method with which to evoke reproducible cholinergic synaptic
responses which were pharmacologically isolated from other "fast" excitatory and
inhibitory synaptic responses. In addition, this chapter presents a pharmacological
profde of synaptic responses evoked by stimulation in s. oriens. Where possible data
is presented to demonstrate preliminary evidence for previously unreported responses
to synaptic activation of cholinergic afferents.
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3.2. RESULTS
3.2.1. General Properties of CA1 Pyramidal Neurones
Recordings in this and subsequent chapters were made from CA1 pyramidal
neurones (Fig. 3.1B) in the rat hippocampus and, unless otherwise stated, were made
using the intracellular recording techniques described in chapter 2. These neurones
had a mean recorded input resistance of 50.8 ± 0.2 MQ and a mean resting Vm of -59
± 1 mV (n = 29). Typical cellular responses to positive and negative current steps
evoked in these neurones are illustrated in figure 3.1 C.
3.2.2. Amino Acid Receptor-Mediated Responses
Single shock stimulation applied in stratum radiatum or stratum oriens (Fig. 3. IX)
evoked an EPSP that was followed by an IPSP (Fig. 3.ID). It was possible to isolate
each component of the EPSP and IPSP using different combinations ofAMPA,
NMDA, GABAa and GABAB-receptor antagonists (Fig. 3.2B-E). As illustrated in
Table 3.1 and Figure 3.2 the response was made up of a fast EPSPA (Fig. 3.2B) which
was followed by a slower EPSPN (Fig. 3.2C) which was normally masked by a fast
IPSPA (Fig. 3.2D) and a slower IPSPB (Fig. 3.2E). The AMPA and NMDA receptor-
mediated responses were inhibited by NBQX and CGP 40116, respectively, and the
GABAa and GABAb receptor mediated responses were inhibited by picrotoxin and
CGP 55845A, respectively (Fig. 3.2 & Table 3.1).
Table 3.1. Antagonists used to inhibit ionotropic glutamate and GABA receptor-
mediated responses.
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Figure 3.1. Characteristics of the passive membrane properties of CA1 pyramidal neurones and
responses to stimulation of stratum radiatum and stratum oriens.
A, shows a schematic diagram of a rat hippocampal slice to illustrate the positioning of recording (R)
and stimulating (SI & S2) electrodes required to evoke the synaptic responses in D. B, is a light
micrograph of a rat hippocampal CA1 pyramidal neurone stained by intracellular biocytin injection.
C, shows voltage responses (upper traces) and current applied (lower traces) for negative (a) and
positive (b) 0.3 nA current steps which result in hyperpolarizing (a) and depolarizing (b) voltage
responses. Note that in Cb the cell depolarized to a potential where action potentials were evoked and
that the frequency of action potential (spike) firing adapted with time (spike frequency adaptation).
Ca, is an average of four successive records taken at the same membrane potential and Cb, is a single
trace. The membrane potential of this neurone was -67 mV. D, shows intracellular recordings from a
CA1 neurone in response to just suprathreshold single shock stimulation in the s. oriens (a) and s.
radiatum (b). Note that a fast EPSP is followed by an IPSP in both responses. In this and subsequent
figures, filled triangles below each synaptic trace indicate the time of afferent stimulation. The
membrane potential of this neurone was -65 mV. In D, traces are averages of two records taken at the
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Figure 3.2. NBQX, CGP 40116, picrotoxin and CGP 55845A inhibit isolated AMPA, NMDA,
GABAa and GABA„ receptor-mediated synaptic responses, respectively.
Aa, shows superimposed intracellular recordings of responses to single shock stimulation of s. oriens.
Note that in control medium (control), following the stimulus, a fast EPSP is followed by an IPSP and
following the addition ofNBQX (2 pM), CGP 40116 (50 pM), picrotoxin (50 pM) and CGP 55845A
(1 pM) this response was abolished (+ Antagonists). Ab, plots the peak amplitudes of the successive
EPSPs and IPSPs expressed as a percentage of the mean amplitude in control medium against time for
a single experiment. The bar indicates the time during which the four antagonists listed in A were
applied. The membrane potential of this neurone was -64 mV. B-E (left hand recordings), show
recordings of isolated EPSPA (B) EPSPN (C), IPSPA (D) and lPSPBs (E) (isolated using appropriate
combinations of ionotropic glutamate and GABA receptor antagonists). The right had recordings in
B-E (+ antagonist) show responses evoked in the additional presence of 2 pM NBQX (B), 50 pM
CGP 40116 (C), 50 pM picrotoxin (£>) or 1 pM CGP 55845A (£). Note that NBQX, CGP40116,
picrotoxin and CGP 55845A completely inhibited the isolated EPSP/IPSPs. Also, note that, for
illustrative purposes, different time scales were used for D and E. The membrane potentials for these
neurones were -70 mV (B), -65 mV (C), -64 mV (D) and -64 mV (£).
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Table 3.2 shows a summary of the kinetics of these responses. All components of
this multi-component response were abolished by the combined application of these
four antagonists (Fig. 3.2A). Table 3.1 summarizes the concentrations of antagonists
used and the receptors and responses that are sensitive to each antagonist.
3.2.3. Stimulation Evoked Slow EPSPs
Increasing the stimulus intensity to 2-10 fold that which evoked a fast EPSP/IPSP
evoked a much slower EPSP in 136 out of 139 neurones in which this was attempted
(Fig. 3.3Aa). In a random group of neurones slow EPSPs which had a mean
amplitude of 7.7 ± 0.4 mV had a time to peak of 2.1 ±0.1 s and an overall duration
of 24.3 ± 2.3 s (n = 29; Table 3.2 and Fig. 3.3A). The peak amplitude and duration of
the EPSP were highly dependent upon the stimulus strength used and both
parameters increased with increasing stimulus intensity (Fig. 3.3Bb). The EPSP
often resulted in intense discharges of action potentials and in some neurones the
EPSP depolarized the membrane beyond the action potential firing threshold to a
region in which action potential generation was inactivated (Fig. 3.3B).
In order to investigate the effects of pharmacological compounds on the slow EPSP,
it was necessary to decide on an optimum stimulation frequency for evoking this
response. If two stimuli were applied to the stratum oriens (s. oriens) separated by 2
min, the response to the second stimulus was reduced in amplitude in 9 out of 14
cells (Fig. 3.4/1 and 3.5Q. In contrast, if an interstimulus interval of 5-8 min was
used, there was no significant reduction in the amplitude of the second response (Fig.
3.45 and 3.5D). In this respect, it was possible to obtain reproducible slow EPSPs at
this stimulation frequency (Fig. 3 AC). As such, this protocol was used routinely in
all experiments investigating the effects of drugs on the slow EPSP.
It seemed possible that a large first response might cause a greater depression of the
second response due to an over-activation of the system, leading to, for example, a
depletion of transmitter. However, further investigation of the depression of the
EPSP revealed no clear correlation between the amplitude of the first response and
the percentage depression of the second response although there was a tendency for


























Figure 3.3. The time course and stimulus dependent properties of the slow EPSP.
Aa, is an intracellular recording of a response to a single stimulus of the s. oriens. Ab, is a plot of the
time course of the slow EPSP using values generated from pooled data from 29 cells as listed in Table
3.2. The x coordinate plots the mean time points at which the start, peak, 50% recovery and 70 %
recovery of the response occur. The y coordinate uses the mean holding potential of the 29 neurones
as the baseline membrane potential and the mean amplitudes of the residual IPSP and slow EPSP.
Values are means ± S.E.M. represented by the error bars. In Ba, the traces are single sweeps, which
illustrate the stimulus-dependent activation of a slow EPSP in the presence of the four amino acid
receptor antagonists. The stimulus intensities used to evoke the responses from left to right were 1.8,
2.3 and 4.0 mA respectively. Action potentials are truncated due to the low sampling rate used to
capture the entire slow EPSP. The membrane potential of this neurone was -64 mV. Bb, shows a
graph in which the stimulus intensity (in mA) is plotted against the amplitude of the resulting slow
EPSP in mV. In this and subsequent figures, unless stated otherwise, traces are individual synaptic
responses recorded intracellularly in response to a single stimulus delivered in the 5. oriens in the
presence of 1-2 pM NBQX, 50 pM CGP 40116, 50 pM picrotoxin and 1 pM CGP 55845A. Each
sweep was taken at the same membrane potential achieved using DC injection to compensate for any












Figure 3.4. Depression of the slow EPSP with interstimulus intervals of less than 8 min.
/4, shows two successive synaptic responses evoked by a single stimulus with an interstimulus interval
of 120 s. Note that the second response is reduced in amplitude. The membrane potential of this
neurone was -64 mV. B, is a bar graph representing the amplitude of a second EPSP when an
interstimulus interval of 30, 60, 120 and 480 s was used. The amplitude of the second response is
expressed as a percentage of the control response. Note that when an interstimulus interval of 30, 60
and 120 s was used, the amplitude of the second EPSP was depressed. In contrast, when an
interstimulus interval of 480 s was used, there was no significant depression of the amplitude of the
second response. C, shows six successive synaptic responses to single stimuli applied with an
interstimulus interval of 480 s. Note that there is no clear depression of the amplitude of the EPSP
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Figure 3.5. Relationship between the amount of depression of the slow EPSP with the amplitude
of the first response with different interstimulus intervals.
Graphs A-D, plot the amplitude of a control (1st) EPSP on the abscissa with the percentage
depression/potentiation of a second (2nd) response evoked following an interstimulus interval of 30 s
(A), 60 s (B), 120 s (C) and 480 s (D). In A-D, the dashed line represents 100 % and the dotted line
represents a regression line. Note that there was no clear correlation between the amplitude of the
first response and the amount of depression of the second response at intervals of 30, 60 and 120 s (A,
B and C) although there is a trend towards greater depression at larger amplitudes of the first
response. Also note that at an interstimulus interval of 480 s (£>) there was no depression of the
second response. Each point, in one particular graph, represents responses evoked in a different
neurone.
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As mentioned above, in a small proportion of neurones, there was little or no
depression of the slow EPSP when the cell was stimulated every 30-120 s (Fig.
3.5A-Q.
Table 3.2 Kinetics of synaptic responses.
Response Time to peak Duration n
epspm 2.1 ±0.1 s 24.3 ± 2.3 s n = 29
epspa 10.3 ± 0.8 ms 72.2 ± 3.0 ms n = 5
ipspa* 18 ± 1 ms 227 ± 3 ms n = 3*
ipspb* 141 ± 3 ms 824 ± 153 ms n — 7*
* Data provided by C. H. Davies.
3.2.4. Pharmacology of the Slow EPSP
The effects of the AChR agonist CCh were compared with the effects of stimulation
of the .s\ oriens. CCh (3 pM), when bath applied for 30-60 s, caused a depolarization
which lasted a matter ofminutes and was reversed following washout {n = 7; Fig.
3.6A). This CCh-induced depolarization was associated with an increase in input
resistance as calculated from the membrane voltage responses to negative current
steps recorded at the same membrane potential (Fig. 3.6A). In a similar manner, the
slow EPSP was associated with an increase in input resistance (n = 3; Fig. 3.6/i).
As illustrated in Fig. 3.7, the slow EPSP was not affected significantly by the
metabotropic glutamate receptor (mGluR) antagonist (+)-MCPG (1000 pM, n — 3,
Fig. 3.7A). Addition of the acetylcholinesterase (AChE) inhibitor physostigmine (1-
5 pM), however, caused a large enhancement of both the peak amplitude and
duration of the slow EPSP (n = 5; Fig. 3.7B&C). In contrast, the mAChR
antagonists atropine (2-5 pM) and AFDX 116(1 pM) abolished or reduced the slow
EPSP (n = 7 & n = 5; Fig. 3.8). In three cells, atropine (2-5 pM) was also effective
at inhibiting responses evoked in the presence of physostigmine (1-5 pM), such that
responses in the combined presence of physostigmine and atropine were 10.1 ±8.1 %
ofmean control responses in the presence of physostigmine alone (data not shown).
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Figure 3.6. A comparison of the effects of carbachol and cholinergic afferent stimulation.
A, shows the effect of carbachol (CCh; 3 pM) on the membrane potential and input resistance of a
neurone. The trace is a chart record of membrane potential and cell input resistance. DC injection
was kept constant except when the increase in input resistance evoked by CCh was measured at the
time point indicated by the arrow. The bar above the chart record represents the time for which CCh
was applied. The initial membrane potential of this neurone was -64 mV. Ab, shows a comparison of
the hyperpolarizing responses in control (Ctrl.) and following application of CCh on an expanded
time scale. The input resistance was measured from this change in membrane potential in response to
hyperpolarizing current steps of -0.3 nA applied for 0.2 s every 2.0 s. In Ba the cell membrane
potential was manually clamped at -59 mV before an EPSPM was evoked so that the voltage response
to the hyperpolarizing current steps could be compared with that evoked at the peak of the EPSPM
(also at a Vm of -59 mV). Bb, shows a comparison of these responses on an expanded time scale. The
current injected into the cell is shown below the voltage traces. The initial membrane potential of this
cell was -64 mV. The filled triangles below each synaptic trace indicate the time of afferent
stimulation. Note that both CCh and stimulation of the s. oriens caused a depolarization and increase
in input resistance.
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Figure 3.7. The effects of (+)-MCPG and physostigmine on the slow EPSP.
In A, and B synaptic traces are single sweeps illustrating the effects of 1000 pM (+)-MCPG (A) and 2
pM physostigmine (5) on slow EPSPs evoked in two separate neurones. The membrane potentials of
these cells were -63 mV and -64 mV respectively. C, is a bar graph in which the pooled data for the
peak amplitude of EPSPMs recorded after 15-30 minutes in the presence of either (+)-MCPG (1000
pM; n = 3) or physostigmine (2 pM; n = 3) is expressed as a percentage of the mean value of the
control EPSPms recorded over a 20-30 nrin baseline period prior to each drug application. Values are
means ± S.E.M. such that 100 % is equivalent to no change. Note that whilst (+)-MCPG had no
significant effect on the slow EPSP (P > 0.05) physostigmine significantly enhanced the slow EPSP
(P < 0.05). In this and all subsequent figures statistical significance is represented by an asterisk and
n.s. represents values that were not significantly different from control values (P > 0.05).
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Figure 3.8. The effects of atropine and AFDX 116 on the slow EPSP.
In A, and B traces are single sweeps illustrating the effects of 2 pM atropine (A) and 1 pM AFDX 116
(B) on slow EPSPs evoked in two separate neurones. The membrane potentials of these cells were -
63 and -64 mV, respectively. C, is a bar graph in which the pooled data for the peak amplitude of
EPSPMs recorded after 15-30 minutes in the presence of either 2 pM atropine (n = 3) or 1 pM AFDX
116 (n = 3) is expressed as a percentage of the mean value of the control EPSPMs recorded over a 20-
30 min baseline period prior to each drug application. Values are means ± S.E.M. such that 100 % is
equivalent to no change. Note that atropine significantly depressed EPSPMs (P < 0.05) and AFDX
116 depressed the slow EPSP by approximately 50 %, although this was not statistically significant (P
> 0.05).
63
These results are entirely consistent with the slow EPSP being mediated by activation
ofmAChRs and, as such, this slow EPSP will be referred to as a mAChR-mediated
EPSP (EPSPm).
Cholinergic (and GABAergic) systems have been linked to the synchronization of 0-
frequency oscillations in the hippocampus (Stewart & Fox, 1990). In some cells, the
response to CCh depolarized the cell past the firing threshold for action potential
generation, causing the cell to fire action potentials at a mean frequency of4-8 Hz
(Fig. 3.9^4). Interestingly, analysis of the decaying phase of EPSPMs also showed
membrane potential oscillations in the frequency range of 4-8 Hz (Fig. 3.9B).
3.2.5. Inhibition of Spike Frequency Adaptation
Physostigmine (1 pM), as well as causing an increase in the amplitude of the EPSPM,
also caused a reduction in SFA as measured by the number of action potentials
(spikes) fired in response to a 300 ms long +0.15-0.30 nA current step (n = 6; Fig.
3.10A&C). This effect presumably occurred as a result of raising extracellular levels
of spontaneously released ACh due to inhibition of AChE activity by physostigmine
(Cole & Nicoll, 1984a; Azouz et al. 1994). A similar inhibition of SFA has been
reported on stimulation of the s. oriens with 10 stimuli at 100 Hz in the presence of
physostigmine (Cole & Nicoll, 1984a). Here, stimulation of the s. oriens with a
single stimulus at an intensity subthreshold for evoking an EPSPM, and in the absence
of physostigmine, also resulted in an inhibition of SFA (Fig. 3.105). As such, in 7
cells, there was a significant increase in the number of spikes fired in response to a
depolarizing step applied 2 s after a stimulus (post-stimulus) when compared with a
step applied 2 s before the stimulus (pre-stimulus) (P < 0.05; students t-test; Fig.
3.10£)). In contrast, when two steps were applied in the absence of a stimulus, there
was no significant difference in the number of spikes fired during the first or second












Figure 3.9. A comparison of the membrane oscillations produced by muscarinic receptor
activation by CCh and cholinergic afferent stimulation.
A, shows the effect of carbachol (CCh; 3 pM) on the membrane potential and input resistance of a
neurone. The trace is a chart record of membrane potential and cell input resistance. DC injection
was kept constant except when the increase in input resistance evoked by CCh was measured. The
bar above the chart record represents the time for which CCh was applied. The initial membrane
potential of this neurone was -64 mV. Ab, shows an expanded time scale of the same response from
the time point indicated by the line below Aa. Note that, in the presence of CCh, the neurone fires
regularly at a rate of approximately 4 Hz. Ba is a EPSPM, evoked using a single stimulus as
previously described. Bb, shows an expanded time scale of the same response from the time point
indicated by the line below Bb. Note that, in the during the falling phase of the EPSPM, the neurone
fires, and later oscillates regularly at a rate of approximately 6 Hz. The membrane potential of this
cell was -64 mV. Note that both CCh and stimulation of the s. oriens caused a depolarization and
induced repetitive firing/oscillations in the frequency range 4-8 Hz.
65


























Control Physo. Control With
Stimulus
Figure 3.10. Inhibition of spike frequency adaptation by endogenous ACh.
A, shows responses evoked by a depolarizing current step (+0.15 nA, 400 ms) in control medium and
in the presence of physostigmine (1 pM). The membrane potential of the cell was maintained at -63
mV throughout this experiment by injecting DC through the recording electrode. In B, traces are
continuous records of the membrane potential of a single cell in which depolarizing current steps
(+0.15 nA, 1000 ms) were delivered twice at fixed time points without (a) and with a stimulus (b)
applied at the time point indicated by the filled triangle. The stimulation was delivered at an intensity
just subthreshold for activating an EPSPM. The responses were obtained in medium containing the
four ionotropic glutamate and GABA receptor antagonists. The membrane potential of the neurone
was -64 mV. The bar graph in C, shows pooled data for the effect of physostigmine (1 pM; n = 4).
The mean number of spikes fired in response to depolarizing current steps are plotted in control
medium and in the presence of physostigmine. Note that there was a significant increase in the
number of spikes fired in the presence of physostigmine. The bar graph in D, shows pooled data (n =
7) for the number of spikes fired during two current steps (1st and 2nd) like those represented in B,
with no intervening stimulus (Control) and with an intervening stimulus (With Stimulus). Note that
there was no significant difference between the number of spikes fired in response to the first and
second step in control (P > 0.05) but there was a significant increase when a stimulus was applied (P
< 0.05). Both physostigmine and cholinergic afferent stimulation reduced SFA.
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3.2.6. Pharmacology of Stimulation Evoked Inhibition of Spike
Frequency Adaptation
The pharmacology of the receptor mediating this inhibition of SFA was also
investigated. To do this CCh (0.5 pM) was used as, when applied to the perfusing
ACSF, it also caused an inhibition of SFA which was subsequently reversed
following washout {n = 4; Fig. 3.11B&D). This CCh-induced inhibition of SFA was
inhibited by atropine (1 pM; n = 2; data not shown); results that are consistent with
previous studies using both CCh and ACh as agonists (Ben Ari et al. 1981, Cole &
Nicoll, 1983; 1984; Azouz et al. 1994).
Likewise, inhibition of SFA evoked by pathway stimulation, in the presence of
ionotropic glutamate and GABA receptor antagonists, was inhibited by the mAChR
antagonist atropine (1 pM). As such, in the presence of the antagonist there was no
significant difference in the number of spikes fired pre- and post-stimulus (« = 3; P>
0.05, students t-test; Fig 3.11A). Taken together with the results using agonist
application, these results are consistent with action ofmAChRs to inhibit SFA and
furthermore that synaptically released ACh is capable of reproducing this effect in
the absence ofAChE inhibitors.
3.2.7. Action Potential Amplitude and Duration
Stimulation ofmAChRs by CCh prolongs the duration and reduces the amplitude of
action potentials in the hippocampus (Figenschou et al. 1996). Therefore, a
preliminary study was carried out to investigate the effect of cholinergic afferent
stimulation in s. oriens on action potential amplitude and duration. In two neurones,
single action potentials were evoked by applying 50 ms depolarizing current steps to
the neurone every 1 s and the resulting action potentials compared before and after
stimulation in 5. oriens. In one neurone, a 3 mA stimulus did not alter the shape of
action potentials evoked following the stimulus. Flowever, at a stimulus intensity of
3.5 mA the duration of the action potentials following stimulation was consistently
greater than the mean duration before the stimulus (Fig. 3.12). The amplitude of the
action potential was not altered.
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Figure 3.11. A comparison of the effects of carbachol and cholinergic afferent stimulation on
spike frequency adaptation.
A, shows, from left to right, responses evoked by a depolarizing current step (+0.2 nA, 400 ms) in
control medium, in the presence of CCh (0.5 pM) and following washout. The membrane potential of
the neurone was maintained at -66 mV throughout this experiment as described in Figure 3.3. In B,
traces are generated as described in Figure 3.10 but using 0.2 nA steps. The responses were obtained
in medium containing the four ionotropic glutamate and GABA receptor antagonists (a) and in the
additional presence of 1 pM atropine (b). The point of pathway stimulation occurs during the break
in each ofBa and Bb. Note that in control medium, SFA was reduced following pathway stimulation
(Ba) and this reduction was abolished by atropine (Bb). The membrane potential of the neurone was
maintained at -65 mV throughout this experiment. In A and B, current applied is represented below
each voltage trace. The bar graph in C, shows pooled data for the effect of CCh (0.5 pM; n = 3). The
mean number of spikes fired in response to a depolarizing current step is plotted in control medium
(Ctrl.) in the presence of CCh (0.5 pM) and following washout (Wash). Note that CCh significantly
increased the number of spikes fired (P < 0.05) and that the number of spikes fired following washout
ofCCh was not significantly different from those fired in control (P > 0.05). The bar graph in D,
shows pooled data (n = 4) for the number of spikes fired in response to current steps evoked before
(Pre) and following a stimulus (Post) in control medium and following the addition of atropine (1
pM). Note there was a significant increase in the number of spikes fired in control (P < 0.05) but
there was no significant increase in the presence of atropine (P > 0.05).
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Figure 3.12. The effects of cholinergic afferent stimulation on action potential kinetics.
In A & B, synaptic traces are action potentials evoked by 50 ms positive current steps before (Control)
and following a single stimulus of the s. oriens (Post-stimulus). In A, a stimulus of 3.0 mA was
applied and in B, a stimulus of 3.5 mA was applied. In Aa and Ba, control action potentials are means
of the 4 action potentials evoked prior to the stimulus and Post-stimulus action potentials are the
means of 4 action potentials evoked following the stimulus. In Ab and Bb, controls are the same as
the means in Aa and Ba, but individual post-stimulus action potentials are plotted to show the
consistency of any change in the shape of the action potential. Note that in A, at the lower stimulus
intensity there was no obvious change in the shape of action potentials evoked following the stimulus.
In contrast, in B, at a slightly higher stimulus intensity there was a consistent lengthening in the
duration of the action potentials evoked following the stimulus.
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3.3. DISCUSSION
3.3.1. The Slow EPSP
Slow EPSPs mediated by mAChRs have been recorded previously from CA1
pyramidal neurones most commonly in response to high frequency bursts of stimuli
e.g. 20-100 Hz for 0.5-1.0 s (Cole & Nicoll, 1984a; Madison et al. 1987; Segal,
1988; Pitler & Alger, 1990; Potier et al. 1992; Azouz et al. 1994). These EPSPs
were often evoked in the presence ofAChE inhibitors, which elevate the effective
synaptic concentration of ACh. In addition, ionotropic glutamate and GABA
receptor antagonists were not added to the perfusing medium and, therefore,
mAChR-mediated EPSPs were superimposed on multiple glutamate- and GABA-
mediated synaptic potentials. Results presented in this chapter have shown that a
slow EPSP can be evoked by a single stimulus in the presence of ionotropic
glutamate and GABA receptor antagonists without the need for AChE inhibitors.
The waveform of this slow EPSP varied considerably between neurones but these
differences could not be readily correlated with differences in other
electrophysiological characteristics of the neurones in which they were recorded.
This slow EPSP was mediated by activation ofmAChRs since it was blocked by the
mAChR antagonists atropine and AFDX 116 and unaffected by the mGluR
antagonist (+)-MCPG. In addition, the slow EPSP and accompanying increase in
input resistance were mimicked by brief bath application of CCh. As such, the slow
EPSP can be defined as a mAChR-mediated EPSP (EPSPM). It is unclear, however,
which subtype ofmAChR mediates this EPSPM as the effects of only two antagonists
were tested. Pitler & Alger (1990) classified the mAChR underlying the mAChR-
mediated slow EPSP as an M3 receptor. In the study by Pitler & Alger (1990),
AFDX 116 inhibited slow EPSPs evoked by high frequency stimulation with an IC50
of 24 pM. In the present study, 10 pM AFDX 116 depressed EPSPMs by
approximately 50 %, although a full concentration response relationship was not
constructed to obtain an IC50. As such, AFDX 116 would appear to be slightly more
potent in the present study compared with the earlier study (Pitler & Alger, 1990).
This small difference may be explained by the different methods used to evoke the
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responses (i.e. the use ofmature male rats rather than young females, the absence of
amino acid antagonists or the use of high frequency trains of stimuli). A more
detailed analysis of the effects of a variety of mAChR antagonists will be required to
confirm the subtype ofmAChR underlying the EPSPM, although this may require the
development ofmore selective mAChR subtype-selective antagonists or transgenic
animals deficient in specific mAChR subtypes.
As shown in previous studies, both the EPSPM and the depolarizing response to CCh
were associated with an increase in input resistance (Cole & Nicoll, 1984a). This is
consistent with the EPSPM being mediated by an inhibition of a K+ leak current
(Weak)) (Fig- 3.13; Cole & Nicoll, 1984a; Madison et al. 1987).
One notable difference, however, between the EPSPM recorded in this study and slow
EPSPs recorded previously was its large magnitude, even when evoked using just a
single stimulus. The reason for this is unclear but it is possible that the ionotropic
glutamate and GABA receptor antagonists relieve an inhibitory influence on the
activation of this synaptic potential (See Chapter 6 for the effect of GABAb receptor
activation on EPSPMs). Alternatively, in some cells a number of voltage activated
conductances may boost the apparent magnitude of the EPSPM (Fraser & McVicar,
1996). Preliminary observations, however, suggest that this is not the case, as the
Ca++ channel antagonist nitrendipine does not significantly affect EPSPMs (data not
shown).
Slow EPSPs, evoked using high frequency stimulation, have been shown to be
reduced in aged animals compared to young animals (Potier et al. 1992). In this
respect, the age of the animals (2-5 weeks of age) may affect the expression of the
mAChR-mediated responses. In addition, M2 mAChRs are thought to mediate
presynaptic autoinhibition of ACh release. M2 mAChR densities and mAChR-
mediated inhibition of field recorded glutamate EPSPs in the hippocampus have been
shown to be reduced in animals younger than 5 weeks of age in comparison to adult
animals (> 5 weeks) (Aubert et al. 1996; Milburn & Prince, 1993). As such, large
magnitude of EPSPMs seen in this study may due to a lower level of autoinhibition in
the age of animals used compared to animals greater than 5 weeks of age.
71
Whatever the reason for the large amplitude of the EPSPMs, the response kinetics
were, in general, similar to those reported for slow EPSPs mediated by either
mAChRs (Cole & Nicoll, 1984a; Pitler & Alger, 1990) as well as pure spontaneous
and evoked mGluR-mediated EPSPs (Charpak & Gahwiler, 1991; Bianchi & Wong,
1995).
3.3.2. Fatigue of The Slow EPSP
A feature of the EPSPM that hampered the ease of its characterization was the ability
to evoke it reproducibly only every 5-10 min. As such, relatively long intracellular
impalements were required to obtain meaningful data. This contrasts with mGluR-
mediated EPSPs which can be evoked every 30-60 s (Gerber et al. 1993). The
reason(s) for the protracted fatigue of the EPSPM is unclear but by comparison with
previous studies it appears to be independent of the stimulation protocol used to
evoke it i.e. a high frequency train versus single stimulus (Cole & Nicoll, 1984a;
Pitler & Alger, 1990). Preliminary observations of the profile of depression suggests
that there is less depression of EPSPMs evoked 15-30 s after the previous response
than, for example, 60-120 s after the first response. This may suggest that there are
multiple mechanisms underlying the fatigue of the response. Indeed in some
neurones a depression was not observed even when a stimulus was reapplied 120 s
after the original stimulus. However, it is clear that this fatigue is not caused by
activation ofAMPA, kainate, NMDA, GABAa or GABAb receptors because these
experiments were carried out in the presence of antagonists of these receptors.
However, a modulation by some other released neuromodulator (such as adenosine;
see chapters 4 & 5) cannot be ruled out. Further experimentation will be required to
ascertain the extent to which, for example, desensitization, transmitter depletion or
shifts in ionic conductances might contribute to the depression.
Some EPSPms were followed by a pronounced hyperpolarization (1-3 mV) which
may have been due to activation of a Ca++ activated K+ conductance IK(Ca) by the
strong depolarization of the neurone beyond the threshold for action potential firing
(For review see Sah, 1996). The long duration of these hyperpolarizations (up to 6
min), however, suggests longer-term effects on cellular physiology. The amount of
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depression is not clearly proportional to the amplitude of the original response, at
least at amplitudes above 3 mV. This may suggest that it is merely the activation of
the EPSPm and not the amount of activation that underlies the fatiguing of the
EPSPm. It is not clear, however, whether mAChR-mediated inhibition of SFA is
subject to the same fatigue. Preliminary results suggest that it is possible to evoke an
inhibition of SFA reproducibly by stimulating at higher rates than those used to
evoke EPSPMs. This may reflect the much lower level of activation required to
evoke inhibition of SFA, which is insufficient to activate the mechanism underlying
the fatigue of EPSPMs.
A rapid desensitization of mAChR-mediated K+ current in atrial myocytes has been
reported and has been shown to be mediated predominantly through a G-protein-
dependent phosphorylation ofmAChRs (Shui et al. 1995). Relevant to the
hippocampus, it has recently been shown that in CA3 neurones, a G-protein-mediated
desensitization of a mAChR-mediated nonselective cation conductance can occur
(Guerineau et al. 1997). It remains to be elucidated whether desensitization of
mAChRs can account for the depression of EPSPMs during repetitive stimulation.
3.3.3. Stimulation Evoked Inhibition of Spike Frequency Adaptation
As with slow EPSPs evoked in previous studies (Cole & Nicoll, 1984a; Segal, 1988;
Azouz et al. 1994), stimulation that was sub-threshold for activating an EPSPM
caused a reduction in SFA. This effect was mimicked by the AChR agonist CCh, an
effect which is mediated by mAChRs (Cole & Nicoll, 1984a & 1984b; Azouz et al.
1994). That synaptically released ACh was acting at mAChRs to inhibition in SFA
was confirmed by the inhibition of this response by the mAChR antagonist atropine.
The stimulation-evoked inhibition of SFA has been shown to be mediated by an
inhibition of a Ca++ activated K+ current IAHP (Lancaster & Adams, 1986; Madison et
al. 1987). This current mediates the slow afterhyperpolarisation (AHP) which
follows a brief depolarization and is the main conductance responsible for the
process of SFA (Lancaster & Adams, 1986; see section 1.1.4.1.). As such, a single
stimulation of the 5. oriens, as well as activating a slow depolarizing EPSPM, which
is likely to be mediated by an inhibition of IK(LEAK), also inhibits SFA which is likely
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to be due to an inhibition of IAHP. Thus, inhibition of IAHP may contribute to the high
degree of action potential firing that accompanies activation of an EPSPM near firing
threshold.
3.3.4. Other Postsynaptic hiAChR-Mediated Effects
Recently, high concentrations of CCh have been shown to modulate action potentials
in hippocampal CA1 pyramidal neurones (Figenschou et al. 1996). Figenschou and
coworkers (1996) demonstrated that CCh increased the duration and, at higher
concentrations, reduced the amplitude of action potentials by activation ofmAChRs.
A broadening of action potentials in response to mAChR stimulation has also been
reported to occur in cultured hippocampal neurones (Nakajima et al. 1986).
Preliminary data presented in this chapter suggests that stimulation of .v. oriens
broadens action potentials evoked in CA1 pyramidal neurones, although no alteration
in the amplitude of the action potential was observed. Particularly high
concentrations of CCh were required to cause substantial changes reported in the
study by Figenschou and coworkers (1996). As such, it is possible that there was no
reduction in amplitude in the present study because there was not sufficient
activation of mAChRs. This may reflect a limited physiological relevance of this
effect. However, small changes in the depolarization produced by an action potential
are likely have important consequences in neuronal processing and synaptic
transmission, e.g. broadening of action potentials is likely to facilitate the entry of
Ca++ into neurones. Further investigation using atropine will be required to confirm
the observation that physiological activation ofmAChRs can broaden action
potentials and that this effect is mediated by mAChRs, however, it seems likely that
the septo-hippocampal cholinergic input can modulate action potentials evoked in
CA1 pyramidal neurones.
3.4. SUMMARY
Stimulation of cholinergic afferents in 5". oriens with a single stimulus in the presence
of ionotropic glutamate and GABA receptor antagonists can evoke reproducible slow
EPSPms in CA1 pyramidal neurones that are associated with an increase in input
resistance. In addition, under these conditions, stimulation in s. oriens, with a
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stimulus intensity sub-threshold for evoking an EPSPM, results in an inhibition of
SFA. Preliminary evidence also suggests that stimulation of cholinergic afferents
alters the shape of evoked action potentials. Both the EPSPM and stimulation-
induced inhibition of SFA are mediated by mAChRs, although the specific
subtype(s) mediating each response remain unclear. Finally, these responses mimic




ADENOSINE RECEPTOR-MEDIATED MODULATION OF
MUSCARINIC RECEPTOR-MEDIATED RESPONSES
4.1. INTRODUCTION
In the previous chapter I discussed how stimulation of the septohippocampal input
activates a slow excitatory postsynaptic potential (EPSPM) and also reduces SFA,
effects which are mediated via mAChR-mediated inhibition of K+ conductances
(Cole & Nicoll, 1983; Cole & Nicoll, 1984a; Madison et al. 1987). As with
glutamate receptor-mediated effects, such prolonged excitation of CA1 pyramidal
neurones, if left unregulated, could be detrimental to these cells and may result in
epileptogenesis (Lothman et al. 1991; Wasterlain et al. 1993). As such, mechanisms
that control the magnitude of the mAChR-mediated postsynaptic responses are likely
to be ofmajor importance in maintaining the normal functioning of the CNS.
A common mechanism of control of synaptic inputs within the brain is via activation
of different receptors to those that mediate the postsynaptic response, e.g. activation
of presynaptic heteroreceptors (Thompson et al. 1993). As such, the possibility that
a neurotransmitter/ neuromodulator other than ACh may restrict the activation of the
mAChR-mediated postsynaptic responses was investigated. Adenosine was chosen
because this neuromodulator plays an important role in controlling the excitability of
neuronal networks by inhibiting other excitatory synaptic inputs, e.g. glutamate
(Thompson et al. 1992; Thompson et al. 1993). Primarily this chapter will deal with
how drugs that affect the function of adenosine at the levels of the receptor and its
metabolism influence both the EPSPM and mAChR-mediated reduction in SFA. The
possibility that endogenous adenosine in the mammalian brain may tonically
modulate cholinergic excitability is also examined.
4.2. RESULTS
4.2.1. Effects of Adenosine ReceptorActivation on the EPSPm.
The non-hydrolyzable broad-spectrum adenosine receptor agonist CADO caused a
depression of the EPSPM that was maintained for the period of the agonist application
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(n = 19) and was reversed on washout (n = 3; Fig. 4.1). The effect ofCADO was
concentration-dependent and had an EC50 of 0.3 pM (Fig. 4.2). At 0.2 pM CADO
caused a substantial depression of the EPSPM with little or no effect on the
postsynaptic membrane potential, input resistance (Fig. 4.3) or SFA in response to a
depolarizing current step. In contrast, at concentrations of 0.5 pM and above, the
depressant action ofCADO on the EPSPMwas invariably accompanied by
postsynaptic hyperpolarization (up to 8 mV) and a reduction in input resistance (up
to 11 %) (See Fig. 5.1). In routine experiments this hyperpolarization was
compensated for by adjusting the current injection into the cell. The maximal effect
ofCADO on the EPSPM was 97 % inhibition. However, in one neurone the EPSPM
was unaffected by CADO. Similar results were obtained using adenosine itself.
Thus, at 100 pM, adenosine caused a hyperpolarization (Segal, 1982) and inhibited
the EPSPm by 78 ± 10 % (n = 3) (Fig. AAA).
4.2.2. Pharmacology of the Adenosine Receptor Mediating the
Depression of the EPSPm
To elucidate which adenosine receptor subtype was mediating the CADO-induced
depression of the EPSPM, the effects of a number of adenosine receptor subtype-
specific agonists were investigated. The selective A,R agonists CCPA (0.1-0.4 pM,
n = l\ Fig. AAB) and R-PIA (1 pM, n = 2; Fig. AAC) depressed the EPSPM and
caused postsynaptic hyperpolarizations associated with a reduction in input
resistance. Thus, for example, at 0.4 pM, CCPA depressed the peak amplitude of the
EPSPm to 34 + 6 % of that in control medium (n = 4). In contrast, the A2aR agonist
CGS 21680, at concentrations up to 1 pM, neither affected significantly the EPSPM
nor the passive membrane properties of the neurones in which it was tested {n - 3;
Fig. 4.4D & E).
The effects of the selective A,R antagonist DPCPX (0.2 pM) were also tested.
DPCPX alone caused a small but variable increase in the size of EPSPMs, with a
mean amplitude of 15 mV ("large" EPSPMs), in three out of four neurones studied
(Fig 4.5a&c). As such, the peak amplitude of the EPSPM in the presence ofDPCPX
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Figure 4.1. The effect of CADO on the EPSPM.
In A, synaptic traces are isolated EPSPMs, evoked in response to a single stimulus, recorded in control
medium (containing the four ionotropic glutamate and GABA receptor antagonists) (a), in the
presence of 1 pM CADO (b) and following washout (c). In this and subsequent figures the point of
afferent stimulation is marked by the filled triangles. The graph (6) shows a plot of the peak
amplitudes of successive EPSPMs normalized to the mean peak amplitude of the five EPSPMs prior to
CADO application versus time, for a single experiment. CADO was applied for the time indicated by
the bar. The points marked a, b and c refer to the synaptic traces illustrated above the graph. Note
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Figure 4.2. The concentration-effect relationship for the effect of CADO on the EPSPM.
A, shows examples of EPSPMs from a single cell, in control medium (a) and following the application
of CADO at 0.2 pM (b), 0.5 pM (c) and 2.0 pM (d). The membrane potential of the neurone was -67
mV. B, plots pooled concentration-effect data for the percentage inhibition of the EPSPM produced by
CADO (0.1-2.0 pM) versus concentration ofCADO (data from 19 neurones). Percentage inhibition
was calculated as the percentage change in the amplitude of EPSPMs in the presence of CADO
compared to the mean amplitude of at least three responses recorded in control medium. Each point
is the mean value obtained from three to nine separate neurones and the error bars represent the S.E.M.
All data (Y) were fitted to the logistic expression Y = M(X' /[X* + K^]) where Xis the concentration
ofCADO, M the maximum effect, K is the IC50 value and the power P determines the slope of the
sigmoid curve. Note that CADO inhibited EPSPMs in a concentration dependent manner with an IC50
of 0.3 pM.
Control 0.2 ^iM 0.5 jiM
?I,.J:N-,I",||| hi ii WW.
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Figure 4.3. A comparison of the effect of 0.2 pM CADO on EPSPMs and on the passive
membrane properties of the neurone.
A, shows superimposed traces of EPSPMs in the presence and absence of 0.2 pM CADO. B, shows
responses to a -0.3 nA current step in the presence and absence of 0.2 pM CADO. As in this and
subsequent figures the trace shown below B represents the current injected into the cell. Note that 0.2
pM CADO caused a substantial reduction in the EPSPM without visibly affecting the input resistance
of the cell. The membrane potential of the neurone was -64 mV.
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Figure 4.4. Effects of adenosine and subtype selective adenosine receptor agonists on the
EPSPm.
In A-D, traces illustrate the respective effects of 100 pM adenosine, 0.4 pM CCPA, 1.0 pM R-PIA
and 1 pM CGS 21680 on EPSPMs evoked in separate neurones. The membrane potentials of these
neurones were -64 mV, -63 mV, -67 mV and -64 mV, respectively. E, is a bar graph in which pooled
data for the effects of adenosine (100 pM; n = 3), CCPA (0.4 pM; n = 4) and CGS 21680 (0.5 pM; n
= 3) on the amplitude of the EPSPM are expressed as a percentage of the mean value of the control
EPSPMs. Note that whilst CGS 21680 had no significant effect adenosine and CCPA significantly
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Figure 4.5. The effect of DPCPX on "just suprathreshold" and "large" EPSPMs
In A, synaptic traces are isolated EPSPMs, evoked in response to a single stimulus, recorded in control
medium (a), and in the presence of 0.2 pM DPCPX (b). In B, traces are continuous records of the
membrane potential of a single cell in which a depolarizing current step (+0.2 nA, 600 ms) was
delivered 1.0 s prior to, and 2.0 and 3.5 s after pathway stimulation. The stimulation was delivered at
an intensity just suprathreshold for activating an EPSPM in control medium containing only the four
ionotropic glutamate and GABA receptor antagonists (Ba) and following the addition of 0.2 pM
DPCPX (Bb). The initial membrane potential of this neurone was -65 mV. Note that in control
medium SFA was reduced following pathway stimulation. After addition of DPCPX this intensity of
stimulation now additionally activated an EPSPM. C, is a bar graph in which pooled data for the
effects of DPCPX (0.2 pM) on "large" EPSPMs with a mean peak amplitude of 15 mV (« = 4) and
"just suprathreshold" EPSPMs with a mean peak amplitude of 1.1 mV ("Small"; n = 3). Values were
calculated as described in Figure 4.4E. Note that DPCPX had a relatively small effect on large
EPSPms but greatly increased the amplitude of small EPSPMs.
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was 122 ± 19 % that of control (n = 4). In addition, in the presence ofDPCPX, a
stimulus that was previously sufficient to reduce SFA but just supra-threshold for
evoking an EPSPM ("small" EPSPM) subsequently evoked an EPSPM that had a peak
amplitude of 8.3 ± 3.9 mV (n = 3; Fig. 4.5b&c).
Next the ability ofDPCPX to antagonize the depressant effects ofCADO and
adenosine was examined. DPCPX (0.2 pM) fully reversed, or prevented, the
inhibition of the EPSPM by CADO (1 pM; n = 6; Fig. 4.6A) and by adenosine (100
pM; n = 3; 4.65). DPCPX made the EPSPM larger than control responses in a
number of neurones and also inhibited the postsynaptic hyperpolarization and
decrease in input resistance evoked by CADO (See Fig. 5.1) and adenosine (data not
shown).
4.2.3. Effects of CADO on the Reduction in Spike Frequency
Adaptation Evoked by Endogenous Acetylcholine
As described in section 3.2.5, stimulation that was sub-threshold for activating the
EPSPm caused a reduction in SFA in response to a depolarizing current step delivered
2 s after pathway stimulation (n = 12; Fig. 4.1A). This reduction in SFA was
inhibited by CADO (Fig. 4.75) in a concentration-dependent manner (1-5 pM; n = 3;
Fig. 4.8) and was re-instated by subsequent application ofDPCPX (0.2 pM; n = 3;
Fig. 4.7C & 4.8E). In two neurones, in the combined presence ofCADO and
DPCPX a small EPSPM was evoked by the previously sub-threshold stimulus (Fig.
4.7C). This EPSPm, along with the reduction in SFA, was abolished by subsequent
application of atropine (1 pM; Fig. 4.8F).
4.2.4. Effects of an Adenosine Kinase Inhibitor on the EPSPm
The increase in the EPSPM that was caused by DPCPX alone suggested that
endogenous adenosine was capable of tonically activating the A,Rs that subsequently
inhibit the EPSPM. Therefore, the possibility that inhibition of the breakdown of
adenosine might potentiate this putative tonic effect was tested. This was achieved
using the selective adenosine uptake inhibitor dipyridamole (DPY) and the adenosine
kinase inhibitor 5-iodotubercidin (5-IT), which raise extracellular adenosine levels by
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Figure 4.6. The effect of DPCPX on the adenosine and CADO-induced depression of EPSPMs.
In A and B, synaptic traces are EPSPMs recorded in control medium (Aa & Ba), in the presence of 1
pM CADO (Ab) or 100 pM adenosine (Bb) and in the additional presence of 0.2 pM DPCPX (Ac &
Be). The membrane potential of both cells was -64 mV. The bar graphs illustrate pooled data for the
effects of 1 pM CADO (n = 8) and 1 pM CADO + 0.2 pM DPCPX (n = 4) (C) and the effects of 100
pM adenosine (n = 3) and 100 pM adenosine + 0.2 pM DPCPX (n = 3) (D) on the EPSPM. Each
value was calculated as described for Fig. 4.4.E. Note that both CADO and adenosine significantly
depressed the EPSPM and responses in the presence of either CADO or adenosine and DPCPX were
not significantly different from control responses. Data are means ± S.E.M.; * represents P < 0.05;
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Figure 4.7. The effect of DPCPX on the CADO-induced inhibition of stimulation-evoked
reduction in spike frequency adaptation.
In A-C, traces are generated as described in Figure 4.5B. The responses were obtained in medium
containing the four ionotropic glutamate and GABA receptor antagonists (A), in the additional
presence of 5 pM CADO (B) and in the additional combined presence of 5 pM CADO and 0.2 pM
DPCPX (C). Note that in control medium SFA was reduced following pathway stimulation, and that
this reduction was abolished by CADO in a DPCPX-sensitive manner. D, shows pooled data for the
number of action potentials fired during a depolarizing step 1.0 s before (Pre) and 2.0 s after (Post) a
sub-threshold stimulus in the absence and presence of 5 pM CADO (n = 3). If two current steps were
delivered without intervening sub-threshold stimulation the level of SFA evoked by the first step was
not significantly different from that evoked by the second step (See Fig. 3.10). In addition, note that
in the presence of CADO + DPCPX previously sub-threshold pathway stimulation now evoked a
small EPSPm that was abolished by the subsequent addition of atropine (not shown). The initial
membrane potential of the neurone was -66 mV.
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Figure 4.8. The concentration-dependent effect of CADO on stimulation evoked inhibition of
spike frequency adaptation.
In A-F, traces are generated as described in Fig. 4.5 however the point of pathway stimulation has
been omitted by a 2 s break, marked by the gap between steps, which has been added for clarity. The
responses were obtained in medium containing the four ionotropic glutamate and GABA receptor
antagonists (A), in the additional presence of 1 pM (B), 2 pM (C), 5 pM (D) CADO, in the combined
presence of 5 pM CADO and 0.2 pM DPCPX (£) and following subsequent addition of 1 pM
atropine (F). Note that in control medium SFA was reduced following pathway stimulation, that this
reduction was inhibited in a concentration dependent manner by CADO. DPCPX reversed this
inhibition such that the neurone subsequently evoked an inhibition of SFA and a depolarization,
which were completely inhibited by atropine. The initial membrane potential of this neurone was -64
mV.
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preventing uptake of adenosine and inhibiting the conversion of adenosine into
adenosine 5'-monophosphate (AMP), respectively (Jackisch et al. 1984; Ohkubo et
al. 1991; Pak et al. 1994). Both DPY (10 pM) and 5-IT (10 pM) caused a
postsynaptic hyperpolarization (2-8 mV), a decrease in input resistance (5-15 %)
and a depression of the EPSPM by 62 ± 7 % and 74 ± 10 % respectively (n = 4 & n =
5; Fig 4.9A-C). However, in three neurones in which 5-IT was tested, subsequent
application ofDPCPX (0.2 pM) completely reversed these effects (Fig. 4.9A). In
contrast, DPCPX (0.2 pM) had little or no effect on depression of EPSPMs by DPY
(10 pM; n = 3; data not shown).
4.3. DISCUSSION
4.3.1. Adenosine ReceptorActivation Inhibits Cholinergic Synaptic
Transmission
In this chapter, compelling and original evidence has been presented showing that
adenosine receptor activation depresses EPSPMs and, in addition, prevents the
reduction in SFA mediated by synaptic activation ofmAChRs. Until now there has
been only limited evidence of pharmacological modulation of cholinergic synaptic
transmission. Most studies have focused on the modulation of release of ACh
evoked by stimulation using high concentrations of K+ and strong electrical stimuli
(Harms et al. 1979; Cunha et al. 1994; Kirk & Richardson, 1994). Although this
technique provides a good model of release systems, it may have limited
physiological significance due to the artificially high levels of stimulation used to
release neurotransmitters. Nevertheless, such neurochemical release studies have
demonstrated that evoked release ofACh can be modulated by adenosine receptor
activation at both peripheral and central synapses (Vizi & Knoll, 1976; Cunha et al.
1994). Moreover, adenosine has been shown to modulate the release of glutamate as
well as glutamate receptor-mediated synaptic responses in the hippocampus (de
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Functional electrophysiological evidence ofmodulation of cholinergic synaptic
transmission has, however, been limited. In one study, the neuropeptide galanin
depressed slow cholinergic EPSPs, evoked in the presence of physostigmine, by
approximately 60 % via a presynaptic mechanism in the ventral hippocampus (Dutar
et al. 1989). In the present study, EPSPMs were inhibited by adenosine receptor
activation. These EPSPMs were evoked in the absence of a cholinesterase inhibitor
and, as such, these results provide the first functional evidence of a modulation of
cholinergic synaptic transmission in the CNS where the metabolism ofACh is
unimpaired. Furthermore, these results provide evidence of a modulation of
cholinergic effects on the firing properties of the postsynaptic neurone, namely SFA,
an effect which may be more likely to mimic the modulatory effects of ACh in vivo.
Unlike the study by Dutar and coworkers (1989), no distinction was made between
dorsal and ventral hippocampus in the present study, therefore these depressant
actions of adenosine are likely to operate throughout the entire CA1 region of the
hippocampus. Interestingly, a differential distribution ofA,Rs has been noted
between dorsal and ventral hippocampus, which has been correlated to the
differential regulation of glutamatergic synaptic responses by adenosine (Lee et al.
1983). More careful consideration of the effects of adenosine on cholinergic
responses evoked in such distinct regions of the hippocampus may provide similar
results. This may also provide some explanation of the large variability of the effect
ofCADO and adenosine on the amplitude of EPSPMs. Alternatively, this may reflect
variation in the concentration of endogenous adenosine in the slice at the time of
recording (Dunwiddie & Diao, 1994). A much larger concentration of adenosine
than that ofCADO was required to inhibit EPSPMs. This is in agreement with
previous studies investigating other synaptic responses and may be due, in part, to
i) the relative stability ofCADO to breakdown by ectoenzymes
ii) uptake of adenosine and,
iii) the lower potency of adenosine at A,Rs (Dalziel & Westfall, 1994).
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4.3.2. Pharmacology of the Adenosine Receptor
EPSPms were not significantly affected by CGS 21680, suggesting that A2aRs do not
mediate the depression of EPSPMs by CADO. Coupled with the high potency of
CADO, which is relatively more potent at A,Rs, this indirectly suggests that A,Rs
mediate this depression. This was confirmed by the depression of EPSPMs by the
selective adenosine A, receptor agonists CCPA and R-PIA and by the inhibition of
these effects by the selective adenosine Aj receptor antagonist DPCPX. Although
DPCPX is relatively selective for A,Rs it also has very low potency at A2bRs.
However, the potent effect ofDPCPX in conjunction with the effect of the selective
A,R agonist CCPA tend to exclude the involvement of an A2bR in the response to
CADO. The action ofDPCPX also excludes possible effects at A3Rs, since DPCPX
is not a potent antagonist at rodent A3Rs (Zhou et al. 1992). In addition, binding
studies have revealed only low levels of A3R binding in the mouse hippocampus
(Jacobson et al. 1993).
This system of regulation of EPSPMs is analogous to that at glutamate synapses in the
CA1 region, where A,Rs inhibit both AMPA and NMDA receptor-mediated synaptic
transmission (de Mendon^a & Ribeiro, 1993; Thompson et al. 1992). The IC50 value
for the CADO-induced depression of the EPSPM (0.3 pM) is slightly less than that
observed for inhibition ofAMPA receptor-mediated EPSPs but is similar to that for
the inhibition ofNMDA receptor-mediated EPSPs by CADO (de Mendonfa &
Ribeiro, 1993; Dunwiddie & Diao, 1994). It is possible that this reflects the greater
need for control of cholinergic and NMDA receptor-mediated synaptic inputs
because of their much greater influence on postsynaptic excitability.
The lack of a significant effect of CGS 21680 is not surprising since autoradiographic
studies using [3H] CGS 21680 have found little A2aR binding in area CA1 of the
hippocampus (Jarvis & Williams, 1989). However, A2aRs may regulate cholinergic
synaptic transmission in other areas of the hippocampus, since activation of this
receptor has been shown to potentiate release of ACh in the CA3 and dentate gyrus
regions, but not the CA1 region (Cunha et al. 1994). Despite this, CGS 21680 has
been shown to inhibit both field recorded glutamate receptor-mediated EPSPs and
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low Ca++ bursting (a putative postsynaptic effect) in the hippocampal CA1 region
(Lupica et al. 1990). However, these effects have been attributed to a lack of
selectivity of CGS 21680 at the concentrations used (10-100 pM), which were much
higher than those used in the present study (0.5-1.0 pM). As such, the previously
reported effects were thought to be mediated by a non-selective action of CGS 21680
at A,Rs (Lupica et al. 1990).
Inhibition of stimulation-evoked reduction of SFA by CADO was also mediated by
DPCPX-sensitive receptors, suggesting that the receptors mediating this effect are
A,Rs. However, other than their similar pharmacology, there is no direct evidence to
suggest that these receptors are from the same population as those responsible for
inhibiting EPSPMs. Indeed a higher concentration ofCADO (5 pM) than that
required to inhibit the EPSPM (1 pM) was required to completely inhibit this
response. This may, however, reflect the need to inhibit more completely cholinergic
transmission, as a lower level ofmAChR activation is required to mediate inhibition
of SFA than to evoke an EPSPM (Madison et al. 1987). The sensitivity of the
responses used in this study may be limited, as a substantial inhibition of IAHP may be
required to significantly inhibit SFA. These observations may be further complicated
by a possible discrepancy between the receptor-effector coupling for IK(LEAK) and IAHP.
Moreover, it is possible that different populations of mAChRs mediate inhibition of
Ik(leak) ar)d IAHP- In this respect mAChRs may differ in their location (synaptic or
extrasynaptic) or in their pharmacological properties. Until these possibilities are
fully investigated, the significance of the differential effects ofCADO in mAChR -
mediated inhibition of Ik(leak) an(I Iahp w'" remain uncertain.
4.3.3. Mechanism of Action of Adenosine
Data presented in this chapter does not provide any direct evidence of the mechanism
of adenosine A, receptor-mediated depression of cholinergic synaptic responses. In
area CA1 of the hippocampus, adenosine has been shown to activate K+
conductances postsynaptically that lead, for example, to a hyperpolarization and
decrease in input resistance (Thompson et al. 1992). Activation of postsynaptic A,Rs
has also been shown to enhance the sAHP and SFA by affecting IAHP (Haas &
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Greene, 1984). This may affect subsequent inhibition of1^ by mAChR activation.
Presynaptically, adenosine could be inhibiting release of ACh by affecting K+ or Ca++
channels or alternatively by directly affecting the release machinery (see section
1.2.4.3.).
There is, however, some indirect evidence as to the locus of the A,R-mediated
effects. In this respect, a presynaptic locus may be tentatively suggested because
activation ofA,Rs inhibits both EPSPMs and mAChR-mediated inhibition of SFA.
These effects are thought to be mediated by two separate mechanisms i.e. inhibition
of IK(leak) and Iahp (Madison et al. 1987). Therefore the most simplistic explanation
is that adenosine A, receptor activation is acting at a point upstream of the
postsynaptic mAChR-mediated signal transduction mechanisms i.e. inhibition of
transmitter release. In addition, a presynaptic locus is suggested as A,R activation
can lead to a depression of the EPSPM with little or no observable postsynaptic
electrophysiological effects. This, however, does not take into account possible
effects on the postsynaptic biochemistry which do not lead to observable
electrophysiological changes e.g. effects on G-protein-receptor interactions.
Numerous studies citing the inhibitory effect of adenosine receptor activation on the
turnover or release of ACh in the hippocampus, striatum and cortex, both in vivo and
in vitro, support a presynaptic locus for these effects (e.g. Cunha et al. 1994; Harms
et al. 1979; Murray et al. 1982; Haubrich et al. 1981). This issue will be addressed
in the context of further experiments presented in chapter 5.
4.3.4. Endogenous Adenosine Activates Adenosine Receptors
As at glutamatergic synapses (Greene et al. 1985; Bauman et al. 1992), a degree of
"adenosinergic" inhibition at cholinergic synapses may be tonically active in the
hippocampal slice, as suggested by the enhancement of the EPSPM by DPCPX. This
putative "purinergic tone" appears to be greatly enhanced when the uptake or
metabolism of adenosine is impaired by DPY or 5-IT respectively. 5-IT and DPY
have also been shown to facilitate the action of endogenous adenosine on
glutamatergic synaptic transmission (Mitchell et al. 1993; Pak et al. 1994;Diao&
Dunwiddie, 1996). While the reversal of the effect of 5-IT by DPCPX suggests an
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increased action of adenosine at A,Rs, the lack of effect ofDPCPX on the action of
DPY would suggest that DPY is not acting via activation of A,Rs by endogenous
adenosine. This is surprising, as DPY is believed to be a selective inhibitor of
adenosine uptake at the concentration used (10 pM). In this respect, one study,
investigating the release of [3H]ACh from rabbit hippocampal slices, DPY decreased
the evoked release ofACh and 8-phenyltheophylline reversed this effect, suggesting
a selective effect ofDPY on adenosine uptake (Jackisch et al. 1984). Nevertheless,
the inhibitory action ofDPY on EPSPMs is in agreement with neurochemical release
studies where DPY was shown to inhibit release of ACh from rabbit hippocampal
slices (Jackisch et al. 1984) and rat cortical slices (Pedata et al. 1983a).
The distribution ofA,Rs in the CNS is generally closely associated with the
distribution of adenosine uptake sites. In the hippocampus however, adenosine
uptake sites, labeled by [3H]NBTI, are not as closely associated with A,Rs as in other
areas (e.g. striatum) (Glass et al. 1996). This may indicate a less important role for
adenosine uptake in the hippocampus. Possibly this reflects the need to control the
relatively high excitability generated in this region by activation ofNMDA receptors
and mAChRs, the hippocampus being the region with the highest density of both
these receptors in the rat brain (Monaghan & Cotman, 1985; Maragos et al. 1988).
The source of the putative endogenous adenosine tonus is, however, unclear. One
possibility is that it is due, at least in part, to non-specific accumulation of adenosine
due to cell damage resulting from slice preparation (Thompson et al. 1992). Another
possibility is that adenosine is released following afferent stimulation (Mitchell et al.
1993) from, for example, GABAergic interneurones (Manzoni et al. 1994).
Whatever the case, there is considerable evidence that the level of extracellular
adenosine in slices is comparable to that in the CNS in vivo (Zetterstrom et al. 1982;
Dunwiddie & Diao, 1994; Fredholm et al. 1984). As such, it is likely that in the
intact animal cholinergic, like glutamatergic, synaptic inputs in the hippocampus are
tonically, and perhaps subtly, inhibited by circulating levels of adenosine.
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4.4. SUMMARY
Adenosine receptor activation inhibits mAChR-mediated synaptic responses in the
CA1 region of the rat hippocampus. The agonist and antagonist profile of this
receptor shows that it closely resembles the adenosine A, receptor, which also
inhibits glutamatergic synaptic transmission in this region. Data presented in this
chapter also suggest that there is a tonic activation of these receptors in vitro and this
provides a potentially important mechanism for the control of neuronal excitability in
CA1 pyramidal neurones in vivo.
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CHAPTER 5
PRE- AND POST SYNAPTIC ADENOSINE RECEPTORS: LOCUS
AND MECHANISM OF ADENOSINE RECEPTOR-MEDIATED
EFFECTS ON CHOLINERGIC SYNAPTIC TRANSMISSION
5.1. INTRODUCTION
As previously discussed, adenosine receptor activation has a variety of effects in the
mammalian hippocampus and these are, through a variety ofmechanisms,
predominantly inhibitory (see section 1.2). In the previous chapter, it was shown that
A,Rs have an inhibitory modulatory role at cholinergic synapses in the rat
hippocampus. However, it is unclear whether this effect is mediated pre- or post-
synaptically. In this respect, there is much experimental evidence to suggest that
A,Rs are located both pre- and postsynaptically in the CNS (Proctor & Dunwiddie,
1987; Thompson et al. 1992; Swanson et al. 1995). As such, A,R-mediated
modulation of cholinergic synaptic transmission could occur presynaptically, e.g. by
an inhibition of transmitter release, or postsynaptically by interfering with the
transduction ofmAChR-mediated responses e.g. by affecting G-protein function. At
glutamatergic synapses in the hippocampus, adenosine receptor activation modulates
synaptic transmission via a presynaptic receptor (Dunwiddie & Hoffer, 1980;
Dunwiddie & Haas, 1985; Proctor & Dunwiddie, 1987). However, the precise
mechanism of action of adenosine, i.e. whether or not A,Rs inhibit presynaptic Ca"
currents, in this system remains controversial (Silinsky, 1986; Fredholm &
Dunwiddie, 1988; Dunwiddie, 1990; Wu & Saggau, 1997).
This chapter deals directly with the issue of determining either a pre- or post-synaptic
locus for the A,Rs that modulate cholinergic synaptic responses in area CA1 of the
rat hippocampus. Particular emphasis is placed on the comparison of the effect of
A,R activation on postsynaptic responses to mAChR agonists with that on responses
due to synaptic activation ofmAChRs. Having dealt with the locus of the A,Rs
which mediate this response, some preliminary work is presented relating to the




Having identified the AjR-mediated depression of cholinergic synaptic responses in
chapter 4, the next group of experiments addressed whether pre- or post-synaptic
A,Rs mediate these effects. Initially, the concentration-response relationships for
known pre- and post-synaptic A,R-mediated effects were compared with that for
A,R-mediated depression of EPSPMs.
5.2.1. The Pre- and Postsynaptic Effects of Adenosine Receptor
Activation
5.2.1.1. The effects of CADO on the passive membrane properties of the
neurone
Activation of postsynaptic adenosine receptors causes membrane hyperpolarization
and reduction in input resistance in hippocampal pyramidal neurones (Greene &
Haas, 1985; Gerber et al. 1989). CADO (0.2-50 pM) caused a hyperpolarization
with an EC50 of 3.0 pM and a reduction in input resistance with an EC50 of 3.2 pM
(Fig. 5.1). Both the reduction in input resistance and the hyperpolarization were
reversed by DPCPX (0.2 pM; Fig. 5. IX).
5.2.1.2. The effects of CADO on ionotropic glutamate-receptor mediated
responses
There is a considerable body of evidence indicating that activation ofA,Rs
presynaptically causes a depression of glutamate-mediated EPSPs (Lupica et al.
1992). Initially, experiments were performed investigating the effects ofCADO on
field recorded EPSPs and subsequently on intracellularly recorded, isolated AMPA
receptor-mediated EPSPs (EPSPAs; Fig. 5.2). Intracellular experiments were used so
that postsynaptic membrane potential changes, that would affect field recorded
EPSPs, could be compensated for using DC current injection. Despite this, CADO
(0.2-5.0 pM) inhibited both field recorded EPSPs and EPSPAs with EC50s of 0.8 pM
(Fig. 5.2C). These effects ofCADO were reversed by DPCPX (0.2 pM) and EPSPAs
were inhibited by the selective AMPA receptor antagonist NBQX (Fig. 5.2 A & B; 2
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Figure 5.1. Concentration-response relationships for CADO-induced postsynaptic
hyperpolarization and reduction in input resistance.
A, shows a continuous chart record to illustrate the effects of CADO and DPCPX on passive
membrane properties of a CA1 neurone. The trace shows the membrane potential (thick line) and
hyperpolarizing voltage responses (downward deflections) of the cell to constant current steps (-0.3
nA, 300 ms). Note (i) that CADO caused a hyperpolarization and reduction in input resistance that
was completely reversed by DPCPX and (ii) that in the presence ofDPCPX the membrane potential
became more depolarized than that before any drug treatment, presumably indicating the presence of
an endogenous adenosine tonus in the slice. The initial membrane potential of this neurone was -62
mV. B, shows plots of the magnitude ofCADO-induced postsynaptic hyperpolarization, from a
starting membrane potential of between -62 and -64 mV, versus concentration ofCADO (•; data
from 14 neurones). Superimposed on this is a plot of the reduction in input resistance of the cell by
CADO versus concentration of CADO (O; data from 14 neurones). In this and subsequent figures all
data (Y) were fitted to the logistic expression Y = M(XP/[XP + Kp]) where X is the concentration of
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Figure 5.3. Comparison of the concentration-response relationships for CADO-induced
depression of the EPSPM with those for postsynaptic hyperpolarization and depression of
glutamate-mediated EPSPs.
This figure shows plots of the percentage inhibition of EPSPMs (•; data from 19 neurones) and of
AMPA receptor-mediated EPSPs (■; data from 4 cells) induced by CADO versus concentration of
CADO. Each point for each plot is the mean value obtained from 3-9 separate neurones and the error
bars represent S.E.M.s. Superimposed on these plots is a plot of the magnitude ofCADO-induced
postsynaptic hyperpolarization, from a starting membrane potential of between -62 and -64 mV,
versus concentration of CADO (♦; data from 14 neurones). All data were fitted to the logistic
expression described in Figure 5.1.
99
5.2.1.3. Comparison of the effects of adenosine receptor activation
As illustrated in Figure 5.3, CADO was more potent at inhibiting the EPSPM than it
was at inhibiting EPSPAs or causing postsynaptic hyperpolarization. The respective
EC50 values for the depression of EPSPMs, EPSPAs and postsynaptic
hyperpolarization were 0.3 pM, 0.8 pM and 3.0 pM (Fig. 5.3). In addition, the
logistic fit for the depressant action ofCADO on the EPSPM more closely paralleled
that for its presynaptic depressant action on glutamate-mediated EPSPs.
5.2.2. The Effects of Adenosine Receptor Activation on Postsynaptic
Responses to Carbachol
If CADO was acting presynaptically to depress both the EPSPMs and reduction in
SFA evoked by sub-threshold stimulation, then it should not affect the equivalent
postsynaptic mAChR-mediated responses evoked by CCh. To maximize the
probability of observing an effect ofCADO on CCh-induced postsynaptic responses
concentrations of CCh were used that (i) were close to the EC50 values reported for
causing postsynaptic depolarization and reductions in SFA (Madison et al. 1987) and
(ii) produced responses similar to those evoked by afferent stimulation (see Figs. 3.6
& 3.11). In addition, concentrations ofCADO were used that were near maximal for
inhibiting the EPSPM and the reduction in SFA evoked by sub-threshold stimulation
(see Figs. 5.3 & 4.8).
5.2.2.1. The effect of adenosine receptor activation on carbachol-induced
depolarization and increase in input resistance
In a first series of experiments, the effect ofCADO on the postsynaptic
depolarization and increase in input resistance evoked by brief bath applications of
CCh (3 pM for 30-60 s) were investigated. In four neurones, repeated applications
of CCh caused consistent and reversible depolarizations that were associated with
increases in input resistance (Fig. 5.4). In these same neurones addition ofCADO (1
pM) caused a hyperpolarization (1-5 mV) that was associated with a small decrease
in input resistance (4-7 %) (Fig. 5.44).
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Figure 5.4. The effects of CADO on postsynaptic depolarizing responses evoked by carbachol:
A comparison with the effect on EPSPMs.
A, shows the effect ofCADO (1 pM) on the change in membrane potential and input resistance
evoked by CCh (CCh; 3 pM). The trace is a chart record ofmembrane potential and cell input
resistance, as described in Figure 5.1, illustrating the effects of CCh on these parameters prior to and
following CADO application. The bar below the chart record indicates where DC injection was used,
in the presence ofCADO, to restore the membrane potential of the cell to that prior to CADO
application. This was kept constant for the period indicated by the length of the bar except for when
the increase in input resistance evoked by CCh was measured. The upward deflections just prior to,
and just after, the point where DC was first applied represent voltage responses to positive constant
current steps (+0.3 nA, 300 ms). The bars above the chart record represent the times for which drugs
were applied. The initial membrane potential of this neurone was -64 mV. B, On the left-hand side
of the bar graph pooled data for the peak amplitude of the two CCh (3 pM)-induced depolarizations
prior to the application ofCADO, and one in the presence of 1 pM CADO, are plotted as a percentage
of the mean value for the responses prior to CADO application (« = 4). On the right-hand side of the
bar graph pooled data for the peak amplitude of the EPSPM evoked in the presence of 1 pM CADO is
plotted as a percentage of control (n = 8; see Fig. 4.2). Note that the same concentration of CADO
depressed the EPSPM to a greater extent than it did the CCh-induced depolarization. The small
reduction in the size of the CCh-induced depolarization in the presence ofCADO is not statistically
significant and can be explained largely on the basis of the decrease in input resistance induced by
CADO in this group of cells. In contrast, CADO significantly depressed the EPSPM (P < 0.05).
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However, CADO had no significant effect on the CCh-induced depolarizations and
increases in input resistance {n = 4; P > 0.05; Fig. 5.45). In five other neurones these
postsynaptic effects ofCCh were abolished by atropine (1-5 pM; not illustrated).
These results contrast with those for the EPSPM which was depressed significantly by
both CADO (1 pM, P < 0.05; Fig. 5.45) and atropine (1 pM, P < 0.05; Fig. 3.8).
5.2.2.2. The effect of adenosine receptor activation on carbachol-induced
inhibition in spike frequency adaptation
In a second series of experiments, the effects ofCADO and CCh on SFA evoked in
response to a depolarizing current step were investigated. CCh (0.5 pM) caused a
small depolarization and a reduction in SFA that was reversible on washout (n = 5;
Fig. 5.5A & 3.11). Subsequent addition ofCADO (5 pM) slightly enhanced the level
of SFA per se, in agreement with previous studies (Haas & Greene, 1984), but did
not significantly affect the reduction in SFA induced by a second application of CCh
(,n = 3; Fig. 5.5). In contrast, atropine (1 pM) abolished the CCh-induced reduction
in SFA (n = 5; data not shown). These results differ from those in which SFA was
reduced using sub-threshold stimulation in that the latter was abolished by both
CADO (5 pM; Fig. 5.5) and atropine (1 pM; Fig. 3.11).
5.2.3. The Mechanism of Action of Adenosine
5.2.3.1. Involvement of 4-AP sensitive potassium channels
As the previous results suggest a presynaptic locus for these A,R mediated effects,
this raises the possibility of an effect on presynaptic K+ channels that subsequently
affects the release of ACh. To investigate this possibility, the K' channel blocker 4-
aminopyridine (4-AP) was used. 4-AP inhibits the ability of adenosine to inhibit
glutamate release in the guinea-pig hippocampus (Okada & Ozawa, 1980). 4-AP
(100 pM) increased the amplitude of EPSPMs from 2.1 ± 0.3 mV to 21.6 ± 1.5 mV (n
= 4; Fig. 5.6A). In the presence of 4-AP (100 pM), CADO (1 pM) depressed the
amplitude of EPSPMs by 54 ± 12 % (n = 4; Fig. 5.6). This contrasts with a
depression of 84 ± 5 % for depression of EPSPMs by 1 pM CADO in the absence of
4-AP (see Fig. 5.45).
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Figure 5.5. The effects of CADO on postsynaptic reduction in spike frequency adaptation by
carbachol: A comparison with the effect on stimulation evoked reduction in spike frequency
adaptation.
A, shows, from left to right, responses evoked by a depolarizing current step (+0.2 nA, 400 ms) in
control medium, in the presence of CCh (0.5 pM), following washout, in the presence ofCADO (5
pM) and in the combined presence ofCADO (5 pM) and CCh (0.5 pM). The membrane potential of
the cell was maintained at -66 mV throughout this experiment by injecting DC through the recording
electrode to compensate for the hyperpolarizing and depolarizing effects of CADO and CCh,
respectively. The trace at the bottom of the figure represents the time during which positive current
steps were injected via the recording electrode. Note that CCh reduced SFA evoked during the
depolarizing step and that this was unaffected by CADO. B, shows a bar graph in which the left-hand
side represents pooled data for the number of action potentials fired during a depolarizing step in the
absence (Ctl) and presence of 0.5 pM carbachol (CCh) plotted for control medium and for medium
containing 5 pM CADO (n = 3). The right-hand side shows pooled data for the number of action
potentials fired during a depolarizing step 1.0 s before (Pre) and 2.0 s after (Post) a sub-threshold
stimulus in the absence and presence of 5 pM CADO (« = 3) (See Fig. 4.7). Statistical significance
was tested for CCh versus control (Ctl) and Post versus Pre data for each of the paired data sets.
Statistical significance was assigned where P < 0.05. Note that CADO completely inhibited the
increase in number of action potentials fired following sub-threshold stimulation without affecting the
increase evoked by CCh application.
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Figure 5.6. The effects of CADO on EPSPMs in the presence of 4-AP.
In A, synaptic traces are isolated EPSPMs recorded in control medium (containing ionotropic
glutamate and GABA receptor antagonists) (a), in the presence of 100 pM 4-AP (b), in the presence
of 100 pM 4-AP + 1 pM CADO (c) and in the additional presence of 0.2 pM DPCPX (d). The graph
(.B) shows a plot of the peak amplitudes of successive EPSPMs normalized to the mean peak amplitude
of the three EPSPMs prior to CADO application in the presence of 100 pM 4-AP versus time, for a
single experiment. 1 pM CADO and 0.2 pM DPCPX were applied for the times indicated by the
bars. The points marked a, b, c and d refer to the synaptic traces illustrated above the graph. C, is a
bar graph illustrating pooled data for the amplitudes of EPSPMs in the presence of 1 pM CADO (n =
4), 1 pM CADO + 0.2 pM DPCPX (n = 2) and in the additional presence of 1 pM atropine (n = 2) all
in the presence of 100 pM 4-AP. Amplitudes are expressed as a percentage of the amplitude of
EPSPms in the presence of 100 pM 4-AP. The values plotted were calculated as described in Figure
4.4E. Note that CADO reversibly inhibited EPSPMs in the presence of 4-AP. The membrane
potential of the neurone was -64 mV.
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The depression of EPSPMs in the presence of 4-AP was subsequently reversed by
DPCPX (0.2 pM; n = 2; Fig 5.6) and the responses in the presence of both CADO
and DPCPX were inhibited by atropine (1 pM; n = 2; Fig 5.6).
5.2.3.2. Involvement of the eAMP/adenylate cyclase system
Classically, A,Rs have been shown to be negatively coupled to AC. To assess the
involvement of a reduction in intracellular cAMP in the inhibitory response to
CADO, the effects of the membrane permeable analogue of cAMP, 8-bromo cAMP
(8-Br cAMP) were also investigated. The rationale behind these experiments was
that the presence of 8-Br cAMP should compensate for any reduction in cAMP. 8-Br
cAMP (1 mM) inhibited SFA but had no significant effect on EPSPMs (n = 5) in
agreement with previous studies (Madison et al. 1987). In addition, 8-Br cAMP (1
mM) reversed or inhibited the depression of EPSPMs by CADO (1 pM; n = 4; Fig.
5.1A&B).
5.3. DISCUSSION
5.3.1. Locus of the Adenosine Receptor-MediatedDepression of the
EPSPm
As A,Rs are found in abundance both pre- and post-synaptically in the CA1 region of
the hippocampus, it is possible that adenosine inhibits mAChR-mediated
postsynaptic responses by activation of one or both populations of these receptors.
Presynaptic inhibition of transmitter release is thought to be the primary mechanism
responsible for A,R inhibition of synaptic transmission at hippocampal glutamatergic
synapses. Three main lines of evidence have led to this hypothesis,
i) adenosine increases paired pulse facilitation (Dunwiddie & Haas, 1985),
ii) adenosine inhibits evoked transmitter release (Cunha et al. 1994), and
iii) adenosine reduces quantal content without reducing quantal size (Lupica &
Dunwiddie, 1992).
In the present study, however, it was not possible to use a paired pulse protocol due


















































Figure 5.7. The effects of CADO on EPSPMs in the presence of 8-Br cAMP.
In A, synaptic traces are isolated EPSPMs recorded in control medium (a), in the presence of 1 pM
CADO (b) and in the additional presence of 1 mM 8-Br cAMP (c). The graph below shows a plot of
the peak amplitudes of successive EPSPMs, normalized to the mean peak amplitude of the three
EPSPms prior to CADO application, versus time for a single experiment. B, shows a similar
experiment to that shown in A in which synaptic traces are isolated EPSPMs recorded in control
medium (a), in the presence of 1 mM 8-Br cAMP (b) and in the additional presence of 1 pM CADO
(c). The graph below is constructed in the same way as that shown in A. In both graphs in A and B, 1
mM 8-Br cAMP and 1 pM CADO were applied for the times indicated by the bars and the points
marked a, b and c refer to the synaptic traces illustrated above each graph. Note that CADO inhibited
EPSPms and that 8-Br cAMP reversed or prevented this inhibition. The membrane potential of both
neurones was -63 mV.
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(see section 3.3.2). Likewise, it was not possible to investigate quantal content, as
mAChR-mediated synaptic transmission is non-quantal. That the concentration-
response relationship for the CADO-induced depression of the EPSPM most closely
paralleled that for the depression of the EPSPA, but not that for the postsynaptic
hyperpolarization, indirectly favors a presynaptic locus of the A,R-mediated
depression. In this respect, at least three additional lines of evidence suggest the
involvement of a presynaptic depressant mechanism:
i) CADO can depress the EPSPM even at concentrations that do not affect
postsynaptic passive membrane properties (see Fig. 4.3),
ii) CADO does not significantly inhibit CCh-induced postsynaptic responses, and
iii) both the EPSPM and mAChR-mediated postsynaptic reduction of SFA evoked
by sub-threshold stimulation, which result from the inhibition of distinct K+
conductances (Ik(leak) and IahpI Madison et al. 1987), are inhibited by CADO.
In addition, neurochemical data from both hippocampal synaptosomes and slices
strongly indicate the existence of a presynaptic A,R-mediated inhibition of evoked
["lH]-ACh release (Cunha et al. 1994). However, it is difficult to compare K+ or
electrically evoked release with synaptic release of neurotransmitter as the
mechanism of synaptic release may differ. Nevertheless, in vivo, adenosine receptor
activation has also been shown to inhibit the turnover rate of ACh (Haubrich et al.
1981; Murray et al. 1982). When taken together these data provide convincing
evidence that a significant proportion of the A,R-mediated inhibition of the EPSPM
and associated reduction in SFA occurs by presynaptic inhibition of ACh release.
Such a mechanism has previously been proposed for cholinergic synapses at the
neuromuscular junction where activation ofA,Rs inhibits the average number of
quanta of ACh released from the nerve terminal without affecting the size of each
individual quantum (Ginsborg & Hirst, 1972; Ribeiro & Walker, 1975; Silinsky,
1984).
It is conceivable that adenosine may also act postsynaptically to depress mAChR-
mediated postsynaptic responses. In this respect, a direct interaction between the
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transduction mechanisms activated by A,Rs and mAChRs seems unlikely, as A,Rs
classically couple to the G-protein G;, which inhibits AC activity. In contrast, neither
the EPSPm nor the mAChR-mediated reduction in SFA is affected by cAMP
mimetics such as 8-Br cAMP (Madison et al. 1987) or antagonists of protein kinase
A (Pedarzani & Storm, 1993). However, negative interactions between A,Rs and the
M, mAChR-mediated inhibition of IM have been reported in the superior cervical
ganglion (Connolly & Stone, 1995). Despite this, IM is unlikely to account for the
actions of synaptically activated mAChRs in the hippocampus (Madison et al. 1987)
even though pyramidal neurones are thought to express both the M, and/or M3
mAChR subtypes (Dutar & Nicoll, 1988a; Pitler & Alger, 1990; Segal & Fisher,
1992). These receptors classically couple through the pertussis-toxin insensitive Gq/11
family ofG-proteins to PLC, the activity ofwhich can, in some cells, e.g. aorta, be
inhibited by A,Rs. However, it is unclear whether activation ofPLC fully accounts
for mAChR-mediated depolarization and reductions in SFA in the hippocampus
(Muller & Misgeld, 1986; Dutar & Nicoll, 1988a; Colino & Halliwell, 1993).
Adenosine (P,) receptor activation has been shown to modulate the effects of CCh on
field recorded synaptic potentials in area CA1 of the rat hippocampus (Brooks &
Stone, 1980). However, these effects are difficult to interpret because it is not
possible to account for the intracellular hyperpolarizing effects of adenosine.
Whatever the case, the inability ofCADO to abolish both CCh-induced
depolarization and reduction in SFA would suggest that this mechanism or, for
example, a membrane delimited interaction between the A,R-mediated signal
transduction mechanism(s) and mAChR coupled K+ conductances, are unlikely to
account for the depressant effects ofA,Rs on the EPSPM and stimulation-evoked
reduction in SFA (see Fig. 5.5). Nevertheless, adenosine, by activating postsynaptic
K+ conductances, will restrict the magnitude of the EPSPM recorded at the soma, to
some extent, by the shunting of membrane currents as well as hyperpolarization
towards the reversal potential of the EPSPM (Cole & Nicoll, 1984a).
5.3.2. Mechanism ofAction of Adenosine Receptor Activation
Having established a likely locus for the A,R-mediated effects on mAChR-mediated
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responses as presynaptic, the mechanism for this effect must involve either
i) an indirect inhibition of presynaptic excitability,
ii) an effect on local network function, or
iii) the modulation of transmitter release.
Firstly, an indirect action on the excitability of the presynaptic neurone can be
excluded because of the preparation used. In the hippocampal slice the
septohippocampal axons projecting from medial septum have been severed. As such,
is not possible for A,Rs to affect the driving force of the presynaptic septal
cholinergic neurone. With respect to the effects on local network function, although
mAChR-mediated synaptic responses are likely to be monosynaptic and septal
afferents also innervate interneurones in the hippocampus, evoked responses in these
experiments were isolated from ionotropic GABA and glutamate receptor-mediated
effects using antagonists at these receptors. These factors suggest that effects of A,R
activation on local network function is unlikely.
In terms of a modulation of transmitter release, activation of presynaptic K+ channels
has been proposed as a mechanism for the inhibition of transmitter release by
adenosine at glutamatergic synapses (Dunwiddie, 1990). In neurochemical release
studies, however, there are conflicting reports regarding the involvement of
inhibition of K+ channels in the inhibitory effect of A,R activation on hippocampal
ACh release (Benishin, 1990; Fredholm, 1990; 1993). Inhibition of 4-AP sensitive
K+ channels facilitated EPSPMs but did not completely block the inhibition of
EPSPMs by CADO. This may suggest that the concentration of 4-AP was not
sufficient to inhibit the particular K+ channel involved, however, a high concentration
of 4-AP was used (100 pM). This concentration of 4-AP has previously been shown
to be sufficient to inhibit the presynaptic inhibitory action of mGluRs (Sladeczek et
al. 1993). Alternatively, this may suggest that 4-AP sensitive K+ channels are not,
exclusively at least, involved in the inhibitory effects of adenosine on EPSPMs.
These data are in contradiction to adenosine receptor-mediated inhibition of
glutamatergic synaptic transmission in the hippocampus and olfactory cortex, which
is abolished by 4-AP (Okada & Ozawa, 1980; Scholfield & Steel, 1988). A potential
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problem with the use of K+ channel blockers in such experiments is that they increase
the magnitude of synaptic responses alone through inhibition of presynaptic K+
channels. Although this did not abolish the ability of A,R activation to inhibit
EPSPms, it was noticeable that the magnitude of depression produced by adenosine
was less in the presence of 4-AP than in control experiments. It is possible that this
reduction in the efficacy ofCADO was due to increased intracellular Ca++ in the
presynaptic terminal swamping the release machinery, thus rendering the release
process unresponsive to inhibition. Other studies, however, have excluded this
mechanism, for example, at glutamatergic synapses (Scholfield & Steel, 1988). As
such, a contribution of 4-AP-sensitive K+ channels to the reduction in the efficacy of
CADO must be considered. This can be further investigated by
i) in the presence of 4-AP increasing the concentration ofMg++ to reduce the
release of transmitter to control levels, or
ii) reducing the stimulus intensity in the presence of 4-AP, to reduce the amplitude
of the EPSPm.
In addition to the activation of presynaptic K+ conductances, inhibition of Ca++
currents or a direct inhibition of the Ca++-sensitive release machinery (Silinsky, 1984;
1986) may modulate transmitter release. These possible mechanisms have gained
some support over the past 12 years and have been reviewed in detail for glutamate
synapses (Silinsky, 1986; Fredholm & Dunwiddie, 1988; Thompson et al. 1993; Wu
& Saggau, 1997). It is unclear which Ca++ channels mediate ACh release. Future
studies may address this issue and ascertain whether ACh release, like glutamate
release, is mediated by N- and Q- and/or P-type Ca++ channels (Luebke et al. 1993;
Wheeler et al. 1994) and whether inhibition ofACh release by A,R activation is also
mediated by effects on N- and/or Q-type Ca++ channels, as at glutamate synapses (Wu
& Saggau, 1994).
Finally, inhibition of release machinery is a possibility. In neurochemical release
studies it has been suggested that the A,R-mediated inhibition of ACh release is
unaffected by co-conotoxin or intracellular Ca++ chelation, suggesting that inhibition
of release is upstream of Ca++ entry and may in fact be a direct effect on the release
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mechanism itself (Fredholm, 1993). It is unclear, however, whether ACh release in
such release studies is modulated by the same release processes as synaptic ACh
release.
Whatever the case it is clear that 8-Br cAMP occludes the effect ofCADO to depress
the EPSPm. There is only limited evidence for the involvement ofAC in the
reduction of transmitter release by adenosine (McCabe & Scholfield, 1985). Data
presented in this chapter suggests, controversially, that cAMP is involved in this
A,R-mediated inhibition ofmAChR-mediated responses. That 8-Br cAMP reversed
or prevented the inhibition of EPSPMs by CADO suggests that it is counteracting an
A,R-mediated reduction in transmitter release by increasing intracellular cAMP
turnover. This is in direct contradiction to results obtained in neurochemical release
studies (Duner-Engstrom & Fredholm, 1988). However, this result may be
misleading, as 8-Br cAMP will activate PKA which could phosphorylate Ca++ and K+
channels presynaptically, thus altering their function. This is unlikely, however, as
8-Br cAMP did not have any effect on EPSPMs suggesting that the release process
was unaffected. Nevertheless, the possibility remains that the resulting activation of
PKA alters the function of other transduction processes exclusively involved in the
A,R-mediated modulation of ACh release. In addition, 8-Br cAMP has been
reported to have a direct agonist effect on A,Rs (Dolphin et al. 1986). If 8-Br cAMP
were acting as an agonist at A,Rs, it would have been expected to affect EPSPMs
directly. However, if 8-Br cAMP did not affect EPSPMs it may alternatively act as a
partial agonist at A,Rs.
The apparent contradictions in this field of research have led to complicated theories
regarding the mechanism(s) of adenosine receptor-mediated inhibition of transmitter
release. It has been speculated that there can be no unifying mechanism to explain
A,R-mediated inhibition of transmitter release (Starke, 1987).
5.4. SUMMARY
Experiments were conducted to assess the pre- or post-synaptic locus of the A,R-
mediated inhibition of EPSPMs. The concentration-response relationship for the
inhibition of EPSPMs more closely resembled that for the presynaptic depression of
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glutamate receptor-mediated EPSPs, indirectly suggesting a presynaptic locus for the
inhibition of EPSPMs by CADO. Postsynaptic depolarization and inhibition of SFA
evoked by CCh were not significantly affected by CADO at concentrations that
significantly depressed cholinergic synaptic responses, suggesting a presynaptic
locus for the effect ofCADO. In addition, the mechanism of action ofCADO
appears to be partially dependent on 4-AP-sensitive K+ channels and may involve an
inhibition of cAMP turnover. As such, the A,Rs that mediate the inhibition of
cholinergic synaptic transmission are located predominantly presynaptically and may
act via a cAMP-dependent mechanism.
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CHAPTER 6
GABAb RECEPTOR MEDIATED MODULATION OF
MUSCARINICRECEPTOR MEDIATED RESPONSES
6.1. INTRODUCTION
Chapters 4 and 5 of this thesis described the modulation of synaptically evoked
cholinergic responses by adenosine receptor activation. In these studies, cholinergic
responses were isolated from ionotropic glutamate and GABA receptor-mediated
effects using antagonists at these receptors. Inhibition of these receptor systems
could, in itself, affect the transmission of cholinergic synaptic responses. The
purpose of this chapter therefore was to assess this possibility. Of the receptors
inhibited by this cocktail of antagonists, the GABAb receptor has most in common
with A,Rs. Thus, GABAb receptor activation leads to activation of similar
transduction mechanisms to A,Rs i.e. activation of G/G0 subtypes of G-protein
(Dutar & Nicoll, 1988b; Trussel & Jackson, 1987). In addition, both A,Rs and
GABAb receptors modulate glutamate synaptic transmission in the hippocampus in
similar ways (e.g. Thompson et al. 1992; Olpe et al. 1982). Evidence of a GABAb
receptor-mediated inhibition of cholinergic synaptic transmission, however, is
limited. In this respect, the GABAb receptor agonist (-)-baclofen has been shown to
inhibit ACh release in the SCG (Brown & Higgins, 1979) and in the superior
colliculus (Wichmann et al. 1987). That said, experiments were conducted to
ascertain whether GABAb receptor activation may also inhibit cholinergic synaptic
transmission in hippocampal area CA1. As such, experiments were conducted to
investigate the effects ofGABA receptor activation on cholinergic synaptic
transmission and to compare these effects with those of adenosine.
6.2. RESULTS
6.2.1. The Effects of GABA ReceptorActivation on the EPSPm.
Initially the effect of GABA receptor activation on EPSPMs, evoked in CA1
pyramidal neurones, was investigated. The selective GABAb receptor agonist (-)-
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baclofen (5-10 pM) caused a depression of the EPSPM that was maintained for the
period of the agonist application (n = 5 ; Fig. 6.1). In addition, in 2 out of 3 cells, 5
pM (-)-baclofen occluded the IPSPB that preceded the EPSPM. At 5 pM, the
depressant action of (-)-baclofen on the EPSPM was invariably accompanied by
postsynaptic hyperpolarization (5-7 mV) which was routinely compensated for using
positive current injection. The maximal inhibition of EPSPMs by 5 pM (-)-baclofen
was 88 %.
To confirm the pharmacological classification of the GABA receptor mediating the
response to (-)-baclofen, the effect of the selective GABA0 receptor antagonist CGP
55845A was also tested. CGP 55845A (1 pM) antagonized the inhibition caused by
5-10 pM (-)-baclofen in all cells tested (Fig. 6.1) such that, in the presence of both (-
)-baclofen and CGP 55845A responses were 121 ± 19 % ofmean control amplitudes
prior to the application of (-)-baclofen (n = 5). In addition, CGP 55845A (1 pM)
reversed the hyperpolarization caused by (-)-baclofen (5 pM).
The action of CGP 55845A alone was tested to investigate the possibility that
endogenously released GABA might inhibit EPSPMs under control experimental
conditions. CGP 55845A (1 pM) alone caused a large but variable increase in the
size of EPSPMs, which had a mean control amplitude of 3.0 mV, while completely
inhibiting the IPSPB. As such, the peak amplitude of the EPSPM in the presence of
CGP 55845A was 253 ± 74 % that of control (n = 3; Fig. 6.2).
6.2.2. Effects of a GABA Uptake Inhibitor on the EPSPm
It is well established that synaptically released GABA activates a late IPSPB in CA1
pyramidal neurones (Dutar & Nicoll, 1988c). The increase in the EPSPM that was
caused by CGP 55845A alone suggested that endogenous GABA within the slice was
also capable of activating GABAb receptors to inhibit the EPSPM. Therefore, the
next group of experiments examined whether it was possible to potentiate the effect
of endogenous GABA by impairing its uptake. To do this the effects of the GABA
uptake inhibitor NNC 05-0711 were investigated. NNC 05-0711 raises extracellular
GABA levels by preventing the uptake ofGABA (Suzdak, et al. 1992).
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Figure 6.1. The effect of (-)-baclofen on EPSPMs and the effect of subsequent addition of CGP
55845A.
In A, synaptic traces are EPSPMs recorded in the presence ofAMPA, NMDA and GABAa receptor
antagonists (Control) (a) and in the additional presence of 5 pM (-)-baclofen (b). The membrane
potential of the cell was -64 mV. The graph (B) shows a plot of the mean peak amplitudes of
successive EPSPMs, for pooled data, normalized to the mean peak amplitude of the five EPSPMs prior
to application of (-)-baclofen versus time to illustrate the depressant effect of (-)-baclofen on the
EPSPM and its reversal by CGP 55845A. The bars above the graph indicate the duration for which the
two drugs were applied. In C, the bar graphs illustrate pooled data for the effects of 5-10 pM (-)-
baclofen (n = 5) and 5-10 pM (-)-baclofen + 1 pM CGP 55845A (n = 5) on the EPSPM. The
amplitudes of EPSPMs are expressed as a percentage of the mean value of the control EPSPMs. Note
that (-)-baclofen significantly depressed the EPSPM and responses in the presence of (-)-baclofen +
CGP 55845A were not significantly different from control responses. Data are means ± S.E.M.; *
represents significance P < 0.05; n.s., not significant (compared with control). Data was obtained in







































Figure 6.2. The effects of CGP 55845A alone on the EPSPM and IPSPB.
In A, synaptic traces are representative EPSPMs recorded in control (a) and in the presence of 1 pM
CGP 55845A (b). Note, that following stimulation, the neurone responds with a hyperpolarization
(IPSPB) followed by a small EPSPM. The membrane potential of this neurone was -64 mV. In B, the
graph is similar to that illustrated in Fig. 6.1 and plots the mean peak amplitude of successive EPSPMs
and lPSPBs, for pooled data (n = 3), versus time to illustrate the enhancement of the EPSPM and the
depression of the IPSPB by CGP 55845A. The bar above the graph indicates the duration for which
CGP 55845A was applied. C, is a bar graph illustrating pooled data for the effect of 1 pM CGP
55845A on the amplitude of the EPSPM (« = 3). The values plotted were calculated as described in
Figure 6.1. Note that CGP 55845A abolished the IPSPB but dramatically increased the amplitude of
the EPSPm.
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NNC 05-0711 (10 pM) increased the amplitude of IPSPBs to 241 ±38 % of control
amplitudes and caused a 58 ± 10 % depression of the EPSPM (n = 4; Fig 6.3). In two
of these neurones, subsequent application of CGP 5 5845A (1 pM) completely
reversed these effects (Fig. 6.3Q.
6.2.3. Effects of (-)-Baclofen on the Reduction in Spike Frequency
Adaptation Evoked by Endogenous Acetylcholine
As shown in chapters 3 and 4, cholinergic afferent stimulation that was sub-threshold
for activating the EPSPM caused a reduction in SFA in response to a depolarizing
current step delivered 2 s after pathway stimulation (n = 12; See Fig. 6.4A and
3.105). The next series of experiments were carried out to examine whether GABAb
receptor activation also affected this kind of cholinergic synaptic response as this
provides information as to whether GABAb receptors act pre- or post-synaptically to
modify cholinergic synaptic transmission. (-)-Baclofen (20 pM) occluded the IPSPBs
evoked by pathway stimulation (Fig. 6.4^4 & 5) but only partly inhibited the
reduction in SFA evoked by cholinergic afferent stimulation (n = 5; Fig. 6.45). The
inhibition of the reduction in SFA by (-)-baclofen (20 pM) was partially reversed by
subsequent application of CGP 55845A (1 pM; n = 3; Fig. 6.4C). The stimulation-
evoked reduction in SFA was abolished by subsequent application of atropine (1 pM;
see Fig. 3.115).
6.3. DISCUSSION
6.3.1. GABAB Receptor Activation Inhibits Cholinergic Synaptic
Transmission
Evidence presented in this chapter suggests that there is a GABA receptor-mediated
inhibition of cholinergic synaptic responses in area CA1 of the rat hippocampus. The
action of both the selective GABAb receptor agonist (-)-baclofen and antagonist CGP
55845A suggests that this effect is mediated by GABAb receptors. In addition,
GABAa receptor contribution to this inhibition can be excluded because GABAa
receptor-mediated responses were inhibited using the selective GABAa receptor
antagonist picrotoxin. Nevertheless, it is possible that GABAa receptors may
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Figure 6.3. The effects of an inhibitor of GABA uptake on EPSPMs and IPSP„s.
In A, synaptic traces are representative IPSPB/EPSPMs recorded in control (a) and in the presence of
NNC 05-0711 (10 pM) (b). The membrane potential of this neurone was -64 mV. In B, the graph is
similar to that illustrated in Fig. 6.2B and plots the mean peak amplitude of successive EPSPMs and
IPSPBs, for pooled data (n = 4), versus time to illustrate the depression of the EPSPM and the
enhancement of the IPSPB by NNC 05-0711. The bars above the graph indicated the duration for
which the two drugs were applied. C, is a bar graph illustrating pooled data for the effects of 10 pM
NNC 05-0711 (n = 4) and 10 pM NNC 05-0711 + 1 pM CGP 55845A (« = 2) on the EPSPM. The
values plotted were calculated as described in Figure 6.1 B. Note that NNC 05-0711 depressed the
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Figure 6.4. The effect of CGP 55845A on the (-)-baclofen-induced inhibition of stimulation-
evoked reduction in spike frequency.
In A-C, traces are generated as described in Figure 4.5A The responses were obtained in medium
containing ionotropic glutamate and GABAa receptor antagonists (A), in the additional presence of 20
pM (-)-baclofen (B) and in the additional combined presence of 20 pM (-)-baclofen and 1 pM CGP
55845A (C). Note that in control medium pathway stimulation evoked an IPSPB and caused a
reduction in SFA. (-)-Baclofen inhibited but did not abolish the stimulation evoked reduction in SFA
and occluded the IPSPB in a CGP 55845A-sensitive manner. D, shows pooled data for the number of
action potentials fired during a depolarizing step 1.0 s before (Pre) and 2.0 s after (Post) a sub¬
threshold stimulus in the absence and presence of 20 pM (-)-baclofen (« = 5) and in the additional
presence of 1 pM CGP 55845A (« = 5). Note that, in the absence of a stimulation, the level of SFA
evoked by the first step was not significantly different from that evoked by the second step (See Fig.
3.10). The initial membrane potential of the neurone was -65 mV.
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provide an additional inhibitory influence on cholinergic synaptic transmission
although further experimentation would be required to address this. Likewise, the
involvement ofGABAC receptors can be ruled out as
i) GABAC receptor-mediated effects are thought to be insensitive to (-)-baclofen
(Bormann & Feigenspan, 1995),
ii) GABAC receptor-like effects have only been observed in hippocampal CA3
neurones in very young rats, and
iii) these effects are blocked by picrotoxin (Strata & Cherubini, 1994).
The evidence for a GABAb receptor-mediated modulation of stimulation induced
reduction in SFA is less clear. (-)-Baclofen inhibits the reduction in SFA caused by
pathway stimulation but does not completely inhibit this response. This is true, even
at a concentration of 20 pM, which is maximal for activating postsynaptic GABAB
receptors as well as inhibiting glutamate and GABA release (Thompson & Gahwiler,
1992). That said, CGP 55845A reverses this inhibition, suggesting that the inhibitory
effect of (-)-baclofen is mediated by GABAb receptors. Flowever, it remains unclear
as to whether
i) 20 pM (-)-baclofen does not activate sufficient numbers ofGABAb receptors to
inhibit the stimulation-induced reduction of SFA, or
ii) it is not possible to inhibit ACh release by activation ofGABAb receptors to
the point when ACh release is sufficiently low to prevent the reduction in SFA.
It should be noted that the mechanism underlying the EPSPM requires the presence of
a higher concentration of ACh than the mechanism underlying the inhibition of SFA.
In addition, it is not yet clear whether these effects require release from just a single
or many nerve terminals simultaneously. In this respect the possibility must be
considered that only certain cholinergic fibers express GABAb receptors.
These results contrast with the A,R-mediated inhibition of cholinergic synaptic
responses (see Chapter 4). Adenosine receptor activation by 5 pM CADO
substantially or completely inhibited both EPSPMs and stimulation evoked reduction
of SFA (see Fig. 4.7). (-)-Baclofen is, if anything, generally more potent than CADO
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in its actions throughout the CNS. Thus, in terms of the postsynaptic
hyperpolarization produced, (-)-baclofen has an EC50 of 1.1 pM (Inoue et al. 1985)
compared with an EC50 of 3 pM for the effect ofCADO. As such, 20 pM (-)-
baclofen is a comparatively higher concentration than 5 pM CADO, and therefore
would be expected to be maximal or near maximal for the depression of the EPSPM.
Further experiments are required to establish the precise maximal effective
concentration of (-)-baclofen. Nevertheless, the results to date might be explained by
i) differences in the efficiency of receptor-effector coupling for A,Rs and GABAb
receptors
ii) differences in the transduction mechanisms which mediate the inhibitory
effects ofA]Rs and GABAb on respective mAChR-mediated responses.
A more detailed quantitative analysis of the concentration-response relationships for
the effects of (-)-baclofen on the EPSPM and inhibition of SFA would help to clarify
whether (-)-baclofen is indeed having a differential effect on these two mAChR-
mediated responses. These experiments would also serve to suggest whether (-)-
baclofen is acting pre- or post-synaptically to inhibit cholinergic synaptic responses.
To date, evidence for GABAb receptor-mediated inhibition ofACh release in the
CNS is limited, providing some support for a postsynaptic site of action of (-)-
baclofen (Waldmeier & Baumann, 1990). In one study however, GABAB receptor
activation has been shown to inhibit the release of ACh in the superior colliculus,
although the pharmacological profile of that receptor did not match that of a classical
GABAb receptor (Wichmann et al. 1987). Alternatively, (-)-baclofen may be acting
both pre- and post-synaptically, or purely postsynaptically, to inhibit cholinergic
responses. In this respect, in hippocampal pyramidal neurones, postsynaptic
activation ofGABAb receptors (like A, R activation) evokes a hyperpolarization
which is accompanied by a reduction in input resistance, mediated by an inwardly
rectifying K+ conductance (Newberry & Nicoll, 1984b; Blaxter & Carlen, 1985;
Inoue et al. 1985). Nevertheless, although (-)-baclofen depressed EPSPMs at a
concentration which also caused a substantial hyperpolarization, this
hyperpolarization alone cannot account for the depression, as this was routinely
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compensated for using positive current injection. Equally, the reduction in input
resistance caused by activation of a K+ conductance could feasibly limit the extent of
depolarization during the EPSPM by shunting ofmembrane currents. This
possibility, however, is unlikely in the case of the effect ofNNC 05-0711, as the
maximum duration of the IPSPB, even in the presence ofNNC 05-0711, is little
greater than 1 s, which is more than 1 s less than the time to peak of the EPSPM.
Likewise, the facilitatory effect ofCGP 55845A alone on the EPSPM cannot be
explained by the shunting ofmembrane currents, unless shunting in the first 1 s of
the EPSPm affects its activation.
Finally, it is possible that GABAb receptor activation somehow interferes with the
postsynaptic signal transduction of mAChR-mediated responses. As mentioned
above, GABAb receptors and A,Rs act via very similar signal transduction
mechanisms. Thus, both receptors are coupled to inhibitory G-proteins of the G, or
G0 subtype (Dutar & Nicoll, 1988b; Thalmann, 1988; Trussel & Jackson, 1987) and
both receptors negatively couple to the AC/cAMP system (Sattin & Rail, 1970;
Wojcik et al. 1990). However, as discussed in chapter 5, it is unlikely that these
mechanisms, when operating postsynaptically, are responsible for the depression of
cholinergic responses because M, and M3 mAChRs couple to the Gq/Gn subtypes of
G-proteins which couple to the PLC second messenger system. Nevertheless,
GABAb receptor activation can enhance IP3 production (Karbon et al. 1990; Wojcik
et al. 1990; Crawford & Young, 1990) which conceivably might interfere with the
M,/M3 mAChRs mediated effects.
The true mechanism ofGABAb receptor mediated inhibition ofmAChR-mediated
effects cannot be elucidated until it is clear
i) whether the effect of (-)-baclofen is pre- or postsynaptic, and
ii) which mAChRs and transduction mechanisms mediate EPSPMs and inhibition
in SFA.
122
6.3.2. Endogenous GABA Activates GABAb Receptors to Inhibit
Cholinergic Synaptic Responses
It is already well known that GABA, which is synaptically released from
hippocampal interneurones, has a physiological role in the hippocampus. In this
respect, synaptically released GABA activates both GABAa and GABAb receptors
that mediate the early IPSPA and late IPSPB, respectively (Krnjevic & Schwartz,
1967; Dutar & Nicoll, 1988c). In addition, synaptically released GABA can activate
presynaptic GABAb auto- and hetero-receptors to inhibit GABA- and glutamate-
mediated synaptic transmission, respectively (Dutar & Nicoll, 1988b; Harrison et al.
1988). The possibility that endogenous GABA could also inhibit cholinergic
synaptic transmission was suggested here by the action of the selective GABAB
receptor antagonist CGP 55845A to increase the amplitude of EPSPMs beyond
control levels. This observation implies that endogenous GABA might inhibit
EPSPms under control conditions. This suggestion is further strengthened by the
effects ofNNC 05-0711, which has been shown to selectively inhibit the uptake of
GABA from synaptosomal and neuronal preparations (Suzdak et al. 1992). In this
respect, NNC 05-0711 increased the amplitude of IPSPBs and inhibited EPSPMs in a
CGP 55845A-sensitive manner. However, it is unclear whether the GABA, that
activates the GABAB receptors that inhibit the EPSPM, is actually present in the
extracellular medium or whether it is released by, for example, GABAergic
interneurones when afferent stimulation is delivered. An intriguing possibility is that
GABA is co-released from cholinergic terminals or from septohippocampal
GABAergic projections, instead of intrinsic GABAergic interneurone terminals.
6.4. SUMMARY
There is a GABAB receptor-mediated inhibition of cholinergic synaptic responses in
area CA1 of the rat hippocampus. Endogenous GABA may activate these GABAb
receptors to inhibit EPSPMs. It is unclear whether this effect is mediated pre- or post-
synaptically. However, the mechanism of this depressant action appears to differ





7.1. CHOLINERGIC SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPUS
The initial aim of this thesis was to establish a protocol for the investigation of
cholinergic synaptic responses at rat septohippocampal CA1 synapses in isolation.
Like earlier studies, mAChR-mediated synaptic responses were evoked using
stimulation of the septohippocampal pathway in 5. oriens (Cole & Nicolh 1983). For
the first time, however, EPSPMs were evoked using just a single stimulus. In this
respect, EPSPMs evoked in the present study differed from those evoked previously
in that:
i) no activity dependent changes, e.g. facilitation/depression, were associated
with their activation.
ii) they were routinely evoked in the absence of cholinesterase inhibitors that
inhibit the breakdown of ACh.
iii) they were isolated from ionotropic glutamate and GABA receptor mediated
synaptic responses to avoid possible effects on the induction and expression of
EPSPms (such as the GABAb receptor-mediated inhibition described in chapter
6).
iv) they were shown, for the first time, to be reproducible over a prolonged period
(several hours).
v) they were reproducibly evoked every 5-10 minutes (compared to every 15
minutes, as in previous studies).
This experimental protocol was utilized for the investigation of cholinergic synaptic
transmission and, in particular, to study the modulation ofmAChR-mediated
synaptic responses by adenosine and GABA receptor activation.
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7.1.1 Cholinergic Synaptic Responses
Data presented in this study have shown that synaptic activation ofmAChRs on
hippocampal CA1 pyramidal neurones, using the protocol described above, inhibits
spike frequency adaptation (SFA) and causes a slow depolarization or EPSPM. In
addition to activation of these classic mAChR-mediated responses, synaptic
activation ofmAChRs should, in theory, mimic other effects ofmAChR agonists. In
this respect, some preliminary data has shown that synaptic activation of mAChRs
may affect the duration of action potentials and evoke membrane oscillations in the
frequency range of theta rhythm (see Chapter 3). As such, this study extends the
mechanisms by which synaptic activation ofmAChRs can modulate postsynaptic
excitability in the hippocampus adding to the many mechanisms described over the
past two decades (Dodd et al. 1981; Cole & Nicoll, 1983; Figenschou et al. 1996).
Both cholinergic systems and the hippocampus are thought to be closely involved in
the process of learning and memory formation (Decker & McGaugh, 1991; Aigner,
1995). Much evidence for this comes from behavioural experiments which show that
disruption of the cholinergic system, using either mAChR antagonists or lesions of
the septohippocampal pathway, impairs the ability of rats and humans to perform
learning and memory tasks (Bartrus et al. 1982). As such, the increased excitability
afforded by mAChRs may be important for modulating the effects of other
neurotransmitters, e.g. glutamate, in the hippocampal region. In this respect, at a
synaptic level, it has been shown that activation ofM, mAChRs can facilitate the
induction of LTP, a synaptic modification believed to be important in learning
(Blitzer et al. 1990).
7.1.2 Modulation of Cholinergic Synaptic Responses
In view of the potential importance ofmAChR-mediated effects in cognitive
function, mechanisms which control their activation are likely to provide a further
level of control of learning and memory processes. Whilst previous studies have
shown that ACh turnover in vivo, or evoked ACh release from isolated hippocampal
slices, is inhibited by A,R activation (Cunha et al. 1994), I have demonstrated, for
the first time, the functional consequences of this inhibition. This is described in
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terms of the presynaptic action ofA,Rs to inhibit the effects of synaptic activation of
mAChRs (chapter 4 & 5).
In addition to A,R-mediated modulation, this thesis also dealt with a modulation of
cholinergic synaptic transmission by GABAb receptor activation. A,Rs and GABAb
receptors share many similarities, in that
i) both positively couple to K+ and negatively couple to Ca++ channels in the
hippocampus,
ii) both are G-protein coupled receptors and negatively couple to the AC/cAMP
system, and
iii) both are located pre- and post-synaptically in the hippocampus.
However, GABA and adenosine differ fundamentally in that, while GABA is
released synaptically at specific locations and acts predominantly at that site of
release, adenosine is produced and released non-synaptically from many locations
and may act at sites distant from the point of release. In this respect, while
mechanisms exist for the breakdown and the uptake of adenosine, adenosine is
thought to maintain a basal extracellular concentration and exert a tonic action in
neuronal tissue. In contrast, GABA has a more temporally discrete action. This
difference may affect the function of these modulators, as GABA will tend to act
predominantly at points close to where GABA synapses are active, whereas
adenosine could act in a "blanket" manner to inhibit numerous cholinergic inputs at
the one time. As such, the two neuromodulatory systems are likely to modulate
mAChR synaptic transmission to different extents during different patterns of
neuronal activity, whether this be during normal physiological functioning or in
pathophysiological states.
7.2. FUTURE RESEARCH
7.2.1 Cholinergic Synaptic Transmission in the Hippocampus
Although this study has concentrated on the modulation of cholinergic synaptic
responses by other receptor systems, there is much to be learned about the
pharmacology ofmAChR-mediated responses and the transduction mechanisms that
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mediate these responses. Indeed, in addition to the large variety of conductances
which are known to be modulated by mAChRs, there are a number of effects (e.g. on
action potential kinetics) which are poorly characterized. Further analysis of the
variety of conductances inhibited or activated by synaptic activation ofmAChRs,
using voltage clamp techniques and using inhibitors of a variety of transduction
mechanisms (e.g. inhibition ofPKC using dihydrosphingosine) would help to clarify
the mechanisms ofmAChR activation in the hippocampus. If drugs which
selectively modulate the cholinergic system are to be effective with few side effects,
it will also be necessary to elucidate which subtype(s) of mAChR mediate each of
these effects and to develop more subtype selective mAChR agonists and
antagonists.
Another factor which limits the ease of study of cholinergic synaptic transmission in
the hippocampus, is the fatigue of EPSPMs on repetitively stimulating at interstimulus
intervals of less than 5-8 min. Initially, further work might focus on determining
whether the mechanism behind this process is pre- or post-synaptically mediated. A
clue to the mechanism underlying this depression may come from the
hyperpolarization sometimes observed following an EPSPM as this often lasts over
the time period during which the fatigue occurs. The prolonged duration of the
fatigue might suggest effects on the postsynaptic biochemistry of the cholinergic
signaling pathway. A G-protein dependent desensitization of mAChR-mediated
responses has been reported in the hippocampus (Guerineau et al. 1997). As such, it
would be interesting to study the involvement of G-proteins in this fatigue.
However, compounds which affect G-protein function, such as the G-protein
activator and inhibitor GTP-y-S and GDP-p-S, respectively, may well disable the
EPSPm itself. In addition, whether mAChRs themselves or other receptor systems,
(e.g. galanin, which is coreleased with ACh), mediate the hyperpolarizing response
should be addressed. Indeed, the mechanism(s) of this response is/are also unclear
and therefore may involve
i) purely ionic mechanisms or
ii) activation of intracellular signal transduction processes such as the PLC/IP3
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system.
The mechanism underlying the fatigue of EPSPMs may have important functional
consequences for cholinergic function in vivo. Depression of EPSPMs or a prolonged
hyperpolarization, could limit the effectiveness of the cholinergic system to modulate
mnemonic processing and, more importantly, could limit the effectiveness of
cholinergic drug treatment in, for example, Alzheimer's Disease.
The effects of cholinergic activity in the hippocampus on the induction of long term
synaptic plasticity should also be addressed. This possibility may be investigated by
examining the effect of cholinergic synaptic activation on synaptic plasticity in area
CA1 and CA3 of the rat hippocampus. The success of such a study will depend on
the degree of synapse specificity of the modulatory effects of cholinergic synaptic
activation. It may be that only synapses, subject to plastic change, which are
spatially adjacent to cholinergic synapses will be affected at lower levels of
cholinergic stimulation. A further complicating factor may be the multiple effects of
mAChR activation in the hippocampus. In this respect, higher levels of cholinergic
synaptic activation could lead to a depression rather than potentiation of the
glutamatergic synaptic responses.
EPSPms have not been shown to occur during normal brain activity in vivo. Indeed,
such prolonged excitation would be expected to be detrimental to hippocampal
neurones. As such, it may be that these large, prolonged depolarizations represent a
pathophysiological response relevant, for example, to when hippocampal inhibition
is impaired. Indeed, the presence of several mechanisms for the control of such
depolarizing responses (the effects of adenosine and GABA and the depression of
responses on repeated stimulation) suggests a need for control to prevent the
overactivation of the cholinergic system. It would be interesting if, using
simultaneous paired cell recording from neurones in the septum and hippocampus, it
is possible to activate EPSPMs purely by depolarizing a presynaptic septal cholinergic
neurone to fire just a single action potential or a series of action potentials. However,
a simultaneous, synchronized stimulation of a number of septal cholinergic neurones
may be required to evoke even small EPSPMs. As such, it is possible that cholinergic
128
synaptic function in vivo consists of only small depolarizations at single synapses
and/or alterations in the firing frequency of pyramidal neurones. In this respect,
mAChR activation would maintain a modulatory influence on excitability of
neurones and possibly individual synapses, rather than having a direct excitatory
action. Nevertheless such a modulatory influence would have profound effects on
the functioning of neuronal networks and synaptic integration.
7.2.2 Adenosine Receptor Modulation ofCholinergic Synaptic
Transmission
The present study shows that A,R activation is an effective mechanism for the
control of both depolarizing responses and inhibition of SFA. Indeed, results
presented in chapter 5 suggest that adenosine, endogenous to the hippocampus, may
tonically modulate cholinergic responses in vitro at least. It is possible that in vivo,
basal levels of adenosine tonically modulate mAChR-mediated synaptic
transmission. Some studies have estimated the concentration of endogenous
adenosine to be 0.03-2.0 pM in brain tissue (Zetterstrom et al. 1982, Fredholm et al.
1984). In the present study adenosine was effective only at much higher
concentrations. However, this does not equate to the concentration of adenosine at
cholinergic synapses in the slice preparation due to diffusional constraints and uptake
mechanisms that are active within the slice. In this respect, where adenosine is
released there may be no uptake such that adenosine levels may be particularly high.
Nevertheless, an increased tonic level of adenosine may be required to inhibit
cholinergic responses in vivo.
Adenosine is released from neuronal tissue and may exert control over of a number
of transmitter systems, although the source of this adenosine is controversial. One
source of adenosine is from the breakdown ofATP. Hippocampal cholinergic nerve
terminals possess the enzymatic machinery to metabolize extracellular ATP to
adenosine (Cunha et al. 1992). ATP is stored and co-released with ACh at
cholinergic motor nerve terminals (Downall et al. 1974; Silinsky, 1975) where both
ATP and adenosine inhibit evoked and spontaneous release of ACh (Ginsborg &
Hirst, 1972; Ribeiro & Walker, 1973). There is no evidence of synaptic release of
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ATP in the hippocampus, although metabolic ATP may be released in the
hippocampus during metabolic stress, e.g. during hypoxia. As such, adenosine is
thought to control excitability during hypoxia. A natural extension of the present
study, therefore, would be to address the effects of experimentally induced hypoxia
on cholinergic synaptic responses and the role of adenosine in the control of
cholinergic excitation during hypoxia.
Whilst this study deals with the presynaptic aspects of control, it is, however, still
possible that A,Rs affect mAChR-mediated responses postsynaptically as well as
presynaptically. In this respect, an inhibitory postsynaptic effect of adenosine may
be "swamped" by the large effects ofmAChR activation. To further investigate this
possibility, it may be prudent to use a lower level of mAChR activation in order to
increase the chance and observing any the postsynaptic inhibitory actions of
adenosine. As such, a better technique for the investigation of lower levels of ACh
release would be to employ patch clamp techniques to voltage clamp neurones and
provide a more accurate quantification of mAChR-mediated inhibition of IAHP, for
example. This would allow the investigation ofmore subtle effects of adenosine
receptor activation on a lower level of mAChR activation which is required to
produce this postsynaptic mAChR-mediated effect. One limitation of this method,
however, is the potential to dialyze intracellular contents essential for the
transduction of the mAChR-mediated response. This may be overcome by the use of
the nystatin perforated patch approach, as this will limit the extent of the dialysis.
Adenosine receptor activation has been shown to bidirectionally modulate the release
ofACh in area CA3 but not area CA1 of the hippocampus (Cunha et al. 1994). In
this respect, in area CA3, activation ofA,Rs inhibits ACh release and A2aRs
enhances ACh release. Thus, adenosine is able to differentially affect cholinergic
synaptic transmission in different areas of the same structure. Further studies might
concentrate on the modulation of cholinergic synaptic transmission at CA3 pyramidal
neurones and look for possible interactions between A,R and A2aR-mediated effects.
Depending on the location of these receptors and the concentration of adenosine to
which they are exposed, differential effects on EPSPMs could be observed.
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Preliminary results presented in chapter 5 suggest that the A,R-mediated inhibition of
EPSPms may in part involve 4-AP-sensitive K+ channels and inhibition of cAMP
turnover. Further work might focus on more detailed classification of any K+
channels involved in the inhibitory action of adenosine using the K+ channel
antagonist a-dendrodotoxin, for example. In addition, the role of the AC/cAMP
system should be addressed using, for example the AC activator forskolin and
inhibitors such as SQ 22,536.
Based of the concept that presynaptic A,Rs modulate cholinergic synaptic
transmission, the involvement of Ca++ channels in the A]R-mediated modulation of
cholinergic synaptic responses should also be addressed. In studies ofA]R-mediated
inhibition of glutamate release, A,R activation appears to involve the inhibition of bl¬
and possibly Q-type voltage activated Ca++ channels (Wu & Saggau, 1994). It would
be advantageous, firstly, to ascertain which subtype(s) of voltage activated Ca++
channels modulate the release of ACh per se in the hippocampus using co-conotoxin-
GVIA and co-agatoxin-IVA. The action ofA,R agonists on the responses which
remain following application of individual or combinations of Ca++ channel blockers
could then give an indication as to the subtype(s) that may be involved in the A,R-
mediated inhibition.
7.2.3 GABA Receptor Modulation of Cholinergic Synaptic
Transmission
Less well defined than the effects ofA,R activation on mAChR-mediated responses
are the effects ofGABAb receptor activation. It is unclear why (-)-baclofen, even at
a high concentration, did not completely inhibit the mAChR-mediated inhibition of
SFA. The effect of a "supramaximal" concentration of (-)-baclofen was not
systematically tested on the EPSPM, but at the highest concentration used this agonist
did not completely inhibit the EPSPM. If the effect of (-)-baclofen is presynaptic, it
may be that GABAb receptor activation does not inhibit the release of ACh as
effectively as A,R activation. In this respect, there may be cholinergic fibers which
differentially express GABAb receptors whereas all express A,Rs. Such a concept is
not unrealistic since differences in cholinergic inputs do exist. Thus, for example
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galanin inhibits cholinergic synaptic responses in ventral but not dorsal hippocampus
(Dutar et al. 1989). As to the source ofGABA, there are two possible sources:
i) from interneurones activated by the stimulus used to evoke the EPSPM, or
ii) from excitatory inputs e.g. from cholinergic afferents themselves.
The involvement ofGABA released from direct activation of interneurones could be
tested by evoking an EPSPM by stimulating at a point distant from the CA1, e.g. the
fimbria, and applying a GABA uptake inhibitor e.g. NNC 05-0711. If there is no
effect of the GABA uptake inhibitor then this would suggest that release of
endogenous GABA from cholinergic afferents is not responsible for inhibition of the
EPSPm and that GABA release under normal experimental conditions is as a result of
direct activation of interneurones in the CA1 alone.
7.2.4 Modulation of Cholinergic Synaptic Transmission byOther
Mechanisms
As well as a modulation by adenosine and GABAb receptors, previous studies
together with those ongoing in this laboratory have shown that other receptor systems
modulate cholinergic synaptic responses and ACh release. These include galanin
receptors and mAChRs themselves (Dutar et al. 1989; Pepeu et al, 1990). mAChR
agonists and antagonists have been shown to modulate the release of radiolabelled
ACh. As such, it may be possible, using selective cholinergic agonists and
antagonists, to promote or inhibit cholinergic synaptic responses, providing the
receptors prove to be pharmacologically distinguishable from postsynaptic mAChRs.
The functional significance of presynaptic mAChRs in modulating evoked EPSPMs
may have already been demonstrated in the observation that atropine sometimes
enhanced EPSPMs prior to inhibiting them (data not shown). As such, in a few cases
atropine may have affected presynaptic mAChRs more rapidly than postsynaptic
mAChRs, so transiently enhancing the release of ACh and hence the amplitude of
EPSPms. However, more detailed experiments are required to confirm this
preliminary observation.
Recent studies have shown that P-amyloid peptide fragments have an inhibitory
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effect on a number of cholinergic neurotransmitter processes in neuronal cell
cultures. In addition, p-amyloid peptide fragments can inhibit ACh release in
hippocampal and cortical slices (see Auld et al. 1998 for review). P-amyloid peptide
has been found to be deposited in neuritic plaques throughout the brains of patients
with Alzheimer's Disease (AD). As such, investigation of the effect(s) of such
peptide fragments on cholinergic synaptic transmission, using the methods described
in this thesis, would allow a more detailed analysis of the inhibitory mechanism of
their action. This would therefore provide a better understanding of the processes
involved in the initial stages ofAD.
7.3. POTENTIAL CLINICAL USES FOR MODULATORS OF
CHOLINERGIC SYNAPTIC TRANSMISSION
Cholinergic neurones are known to degenerate in AD (Coyle, 1983; Fibiger, 1991).
In addition, there is a large body of evidence to suggest that activation of mAChRs
facilitates, whereas antagonism and lesioning of cholinergic pathways impairs
learning and memory processes (Bartrus et al. 1982). Moreover, mAChR activation
has been shown to be involved in the induction of certain forms of long-term
synaptic plasticity (e.g. LTP) which are thought to represent in vitro models of
learning and memory processes in vivo (Blitzer et al. 1990; Auerbach & Segal,
1996). As such, agents which modify cholinergic function may have clinical uses in
disease processes where mnemonic processing is compromised, e.g. AD (Giacobini,
1990; Thai, 1996).
AD and dementia syndromes are often associated with aging. In this respect
cholinergic function has been investigated in aged animals. Cholinergic receptor
binding has been shown to be compromised in aged gerbils and rats (Hara et al.
1992). However, changes in mAChR binding in postmortem human brains ofAD
patients are less clear. In some, mAChR binding is unaffected in the hippocampus
but not in the cortex ofAD patients (Lang & Henke, 1983). In contrast, another
group has reported an increase in mAChR number in AD patients, although this is
thought to be due to a compensatory increase in receptor number in response to
reduced ACh release. In the same study, however, reduced mAChR binding was
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seen in more severe AD cases, although it is unclear whether this is due to a loss of
select populations of neurones (Probst et al. 1988). In addition, functional studies
have shown that ACh release and slow cholinergic synaptic responses are impaired in
aged rats (Potier et al. 1992; Pedata et al. 1983b; Wu et al. 1988). As such, there is a
large body of evidence to suggest that therapies that facilitate cholinergic function
may be useful in the treatment of dementia or AD. In this respect, drug companies
continue to develop subtype selective mAChR agonists as well as AChE inhibitors.
In contrast, endogenous "adenosinergic" inhibition has been shown to be enhanced in
aged animals (Bauman et al. 1992). Based on the present evidence, this enhanced
adenosinergic inhibition would contribute to the decline of cholinergic function in
aged animals due to an increased A,R-mediated inhibition of cholinergic synaptic
transmission. As such, therapies that inhibit A,R-mediated inhibition of cholinergic
synaptic transmission may be advantageous in the treatment of dementia or AD.
However, A,R agonists may not be of clinical use because of their multiple actions
throughout the nervous system and vasculature.
A similar problem exists with respect to the clinical use ofGABAb receptor
antagonists to counteract a decline in cholinergic function, in that GABA is the most
prominent inhibitory neurotransmitter in the CNS. As such, drugs which affect
GABAb receptor function would potentially have poor specificity and may result in,
for example, epileptogenesis, due to a reduced inhibition of glutamatergic synaptic
transmission in the hippocampus. Saying this, to date GABAb receptor antagonists
have been shown to be reasonably well tolerated by humans and indeed are capable
of enhancing cognitive performance in humans and primates (Mondadori et al.
1992). More promising may be the development of drugs which affect other receptor
systems which inhibit or enhance cholinergic function but have fewer effects in the
brain than A,Rs and GABAb receptors. Of possible interest is the limited
distribution of A2aRs. The enhancement ofACh release by adenosine has been noted
in area CA3 in the hippocampus but not the CA1 (Cunha et al. 1994). In this respect,
A2aR agonists could be used to facilitate cholinergic synaptic function although again
these receptors also promote glutamate release (Okada et al. 1992). In addition to
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modulation of cholinergic function by such heteroreceptors, mAChR autoreceptors
may prove to be pharmacologically distinct from mAChRs which mediate
postsynaptic responses. As such, selective enhancement of ACh release could be
achieved using antagonists at these receptors. Clearly there are numerous
possibilities for modulation of cholinergic synaptic transmission, however, it remains
to be seen whether any of these has potential for therapeutic usage.
In this respect, the development of cholinergic therapies in the past has led to only
limited success in relieving the cognitive impairment found in AD and dementia
(Thai, 1996). Part of the problem no doubt reflects the fact that cholinergic
impairment is thought to represent just one aspect of the cognitive impairments found
in such disorders. Nevertheless, other disease processes, e.g. Parkinson's disease and
Huntingdon's disease, also exhibit a degree of cholinergic dysfunction and might
benefit more from the development of drugs which modify cholinergic function in
vivo.
Finally an additional problem, with respect to the development of cholinergic
therapies, exists. Systemic administration of drugs which act at AChRs will result in
many side effects due to the many peripheral effects mediated by AChRs both in
sympathetic and parasympathetic nervous system. This has been a long standing
problem with many CNS drugs such as neuroleptics, which classically exhibit
atropine-like side effects, such as dry mouth and constipation. Such problems can be
counteracted to some extent by developing pro-drugs which can be converted to the
active form at or near the site of action.
Whatever the case the development of therapies which modulate the cholinergic
system in the CNS will require further investigation of the pharmacology and
mechanisms of cholinergic synaptic transmission and its possible functional
significance in mnemonic processing.
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Adenosine receptor-mediated modulation of
cholinergic synaptic transmission in the rat
hippocampus in vitro
R.A. Morton and C.H. Davies
Department of Pharmacology, 1 George Square, University
of Edinburgh, Edinburgh EH8 9JZ
The hippocampus receives a dense cholinergic input from
the medial septal nucleus, which is believed to play an
important role in learning and memory processes (Dutar el
al. 1995). Stimulation of this pathway has been shown to
evoke a slow muscarinic cholinergic receptor (mAChR)-
mediated excitatory postsynaptic potential (EPSP; Cole &
Nicoll, 1984). Unlike amino acid-mediated synaptic
transmission, this synaptic input has received relatively
little attention in terms of its modulation by other receptor
systems. The purpose of the present study, therefore, was to
investigate how adenosine receptor activation affects isolated
slow cholinergic EPSPs.
Transverse hippocampal slices from 2- to 4-week-old
female Wistar rats were prepared using standard techniques
and maintained at 33-35 °C in an interface recording
chamber. Intracellular recordings were made from CA1
pyramidal neurones using electrodes (70-110 Mf2) filled
with potassium methylsulphate (2 m). In all experiments
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 /im),
D-(E)-2-amino-4-methyl-5-phosphono-3-pentanoic acid
(CGP 40116; 50 /im), picrotoxin (50 /im) and 3-IV-(l-(S)-(3,4-
dichlorophenyl) ethyl) amino-2-(5)-hydroxypropyl-p-benzyl-
phosphonic acid (CGP 55845A; 1 /im) were included in the
perfusing medium to block a-amino-3-hydroxy-5-methyl-
1,4-isoxazole (AMPA), IV-methyl-D-aspartate (NMDA),
y-aminobutyric acid (GABA)a and GABAb receptors,
respectively. Under these conditions, reproducible slow
EPSPs could be evoked every 8 min using a single, high
intensity stimulus delivered in stratum oriens. The
amplitude and duration of these EPSPs were increased by
physostigmine (1 /im), and were inhibited by atropine
(1-2 /im).
2-Chloroadenosine (CADO, 0-2-2 /im) reversibly depressed
slow EPSPs in a concentration-dependent manner; for
example, at 1 /im, CADO depressed the EPSP by 87 + 9%
(n = 8, mean + s.e.m.). Likewise, 2-chloro-A6-cyclopentyl
adenosine (CCPA, 0-1-0-4 /im) inhibited slow EPSPs (n = 3),
whereas 2-p-(2-carboxyethyl) phenethylamino-5'-IV-ethyl-
carboxamidoadenosine (CGS 21680, 1 /lm) did not (n = 3).
8-Cyclopentyl-l ,3-dipropylxanthine (DPCPX; 200 nM) fully
reversed the CADO-induced depression of slow EPSPs such
that responses in DPCPX plus CADO (1 /jlm) were
107 + 11 % of control (n = 3).
These data suggest that in the presence of ionotropic
amino acid receptor antagonists it is possible to evoke slow
mAChR-mediated EPSPs in CA1 pyramidal neurones that
are depressed by adenosine A, receptor activation.
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Adenosine A, Receptors Presynaptically Inhibit Muscarinic Cholinergic EPSPs
in the Rat Hippocampus) R.A. Morton and C H Davies. (SPON: Brain Research
Association) Department of Pharmacology, University of Edinburgh, 1 George
Square. Edinburgh, EH8 9JZ, UK.
Stimulation of septo-hippocampal cholinergic fibers in stratum oriens produces a
slow muscarinic cholinergic excitatory post-synaptic potential (EPSP) in CA1
pyramidal neurones of the rat hippocampus. This pathway is believed to be
particularly important in learning and memory in the vertebrate central nervous
system As such, mechanisms that control this synaptic input are of particular
interest. In this respect, we have demonstrated previously that adenosine Ai receptors
inhibit muscarinic EPSPs in CA1 pyramidal neurones (Morton & Davies,./ Physiol.,
1996). Here we focus on whether this effect is pre- or post-synaptically mediated
Extracellular recording from stratum radtatum and intracellular current clamp
recording from CA1 pyramidal neurones was used to compare known pre- and post¬
synaptic effects of the adenosine receptor agonist 2-chloroadenosine (CADO) with its
effect on muscarinic EPSPs. CADO caused a concentration dependent presynaptic
inhibition of field recorded glutamate EPSPs (n=4) with an ICM of 0.6 pM.
Postsynaptically, CADO caused a hyperpolarization (up to 15 mV) and a
concomitant reduction in input resistance (n=4) with an ECjo of 2 7 pM The lC5o for
the depressant action of CADO on cholinergic EPSPs was 0.4 pM, which is
comparable with the ICso for the presynaptic inhibition of glutamatergic EPSPs All
these effects were reversed by DPCPX (200 nM) In a separate series of experiments,
brief bath applications of carbachol caused consistent depolarizations and increases
in input resistance. These effects were unaffected by CADO (1 pM; n=4) but were
abolished by atropine (1-5 pM; n=3).
These data suggest that CADO exerts its inhibitory effect on muscarinic
cholinergic synaptic transmission by inhibiting acetylcholine release via presynaptic
adenosine A, receptors. (R. Morton is an M.R.C funded PhD student)
274P GABAB RECEITOR-MEDIATED MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR-MEDIATED
SYNAPTIC RESPONSES IN THE RAT HIPPOCAMPUS
R.A. Morton, D O. Bulters & C.H. Davies, Dept. of Pharmacology,
University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ.
The hippocampus receives a dense cholinergic input from the
medial septal nucleus, which is believed to have an important role
in learning and memory processes in vivo. Stimulation of this
pathway in vitro has been shown to evoke muscarinic acetylcholine
receptor (mAChR)-mediated responses in hippocampal pyramidal
neurones. Recently we have shown that adenosine Ai receptors,
which couple to similar effector systems to y-aminobutyric acid
(GABA)b receptors, modulate mAChR-mediated responses
(Morton & Davies, 1997). Here we report the effects of GABAb
receptor activation on mAChR-mediated synaptic responses in the
CA1 region of the rat hippocampus.
Transverse hippocampal slices from 2- to 4-week-old female Cob-
Wistar rats were prepared using standard techniques and
maintained at 32 ± 2 °C in an interface recording chamber
continuously perfused with artificial cerebrospinal fluid gassed
with 95 % 02/5 % C02. Intracellular current clamp recordings
were made from CA1 pyramidal neurones using electrodes (70-110
MD) filled with potassium methylsulphate (2 M). In all
experiments 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione
(NBQX; 2-4 pM), D-(E)-2-amino-4-methyl-5-phosphono-3-
pentanoic acid (CGP 40116; 50 pM) and picrotoxin (50 pM) were
included in the perfusing medium to block a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate
(NMDA) and GABAa receptors respectively. Under these
conditions, reproducible GABAb receptor-mediated IPSPs (EPSPbs)
followed by slow mAChR-mediated EPSPs (EPSPMs) could be
evoked using a single stimulus delivered in the stratum oriens.
The selective GABAb receptor agonist baclofen (5 pM) occluded
IPSPbS and inhibited EPSPMs by 71 ± 15 % (n = 4, mean ±
s.e.mean). The selective GABAb receptor antagonist [l-(5)-3,4-
(dichlorophenyl)ethyl] amino-2-(S)-hydroxypropyl-p-benzyl-
phosphonic acid (CGP 55845A; 1 ^iM), when applied alone,
inhibited EPSPBs and increased the amplitude of EPSPMs to 253 ±
74 % of control responses (n = 3). In contrast, the GABA uptake
inhibitor diphenylmethanone, 0-[2-(3-carboxy-1,2,5,6-tetrahydro-l-
pyridinyl)ethyl]oxime, HC1 (NNC 05-0711, 10 pM) increased the
amplitude of IPSPBs to 241 ± 38 % of control amplitudes and
depressed EPSPMs by 58 ± 10 % (n = 4). CGP 55845A (1 pM)
reversed this inhibition of EPSPMs and abolished the IPSPbS (n =
2).
These data suggest that there is a GABAb receptor-mediated
inhibition of cholinergic synaptic transmission which can be
activated by endogenously released GABA.
R.A.M. is an MRC funded Ph.D. student. We thank Dr. W. Froestl
and Dr. M.F. Pozza (Novartis, Basle) for gifts of CGP55845A and
CGP 40116.
R.A. Morton and C.H. Davies (1997), J. Physiol. 502.1, 75-90.
6246 Journal of Physiology (1997), 502.1, pp.75-90 75
Regulation of muscarinic acetylcholine receptor-mediated
synaptic responses by adenosine receptors in the rat hippocampus
Robin A. Morton and Ceri H. Davies
Department of Pharmacology, University of Edinburgh, 1 George Square,
Edinburgh EH8 9JZ, UK
1. Intracellular current clamp recordings were made from CA1 pyramidal neurones in rat
hippocampal slices. Experiments were performed in the presence of ionotropic glutamate
receptor antagonists and y-aminobutyric acid (GABA) receptor antagonists to block all fast
excitatory and inhibitory synaptic transmission. A single stimulus, delivered extracellularly in
the stratum oriens, caused a reduction in spike frequency adaptation in response to a
depolarizing current step delivered 2 s after the stimulus. A 2- to 10-fold increase in stimulus
intensity evoked a slow excitatory postsynaptic potential (EPSP) which was associated with a
small increase in input resistance. The peak amplitude of the EPSP occurred approximately
2-5 s after the stimulus and its magnitude (up to 30 mV) and duration (10—50 s) increased with
increasing stimulus intensity.
2. The slow EPSP was unaffected by the metabotropic glutamate receptor antagonist (-t-)-a-methyl-
4-carboxyphenylglycine ((+)-MCPG; 1000 ym) but was greatly enhanced by the acetyl¬
cholinesterase inhibitor physostigmine (1—5 ym). Both the slow EPSP and the stimulus-evoked
reduction in spike frequency adaptation were inhibited by the muscarinic acetylcholine receptor
(mAChR) antagonist atropine (1-5 yw). These results are consistent with these effects being
mediated by mAChRs.
3. Both the mAChR-mediated EPSP (EPSPm) and the associated reduction in spike frequency
adaptation were reversibly depressed (up to 97%) by either adenosine (100 ym) or its non-
hydrolysable analogue 2-chloroadenosine (CADO; 0*1—5'0/<m). These effects were often
accompanied by postsynaptic hyperpolarization (up to 8 mV) and a reduction in input
resistance (up to i 1 %). The selective adenosine Aj receptor agonists 2-chloro-IV -cyclopentyl-
adenosine (CCPA; 0-l—0*4 ym) and R(—)iV6-(2-phenylisopropyl)-adenosine (R-PIA; 1 ym) both
depressed the EPSPm. In contrast, the adenosine A2A receptor agonist 2-p-(2-carboxyethyl)-
phenethylamino-5'-IV-ethylcarboxamidoadenosine (CGS 21680; 0-5—1-0 yu) did not significantly
affect the EPSPm.
4. The selective adenosine Ax receptor antagonist 8-cyclopentyl-l,3-dipropylxanthine (DPCPX;
0*2 yu) fully reversed the depressant effects of both adenosine (100 ym) and CADO (1 yu) on
the EPSPm and the stimulus-evoked reductions in spike frequency adaptation.
5. DPCPX (0-2 ym) alone caused a small but variable mean increase in the EPSPm of 22 + 19%
and enabled activation of an EPSPm by a previously subthreshold stimulus. In contrast, the
selective adenosine kinase inhibitor 5-iodotubercidin (5-IT; 10 ym) inhibited the EPSPm by
74 + 10%, an effect that was reversed by DPCPX.
6. The concentration—response relationship for the depressant action of CADO on the EPSPm more
closely paralleled that for its presynaptic depressant action on glutamate-mediated EPSPs than
that for postsynaptic hyperpolarization. The respective mean IC60 and ECS0 concentrations for
these effects were 0-3, 0-8 and 3-0 ym.
7. CADO (1-5 //.m) did not have a significant effect on the postsynaptic depolarization, increase in
input resistance and reduction in spike frequency adaptation evoked by carbachol (0'5—3-0 ym).
All these effects were abolished by atropine (1 ym).
8. These data provide good evidence for an adenosine Aj receptor-mediated inhibition of mAChR-
mediated synaptic responses in hippocampal CA1 pyramidal neurones. This inhibition is
mediated predominantly presynaptically, is active tonically and can be enhanced when
extracellular levels of endogenous adenosine are raised.
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CA1 pyramidal neurones in the hippocampus receive multiple
intrinsic synaptic inputs as well as a number of extrinsic
synaptic inputs from diverse areas of the brain. One of the
most characterized extrinsic inputs is the septohippocampal
input (Dutar, Bassant, Senut & Lamour, 1995), which
comprises a heterogeneous population of afferents that
mediate their effects through the release of numerous neuro¬
transmitters including y-aminobutyric acid (GABA),
acetylcholine (ACh) and a variety of neuropeptides (Decker &
McGaugh, 1991; Dutar et al. 1995). Of these heterogeneous
inputs the cholinergic aspect of the septohippocampal input
to the hippocampus has probably received most attention
due to its involvement in mnemonic processing (Cole &
Nicoll, 1983; Decker & McGaugh, 1991; Dutar et al. 1995).
This input has been shown to activate a slow excitatory
postsynaptic potential (EPSP) and to reduce spike frequency
adaptation (sometimes referred to as action potential
accommodation) via muscarinic acetylcholine receptor
(mAChR)-mediated inhibition of K+ conductances (Cole &
Nicoll, 1983, 1984; Madison, Lancaster & Nicoll, 1987;
Segal, 1988; Pitler & Alger, 1990). This prolonged excitation
of CA1 pyramidal neurones, if left unregulated, can be
detrimental to these cells and may result in epileptogenesis
(Lothman, Bertram & Stringer, 1991; Wasterlain, Fujikawa,
Penix & Sankar, 1993). As such, mechanisms that control the
magnitude of the mAChR-mediated postsynaptic responses
are likely to be of major importance in maintaining the
normal functioning of the CNS.
A common mechanism of control of synaptic inputs within
the brain is via activation of different receptors from those
that mediate the postsynaptic response, e.g. activation of
autoreceptors, or presynaptic heteroreceptors (Thompson,
Capogna & Scanziani, 1993). The aim of this study, therefore,
was to investigate the possibility that a neurotransmitter/
neuromodulator other than ACh may restrict the activation
of the mAChR-mediated postsynaptic responses. We chose
to study adenosine since this neuromodulator plays an
important role in controlling the excitability of neuronal
networks by inhibiting other excitatory synaptic inputs, e.g.
glutamate (Thompson, Haas & Gahwiler, 1992; Thompson et
al. 1993). To do this we isolated stimulus-evoked mAChR-
mediatecl synaptic responses (i.e. the mAChR-mediated
EPSP (EPSPm) and the stimulus-evoked reduction in spike
frequency adaptation in CA1 pyramidal neurones) using a
cocktail of ionotropic glutamate and GABA receptor
antagonists to block all 'fast' excitatory and inhibitory
synaptic transmission. Using this approach we have been able
to investigate how drugs that affect the function of
adenosine at the levels of the receptor and its metabolism
influence both the EPSPm and the mAChR-mediated
reduction in spike frequency adaptation. Preliminary
accounts of part of this work have appeared in abstract form
(Morton & Davies, 1996a, 6).
METHODS
Female Wistar rats (2-4 weeks old) were cervically dislocated and
subsequently decapitated in accordance with UK Home Office
guidelines. The brain was removed rapidly and transverse
hippocampal slices were prepared by hemisecting the whole brain
minus the cerebellum and cutting 400 fim thick transverse coronal
slices containing hippocampal slices, using a vibroslicer (Campden
Instruments, Loughborough, UK). The CA3 region of each slice
was then cut away to eliminate changes in network function that
can occur due to epileptiform bursting in area CA3 when picrotoxin
is applied to the slice. The resultant CA3-ectomized slices were
placed on a nylon mesh at the interface of a warmed (32—34 °C),
perfusing (1-2 ml min-1) artificial cerebrospinal fluid and an
oxygen-enriched (95% 02—5% C02) humidified atmosphere. The
standard perfusion medium comprised (mM): NaCl, 124; KC1, 3;
NaHCOs, 26; NaH2P04, 1-25; CaCl2, 2; MgS04, 1; D-glucose, 10;
and was bubbled with 95% 02-5% C02.
Following a 1 h equilibration period, intracellular recordings were
obtained from the CA1 pyramidal cell body region using 2 m
potassium methylsulphate-filled microelectrodes (60-110 MQ). An
Axoclamp-2B amplifier (Axon Instruments) was used in
discontinuous (3-5 kHz switching frequency) current clamp mode.
All impalements were made in control medium. Once stable
recordings had been made for at least 10 min, all fast ionotropic
glutamate receptor-mediated synaptic transmission was blocked
using a combination of the a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA)/kainate receptor antagonists
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 fiu; Tocris
Cookson Ltd, Bristol, UK) or 6-nitro-7-sulphamoylbenzo(/)quin-
oxaline-2,3-dione (NBQX; 2-4/tM; Tocris Cookson Ltd), and the
Ar-methyl-D-aspartate (NMDA) receptor antagonists d-(E)-2-
amino-4-methyl-5-phosphono-3-pentanoic acid (CGP 40116; 50 /tM;
Ciba-Geigy Ltd) or D-2-amino-5-phosphonopentanoate (AP5;
50 /tM; Tocris Cookson Ltd), and all GABA-mediated synaptic
transmission was abolished using the GABAa receptor antagonist
picrotoxin (50 /tM; Sigma) and the GABAe receptor antagonist
3-lV-[l-(«S')-(3,4-dichlorophenyl)ethyl]amino-2-(iS)-hydroxypropyl-p-
benzyl-phosphonic acid (CGP 55845A; 1 /tM; Ciba-Geigy Ltd).
Bipolar stimulating electrodes, made from 55 /tin diameter
insulated nickel—chromium wire, were positioned in the stratum
oriens close to the recording electrode in the stratum pyramidale
(Fig. 14) to provide extracellular orthodromic activation of CA1
neurones. In each series of experiments, stimuli comprised square-
wave pulses (20-200 /ts; 5-30 V) delivered homosynaptically at a
fixed intensity every 5-10 min. Data were captured using
pCLAMP 6 software (Axon Instruments) and digitized records
were stored on the hard disk of a PC and on DAT tape (DTR-1404;
Biologic Scientific Instruments, Claix, France) for off-line analysis
using Clampfit software (Axon Instruments). During the period
between stimuli the input resistance and the extent of spike
frequency adaptation of each neurone were measured routinely
every 2 min using 300-600 ms long hyperpolarizing and depolar¬
izing current steps (+0T5—0-40 nA), respectively. In all experiments
in which EPSPms or stimulation-induced reductions in spike
frequency adaptation were evoked, baseline recordings comprised
either three successive EPSPms which had peak amplitudes that
differed by no more than 15%, or reductions in spike frequency
adaptation that were consistent over 20-30 min, respectively. Al!
drugs were applied by addition to the perfusion medium. To
compare the EPSPms evoked in the presence and absence of a drug
at the same membrane potential, DC was injected through the
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electrode to compensate for any drug-induced changes in membrane
potential. 2-p-(2-Carboxyethyl)phenethylamino-5'-lV-ethylcarbox-
amidoadenosine (CGS 21680), 8-cyclopentyl-l,3-dipropylxanthine
(DPCPX), 5-iodotubercidin (5-IT), (+)-a-methyl-4-carboxyphenyl-
glycine ((-l-)-MCPG) and nitrendipine were obtained from Research
Biochemicals International. Adenosine, atropine, carbachol,
2-chloroadenosine (CADO), 2-chloro-A6-cyclopentyladenosine
(CCPA), R(—)lV6-(2-phenylisopropyl)-adenosme (R-PIA), physostig-
mine and picrotoxin were purchased from Sigma.
Data are presented as means + standard error of the mean (s.e.m.)
and statistical significance was assessed using Student's paired or
unpaired t tests performed on raw data with P < 0-05 being taken
as indicating statistical significance, n values refer to the number of
times a particular experiment was performed, each in a different
slice taken from a different rat.
RESULTS
Data were obtained from 168 stable intracellular recordings
(2-6 h) from CA1 pyramidal neurones with overshooting
action potentials, resting membrane potentials that were
more negative than —55 mV and input resistance values of
30 Mil or greater.
Characterization of a slow EPSP
Single shock stimulation in the stratum oriens evoked an
EPSP which was followed by a biphasic inhibitory
postsynaptic potential (IPSP). All components of this
response were abolished by the combined application of
NBQX (1-3 /cm) or CNQX (20 /cm), AP5 (50 /cm) or CGP
40116 (50 /cm), picrotoxin (50 /cm) and CGP 55845A (1 /cm)
(Fig. IB). A 2- to 10-fold increase in the stimulus intensity
evoked a much slower EPSP in 126 out of 129 neurones in
which this was attempted (Fig. 1C). This EPSP could be
evoked reproducibly every 5-10 min. In a random group of
cells the slow EPSP had a mean amplitude of 9*6 + 2-1 mV,
a time to peak of 2-6 + 0*4 s and an overall duration of
32-6 + 6*9 s (n = 6). The peak amplitude and duration of
the EPSP were highly dependent upon the stimulus
strength used, both increasing with increasing stimulus
intensity (Fig. 1C). The EPSP often resulted in intense
discharges of action potentials and in some neurones the
EPSP depolarized the membrane beyond the action potential
firing threshold and into a region where action potential
generation was inactivated. The slow EPSP was accompanied
by an increase in cell input resistance as measured by
comparing responses to hyperpolarizing current steps
applied to the cell before and during the EPSP (Fig. ID).
As illustrated in Fig. 2A, the slow EPSP was not affected
significantly by the metabotropic glutamate receptor
antagonist (-t-)-MCPG (1000 /im; n= 3). Addition of the
acetylcholinesterase inhibitor physustiginine (1—5 /cm),
however, caused a large enhancement of both the peak
amplitude and duration of the slow EPSP (re = 5; Fig. 2B).
Physostigmine also caused a reduction in spike frequency
adaptation as measured by the number of action potentials
fired in response to a 300 ms long +0-2 or +0*3 nA current
step (re = 6; not illustrated). This effect presumably occurred
as a result of raising extracellular levels of spontaneously
released ACh due to inhibition of acetylcholinesterase
activity by physostigmine (Cole & Nicoll, 1984; Azouz,
Jensen & Yaari, 1994). In contrast, atropine (2-5 /cm)
reduced or abolished the slow EPSP (re = 7; Fig. 2C). These
results are entirely consistent with the slow EPSP being
mediated by activation of mAChRs and, as such, this EPSP
will be referred to as a mAChR-mediated EPSP (EPSPm).
Effects of adenosine receptor activation on the EPSPm
We next addressed whether activation of adenosine receptors
might affect the EPSPm. The non-hydrolysable adenosine
receptor agonist CADO (0-2—1 /cm) caused a depression of the
EPSPm that was maintained for the period of the agonist
application and was fully reversed on washout (re =4;
Fig. 3d). This effect was concentration dependent and, at a
concentration of 0-2 /cm, CADO sometimes caused a
substantial depression of the EPSPm without any effect on
the postsynaptic membrane potential, input resistance
(Fig. 3B) or spike frequency adaptation in response to a
depolarizing current step. In contrast, at concentrations of
0-5 /cm and above the depressant action of CADO on the
EPSPm was invariably accompanied by postsynaptic hyper-
polarization (up to 8 mV) and a reduction in input resistance
(up to 11 %). In one neurone the EPSPm was unaffected by
CADO. The maximal effect of CADO on the EPSPm was
97% inhibition. Similar results were obtained using
adenosine itself. Thus, at a concentration of 100 /cm,
adenosine inhibited the EPSPm by 78 + 10% (re = 3).
Pharmacology of the adenosine receptor mediating
the depression of the EPSPm
To elucidate which adenosine receptor subtype mediated the
CADO-induced depression of the EPSPm, we investigated
the effects of a number of adenosine receptor subtype-
specific agonists. The adenosine receptor agonists CCPA
(0*1—0*4 /cm.', re = 7; Fig.4A) and R-PIA (1 /im; re =2)
depressed the EPSPm and caused postsynaptic hyper-
polarizations associated with reductions in input resistance.
Thus, at a concentration of 0*4 /cm, CCPA depressed the
peak amplitude of the EPSPm to 34 + 6% of that in control
medium and produced an accompanying hyperpolarization
of 4—5 mV and a reduction in input resistance of 5-10%
(re = 4). In contrast, the adenosine A2A receptor agonist CGS
21680, at concentrations up to 1 /im, neither affected the
EPSPm nor the passive membrane properties of the neurones
in which it was tested (re = 3; Fig. 4B).
The effects of the selective adenosine At receptor antagonist
DPCPX (0*2 /cm) weie alsu tested. DPCPX fully reversed,
or prevented, the inhibition of the EPSPm (Fig. 5A) as well
as the postsynaptic hyperpolarizations and decreases in
input resistance (see Fig. 8d) evoked by CADO (1-2 /cm;
n — 8) and adenosine (100 /cm; n = 3; not illustrated).











Figure 1. Characteristics of the pharmacologically isolated slow EPSP evoked in response to a single
high intensity stimulus in the stratum oriens
A, schematic diagram of a rat hippocampal slice illustrating the positioning of recording (1) and stimulating (2)
electrodes required to evoke the synaptic responses in B-D. B, intracellular recordings from a CA1 neurone in
response to single shock stimulation in the stratum oriens. Note that in control medium an EPSP is followed by
an IPSP and that the combination of CNQX (20 /tin), CGP 40116 (50 /iu), picrotoxin (50 fiM) and CGP 55845A
(1 jum) abolished this response (superimposed horizontal line). Traces are averages of four successive records taken
at the same membrane potential. In C, the traces are single sweeps which illustrate the stimulus-dependent
activation of a slow EPSP in the presence of the four amino acid receptor antagonists listed above. The stimulus
intensities used to evoke the responses from left to right were 1-8, 2-3 and 4 mA, respectively. (The intensity that
was required to evoke an AMPA/kainate receptor-mediated EPSP that was just suprathreshold for evoking an
action potential was O04 mA.) The action potentials evoked by the slow EPSP are truncated due to the low
sampling rate used to capture the entire response. The membrane potential of this neurone was —64 mV. D, the
increase in input resistance associated with the slow EPSP. The input resistance was measured from the change
in membrane potential in response to hyperpolarizing current steps of —0-3 nA applied for 0'2 s every 2'0 s. In
Da, the cell membrane potential was manually clamped at a depolarized level before the stimulus so that the
voltage response to the hyperpolarizing current steps could be compared with that evoked near the peak of the
slow EPSP. Db, comparison of the responses in a on an expanded time scale. The current injected into the cell is
shown below the voltage traces. The initial membrane potential of this cell was —64 mV. In this and all
subsequent figures, the arrowheads below each synaptic trace indicate the time of afferent stimulation.
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Figure 2. Effects of (+)-MCPG, physostigmine and atropine on the slow EPSP
In A-C., each trace is a single sweep illustrating the effects of 1000 /im (+J-MCPG, 2 /m physostigmine and
2 fiM atropine, respectively, on slow EPSPs evoked in three separate neurones. The membrane potentials of
these cells were —63, —64 and —63 mV, respectively. D, bar graph in which the pooled data for the peak
amplitude of EPSPms recorded after 15-30 min in the presence of either (+)-MCPG (1000 /im; n = 3),
physostigmine (2 /im; n = 3) or atropine (2 /im; n = 3) is expressed as a percentage of the mean value of
the control EPSPms recorded over a 20-30 min baseline period prior to each drug application. Values are
means + s.e.m.; 100% is equivalent to no change. Mote that whilst (+J-MCPG did not have a significant,
effect on the slow EPSP, physostigmine significantly enhanced the slow EPSP and atropine significantly
inhibited the slow EPSP. *P < 0-05; n.s., not significant (compared with control). In this and all
subsequent figures, unless stated otherwise, traces are individual synaptic responses recorded intra-
cellularly in response to a single stimulus delivered in the stratum oriens in the presence of 2-4 /im NBQX,
50 fiM CGP 40116, 50 /im picrotoxin and 1 /im CGP 55845A. Each sweep was taken at the same membrane
potential, which was achieved using DC injection to compensate for any drug-induced changes.
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DPCPX alone caused a small but variable increase in the
size of the EPSPm in three out of four neurones studied: the
peak amplitude of the EPSPm in the presence of DPCPX
was 122 + 19% that of control (n = 4). In addition, in the
presence of DPCPX, a stimulus that was previously sufficient
to reduce spike frequency adaptation but was either sub¬
threshold or just suprathreshold for evoking an EPSPm
subsequently evoked a greatly enhanced EPSPm that had a
peak amplitude of 8-10 mV (n = 2; Fig. 5B).
Effects of CADO on the reduction in spike frequency
adaptation evoked by endogenous ACh
Stimulation that was subthreshold for activating the EPSPra
caused a reduction in spike frequency adaptation in response
to a depolarizing current step delivered 2 s after pathway
stimulation (n = 12; Figs 5B and 6.4). This reduction in
spike frequency adaptation was inhibited by CADO (Fig. 6B)
in a concentration-dependent manner (1—5 /im; n = 3) and
was reinstated by subsequent application of DPCPX (0-2 fiM\




























Figure 3. The effect of CADO on the EPSPm
In A, synaptic traces are EPSPms, evoked in response to a single stimulus, recorded in control medium (a),
in the presence of 1 fiM CADO (b) and following washout (c). The graph shows a plot of the peak amplitudes
of successive EPSPms normalized to the mean peak amplitude of the five EPSPms prior to CADO
application versus time for a single experiment. CADO was applied for the time indicated by the bar. a, b
and c refer to the synaptic traces illustrated above the graph. B, superimposed traces of EPSPms (left) and
responses to a —0'2 nA current step (right) in the presence and absence of 0'2 fiM CADO. Note that 0'2 /mm
CADO caused a substantial reduction in the EPSPm without affecting the input resistance of the cell. The
membrane potential of both cells was —64 mV.
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n = 3; Fig. 6C). In two neurones, in the combined presence
of CADO and DPCPX, a small EPSPm was evoked by the
previously subthreshold stimulus. This EPSPm, along with
the reduction in spike frequency adaptation, was abolished
by subsequent application of atropine (1 fim; Fig. 6D).
Effects of an adenosine kinase inhibitor on the
EPSPm
The increase in the EPSPm that was caused by DPCPX alone
suggested that endogenous adenosine within the slice was
capable of tonically activating the adenosine Aj receptors
which inhibit the EPSPm. Therefore, we next examined
whether it was possible to potentiate this tonic effect by
impairing the breakdown of adenosine. To do this we
investigated the effects of the selective adenosine kinase
inhibitor 5-IT which raises extracellular adenosine levels by
preventing the breakdown of adenosine into adenosine mono¬
phosphate (AMP) (Pak, Haas, Decking & Schrader, 1994).
5-IT (10 /im) caused a postsynaptic hyperpolarization of
2—8 mV, a decrease in input resistance of 5—15% and a
74+ 10% depression of the EPSPm (n — 4; Fig. IB). In









Figure 4. Effects of subtype-selective adenosine receptor agonists on the EPSPm
In A and B, traces illustrate the respective effects of +4 fiM CCPA and 1 fim CGS 21680 on EPSPms evoked
in separate neurones. The membrane potentials of these cells were —63 and —64 mV, respectively. C, bar
graph in which pooled data for the effects of CCPA (0-4 n = 4) and CGS 21680 (0*5 fim-, n = 3) on the
EPSPm are plotted as described in Fig. '2D. Note that whilst CGS 21680 did not have a significant effect,
CCPA significantly inhibited the EPSPm. Means + s.e.m.; * P < 0-05; n.s., not significant (compared with
control).
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three of these neurones, subsequent application of DPCPX
(0-2 /I'M.) completely reversed these effects (Fig. 7/1).
Is the adenosine-mediated depression of mAChR-
mediated postsynaptic responses pre- or
postsynaptic?
Having established a depressant action of adenosine on post¬
synaptic mAChR-mediated responses evoked by afferent
stimulation, we addressed next whether these effects were
mediated pre- or postsynaptically. Initially, we compared
the concentration—response relationships for the depression
of the EPSPm with those of known post- and presynaptic
adenosine At receptor-mediated effects, i.e. membrane hyper-
polarization (Fig. 8d; Greene & Haas, 1985; Gerber, Greene,
Haas & Stevens, 1989) and depression of glutamate AMPA/
kainate receptor-mediated EPSPs (Fig. 8B\ Lupica, Proctor
& Dunwiddie, 1992), respectively. As illustrated in Fig.8C,
CADO was more potent at inhibiting the EPSPm than it was
at inhibiting pure AMPA/kainate receptor-mediated EPSPs
or causing postsynaptic hyperpolarization. The respective
IC50 values and EC50 value for these effects were 03, 08
and 3-0 /im (Fig. 8G). In addition, the logistic fit for the
depressant action of CADO on the EPSPm more closely
paralleled that for its presynaptic depressant action on
glutamate-mediated EPSPs.
If CADO was acting presynaptically to depress both the
EPSPm and the reduction in spike frequency adaptation
evoked by subthreshold stimulation then it should not affect
the respective postsynaptic responses evoked by carbachol.
To maximize the probability of observing an effect of CADO
on carbachol-induced postsynaptic responses, we used
concentrations of carbachol that (i) were close to the EC50
values reported for causing postsynaptic depolarization and
B




















Figure 5. Effects of DPCPX on the EPSPm and the CADO-induced depression of the EPSPm
In A, synaptic traces are EPSPms recorded in control medium (a), in the presence of 2 fiu CADO (b) and in
the combined presence of 2 /im CADO and 0-2 /im DPCPX (c). The membrane potential of the cell was
—64 mV. The bar graph illustrates pooled data for the effects of 1 /im CADO (n = 8) and 1 /im
CADO + 0'2 /iM DPCPX (n = 4) on the EPSPm. Each value was calculated as described for Fig. 2D. Note
that CADO significantly depressed the EPSPm and that responses fully recovered in the additional presence
of both CADO and DPCPX. Means + s.e.m.; *P< 0-05; n.s., not significant. In B, traces are continuous
records of the membrane potential of a single cell in which depolarizing current steps (+02 nA, 600 ms)
were delivered 1 s prior to, and 2 and 3'5 s after pathway stimulation at an intensity just suprathreshold for
activating the EPSPm in medium containing the four glutamate and GABA receptor antagonists (top trace)
and following the addition of 0'2 /im DPCPX (middle trace). The bottom trace represents the current
injected into the cell. The membrane potential of the cell was —65 mV. Note that in control medium spike
frequency adaptation was reduced following pathway stimulation. After addition of DPCPX this intensity
of stimulation now additionally activated a substantial EPSPm.
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Figure 6. CADO depressed the reduction in spike frequency adaptation evoked by pathway
stimulation that was subthreshold for activating the EPSPm
Traces were generated as described in Fig. 5B except that only the response to the first depolarizing current
step after afferent stimulation is illustrated. The responses were obtained in medium containing the four
glutamate and GABA receptor antagonists (d), in the additional presence of 5 fiu CADO (B), in the
combined presence of 5 fiM CADO and 02 fiwi DPCPX (C) and following subsequent addition of 1 /tm
atropine (D). The point of pathway stimulation is indicated by the arrowheads and the trace at the bottom
of the figure illustrates the points at which current was injected into the cell. Note that in control medium
spike frequency adaptation was reduced following pathway stimulation, that this reduction was abolished
by CADO in a DPCPX-sensitive manner and that it was also completely inhibited by subsequent addition
of atropine. If two current steps were delivered without intervening subthreshold afferent stimulation, the
level of spike frequency adaptation evoked by the second step was not significantly different from that
evoked by the first step (n = 4; P > 0-05; not illustrated). Note that in the presence of CADO + DPCPX
previously subthreshold pathway stimulation now evoked a small EPSPm that was abolished by the
subsequent addition of atropine. The initial membrane potential of the neurone was —66 mV.
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reduction in spike frequency adaptation (Madison et al.
1987), and (ii) produced responses similar to those evoked
by afferent stimulation (see Fig. 10). In addition, we used
concentrations of CADO that were near-maximal for
inhibiting the EPSPm and the reduction in spike frequency
adaptation evoked by subthreshold stimulation (see Figs 6
and 8C).
In a first series of experiments, we tested the effect of
CADO on the postsynaptic depolarization and increase in
input resistance evoked by brief bath applications of
carbachol (3 /im for 30-60 s). In four neurones, repeated
application of carbachol caused consistent and reversible
depolarizations that were associated with increases in input
resistance (Figs 9A and 10A). In these same neurones,
addition of CADO (1 /im) caused a hyperpolarization
(1 -5 mV) that was associated with a small decrease in input
resistance (4—7 %). However, CADO did not have a
significant effect on the carbachol-induced depolarizations
and increases in input resistance (n = 4; P > 0-05; Fig. 9A).
In five other neurones, these postsynaptic effects of carbachol
were abolished by atropine (1-5 /im; not illustrated). These
results contrast with those for the EPSPm, which was
depressed significantly by both CADO (1 /am, P< 0-05;
Fig. 10A) and atropine (1-5 /im, P < 0-05; Fig. 2C).
In a second series of experiments, we investigated the effects
of CADO and carbachol on spike frequency adaptation



































5-IT 5-IT + DPCPX
Figure 7. The effects of an inhibitor of adenosine kinase on the EPSPm
A, the bottom graph is similar to that illustrated in Fig. 3 and shows the peak amplitude of successive
EPSPms, for a single experiment, versus time to illustrate the depressant effect of 10 /im 5-IT on the EPSPm
and its reversal by 0'2 /im DPCPX. The duration of application of each drug is indicated by the bars above
the graph. The synaptic traces (top) are representative EPSPms recorded in control (a), in the presence of
5-IT (6) and in the presence of 5-IT + DPCPX (c) taken at the time points indicated. The membrane
potential of this neurone was —66 mV. B, bar graph illustrating pooled data for the effects of 5-IT (10 /im;
n = 4), and 5-IT + 0*2 /im DPCPX (n = 3) on the EPSPm. The values plotted were calculated as described
in Fig. 2D. Note that 5-IT significantly depressed the EPSPm and that responses in the presence of both
5-IT and DPCPX were not significantly different from controls. Means ± S.E.M.; *P<0-05; n.s., not
significant.





















Figure 8. Comparison of the concentration-response relationships for CADO-induced depression of the
EPSPm with those for postsynaptic hyperpolarization and depression of glutamate-mediated EPSPs
A, continuous chart record illustrating the effects of 2 pM CADO and 0'2 pM DPCPX on passive membrane properties
of a CA1 neurone. The trace shows the membrane potential (thick line) and hyperpolarizing voltage responses
(downward deflections) of the cell to constant current steps (—0*3 nA, 300 ms). The arrow indicates the point at which
DC was injected for 90 s to reset the membrane potential of the cell to the level prior to CADO application. Note: (i)
that CADO caused a hyperpolarization and a reduction in input resistance that was completely reversed by DPCPX,
and (ii) that in the presence of DPCPX the membrane potential became more depolarized than that before any drug
treatment, presumably indicating the presence of an endogenous adenosine tonus in the slice. The membrane potential
of this neurone was —62 mV. In B, the responses are pure AMPA/kainate receptor-mediated EPSPs (EPSPAs) recorded
in the combined presence of 50 pu CGP 40116, 50 pu picrotoxin and 1 pu CGP 55845A. The traces, from left to
right, are representative EPSPAs recorded in control medium, in the presence of 5 pu CADO, in the combined
presence of 5 pu CADO and 02 pu DPCPX and following subsequent addition of 2 pu NBQX. Note that DPCPX
reversed the CADO-induced depression of the EPSPA and that in the presence of DPCPX the EPSPA gave rise to
multiple action potentials. This increase in magnitude above control levels again presumably reflects the presence of an
endogenous adenosine tonus in the slice. Each trace is an average of four successive responses evoked 15 s apart and
the membrane potential of this neurone was —70 mV. C, plots of the percentage inhibition of EPSPms (•: data from 19
neurones) and of EPSPAs (■; data from 4 cells) induced by CADO versus concentration of CADO. Superimposed on
these plots is a plot of the magnitude of CADO-induced postsynaptic hyperpolarization, from a starting membrane
potential of between —62 and —64 mV, versus concentration of CADO (♦; data from 18 neurones). Each point for each
of the three plots is the mean value obtained from three to nine separate neurones and the error bars represent s.e.m.
All data (F) were fitted to the logistic expression: Y = M(Xl'/(XP + Kp)), where X is the concentration of CADO, M is
the maximum effect, A' is the IC50 or EC50 value and the power Pdetermines the slope of the sigmoidal curve.
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evoked in response to a depolarizing current step. Carbachol
(0'5 /im) caused a small depolarization and a reduction in
spike frequency adaptation that was reversible on washout
{n = 5). Subsequent addition of CADO (5 pu) slightly, but
not significantly, enhanced the level of spike frequency
adaptation per se but did not significantly affect the
reduction in spike frequency adaptation induced by a second
application of carbachol («= 3; Fig. 95). In contrast,
atropine abolished the carbachol-induced reduction in spike
frequency adaptation (n = 5; not illustrated). These results
differ from those in which spike frequency adaptation was
reduced using subthreshold stimulation in that the latter
was abolished by both CADO (5 /cm; Fig. 105) and atropine
(1 /im).
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Figure 9. The effects of CADO on postsynaptic responses evoked by carbachol
A shows the effect of CADO (1 /im) on the change in membrane potential and input resistance evoked by
carbachol (CCh; 3 pm). The trace is a chart record of membrane potential and cell input resistance, as
described in Fig. 8, and illustrates the effects of carbachol on these parameters prior to and following CADO
application. The arrows just after the end of each carbachol application indicate the points at which DC was
injected for 60 s to reset the membrane potential of the cell to the level prior to the application of the
agonist. The bar below the chart record indicates the period during which DC injection was used in the
presence of CADO to restore the membrane potential of the cell to that prior to CADO application. This was
kept constant for the period indicated by the length of the bar except for when the increase in input
resistance evoked by carbachol was measured. The upward deflections just prior to and just after the point
at which DC was applied in the presence of CADO represent voltage responses to depolarizing current steps
(+0-3 nA, 300 ms). The bars above the chart record represent the periods during which carbachol and
CADO were applied. The initial membrane potential of this neurone was —64 mV. B, responses (from left to
right) evoked by a depolarizing current step (+02 nA, 400 ms) in control medium, in the presence of
carbachol (0-5 pM), following washout, in the presence of CADO (5 pm) and in the combined presence of
CADO (5 pyi) and carbachol (0'5 /cm). The membrane potential of the cell was maintained at —66 mV
throughout the experiment by injecting DC through the recording electrode to compensate for the hyper-
polarizing and depolarizing effects of CADO and carbachol, respectively. The trace at the bottom of the
figure represents the time during which depolarizing current steps were injected via the recording
electrode. Note that carbachol reduced spike frequency adaptation evoked during the depolarizing step and
that this was unaffected by CADO.
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DISCUSSION
The mAChR-mediated EPSP
mAChR-mediated EPSPs have been recorded previously
from CA1 pyramidal neurones most commonly in response
to high frequency bursts of stimuli, e.g. 20—100 Hz for
0-5-1-0 s (Cole & Nicoll, 1984; Madison et al. 1987; Segal,
1988; Pitler & Alger, 1990; Azouz et al. 1994). These EPSPs
were often evoked in the presence of acetylcholinesterase
inhibitors which prolong the effective synaptic concentration
of ACh. In addition, ionotropic glutamate and GABA
receptor antagonists were not added to the perfusion
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Figure 10. Comparison of the effects of CADO on postsynaptic mAChR-mediated responses
evoked by endogenous ACh with those evoked by carbachol
A, pooled data (left) for the peak amplitude of the two carbachol (3 /tM)-induced depolarizations prior to the
application of CADO (Control) and one depolarization in the presence of 1 CADO plotted as a percentage
of the mean value for the responses prior to CADO application (n = 4; data as generated in Fig. 9d); and
pooled data (right) for the peak amplitude of the EPSPm evoked in the presence of 1 /iu CADO plotted as a
percentage of control (n = 8; data generated as in Fig. 3). Note that the same concentration of CADO
depressed the EPSPm to a much greater extent than it did the carbachol-induced depolarization. The small
reduction in the size of the carbachol-induced depolarization in the presence of CADO is not statistically
significant and can be explained largely on the basis of the decrease in input resistance induced by CADO in
this group of cells. In contrast, CADO significantly depressed the EPSPm. B, pooled data (left) for the
number of action potentials fired during a depolarizing step in the absence (Ctl) and presence (CCh) of
0'5 fiM carbachol plotted for control medium and for medium containing 5 /im CADO (n— 3; data
generated as in Fig. 9B)\ and pooled data (right) for the number of action potentials fired during a
depolarizing step 1 s before (Pre) and 2 s after (Post) a subthreshold stimulus in the absence and presence of
5 /tM CADO (n = 3; data generated as in Fig. 6). Statistical significance was tested for CCh versus Ctl and
Post versus Pre data for each of the paired data sets. Note that CADO completely inhibited the increase in
number of action potentials fired following subthreshold afferent stimulation in stratum oriens without
affecting the increase evoked by carbachol application. Means + s.e.m.; * P < 0-05; n.s., not significant.
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superimposed on glutamate- and GABA-mediated synaptic
potentials. Here we have shown that a slow EPSP can be
evoked by a single stimulus in the presence of ionotropic
glutamate and GABA receptor antagonists without the need
for acetylcholinesterase inhibitors. This EPSP is mediated
by activation of mAChRs since it was blocked by atropine
and unaffected by (+)-MCPG. Its waveform varied
considerably between neurones and could not be readily
correlated with differences in any of the other electro¬
physiological characteristics of the neurones in which it was
recorded. One notable difference, however, between the
EPSPm recorded in this study and those recorded
previously was its large magnitude, even when evoked using
just a single stimulus. The reason for this is unclear but it is
possible that the amino acid receptor antagonists may
relieve an inhibitory influence on the activation of this
synaptic potential. Alternatively, in some cells, a number of
voltage-activated conductances may boost the apparent
magnitude of the EPSPm (Fraser & MacVicar, 1996).
However, preliminary observations that the Ca2+ channel
antagonist nitrendipine (10 fim) has little or no effect on the
EPSPm suggest that a Ca -dependent plateau potential
does not necessarily contribute to the EPSPm. Whatever the
case, the response kinetics of the EPSPm were, in general,
similar to those reported for EPSPms evoked by high
frequency bursts of stimuli (Cole & Nicoll, 1984; Gahwiler &
Brown, 1985; Pitler & Alger, 1990) as well as pure
spontaneous and evoked metabotropic glutamate receptor-
mediated EPSPs (Charpak & Gahwiler, 1991; Bianchi &
Wong, 1995). As with these EPSPs, the EPSPm described
here was accompanied by a reduction in spike frequency
adaptation. This effect was mimicked by physostigmine,
presumably because this drug increased extracellular levels
of spontaneously released ACh by inhibiting acetyl¬
cholinesterase activity (Cole & Nicoll, 1984; Azouz et at.
1994). A feature of the EPSPm, however, that hampered its
investigation was that it could be evoked reproducibly only
every 5-10 min. As such, relatively long intracellular
impalements were required to obtain meaningful data. This
contrasts with metabotropic glutamate receptor-mediated
EPSPs which can be evoked reproducibly every 30—60 s
(Gerber, Liithi & Gahwiler, 1993). The reason(s) for the
protracted fatigue of the EPSPm is unclear but by comparison
with previous studies it appears to be independent of the
stimulation protocol used to evoke it, i.e. a high frequency
train versus a single stimulus (Cole & Nicoll, 1984; Pitler &
Alger, 1990).
Adenosine receptor-mediated depression of
postsynaptic responses to synaptically released ACh
To date, few studies have addressed the mechanisms by
which mAChR-mediated synaptic transmission is regulated.
In one study, the neuropeptide galanin was reported to
depress the EPSPm in the ventral hippocampus by 60% via
a presynaptic mechanism (Dutar, Lamour & Nicoll, 1989).
Here we have provided compelling evidence that adenosine
also inhibits the EPSPm and that, in addition, it prevents
the reduction in spike frequency adaptation mediated by
synaptic activation of mAChRs. No distinction was made
between dorsal and ventral hippocampus in the present
study and, as such, these depressant actions of adenosine
are likely to operate throughout the entire CA1 region of the
hippocampus. Pharmacological analysis of these effects
revealed that they were mediated by adenosine Aj receptors
and that activation of these receptors was capable of
abolishing both the EPSPm and synaptically induced
mAChR-mediated reduction in spike frequency adaptation.
This is analogous to the situation at glutamate synapses
where adenosine receptors also completely inhibit both
AMPA and NMDA receptor-mediated synaptic transmission
(Thompson et at. 1992; De Mendonga & Ribeiro, 1993). The
IC50 value for the CADO-induced depression of the EPSPm
is slightly less than that observed for inhibition of AMPA
receptor-mediated EPSPs but is similar to that for NMDA
receptor-mediated EPSPs (De Mendonga & Ribeiro, 1993;
Dunwiddie & Diao, 1994). This possibly reflects the greater
need for control of cholinergic and NMDA receptor-
mediated synaptic inputs because of their much greater
influence on postsynaptic excitability. Indeed, a small
degree of adenosinergic inhibition is active tonically as
suggested by the enhancement of the EPSPm by DPCPX.
This tonus is greatly enhanced when the metabolism of
adenosine is impaired by 5-IT, as is also reported for
glutamate synapses (Pak et al, 1994). However, the source of
the endogenous adenosine tonus is unclear. One possibility is
that it is due, at least in part, to non-specific accumulation
of adenosine due to cell damage resulting from slice
preparation (Thompson et at. 1992). Another possibility is
that adenosine is released following afferent stimulation
(Mitchell, Lupica & Dunwiddie, 1993), e.g. from GABAergic
interneurones (Manzoni, Manabe & Nicoll, 1994). Whatever
the case, there is considerable evidence that the level of
extracellular adenosine in slices is comparable to that in the
CNS in vivo (Zetterstrom, Vernet, Ungerstedt, Tossman,
Jonzon & Fredholm, 1982; Fredholm, Dunwiddie, Bergman
& Lindstrom, 1984; Dunwiddie & Diao, 1994). As such, it is
likely that in the intact animal cholinergic synaptic inputs
are tonically inhibited by circulating levels of adenosine.
Locus of the adenosine Ax receptor-mediated
depression of the EPSPm
Since adenosine A: receptors are found in abundance both
pre- and postsynaptically in the CA1 region of the
hippocampus, it is possible that adenosine inhibits mAChR-
mediated postsynaptic responses by activation of one or
both populations of these receptors (Greene & Haas, 1985;
Gerber et al. 1989). That the concentration-response
relationship for the CADO-induced depression of the EPSPra
most closely paralleled that for the depression of the AMPA/
kainate receptor-mediated EPSP, but not that for the
postsynaptic hyperpolarization, indirectly favours a
presynaptic locus of the adenosine Aj receptor-mediated
depression. In this respect, at least three additional lines of
evidence suggest the involvement of a presynaptic depressant
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mechanism: (i) CADO can depress the EPSPm even at
concentrations that do not affect postsynaptic passive
membrane properties, (ii) CADO does not significantly inhibit
carbachol-induced postsynaptic responses, and (iii) both the
EPSPm and mAChR-mediated postsynaptic reduction of
spike frequency adaptation evoked by subthreshold
stimulation, which result from the inhibition of distinct K+
conductances (Madison et al. 1987), are inhibited by CADO.
In addition, neurochemical data from both hippocampal
synaptosomes and slices strongly indicate the existence of a
presynaptic adenosine A, receptor-mediated inhibition of
[3H]ACh release (Cunha, Milusheva, Vizi, Ribeiro &
Sebastiao, 1994). When taken together these data provide
convincing evidence that a significant proportion of the
adenosine At receptor-mediated inhibition of the EPSPm and
associated reduction in spike frequency adaptation occurs by
presynaptic inhibition of ACh release. Such a mechanism has
previously been proposed for cholinergic synapses at the
neuromuscular junction where activation of adenosine Aj
receptors inhibits the average number of quanta of ACh
released from the nerve terminal without affecting the size
of each individual quantum (Ginsborg & Hirst, 1972;
Silinsky, 1984).
It is conceivable, however, that adenosine may also act post-
synaptically to depress mAChR-mediated postsynaptic
responses. In this respect, a direct interaction between the
transduction mechanisms activated by adenosine At receptors
and mAChRs seems unlikely as adenosine At receptors
classically couple to the G-protein Gj which inhibits adenylate
cyclase activity and neither the EPSPm nor the mAChR-
mediated reduction in spike frequency adaptation are
affected by cAMP mimetics (Madison et al. 1987; R. A.
Morton, unpublished observations) or antagonists of protein
kinase A (Pedarzani & Storm, 1993). However, negative
interactions between adenosine Ax receptors and the
Mj mAChR-mediated inhibition of the M-current have been
reported in the superior cervical ganglion (Connolly & Stone,
1995). Despite this, the M-current is unlikely to account for
the actions of synaptically activated muscarinic receptors in
the hippocampus (Madison et al. 1987) even though
pyramidal neurones are thought to express both the Mt and
M3 mAChR subtypes (Dutar & Nicoll, 1988; Pitler & Alger,
1990; Segal & Fisher, 1992). These receptors classically
couple through the pertussis-toxin insensitive Gq/U family
of G-proteins to phospholipase C (PLC), the activity of
which can, in some cells, e.g. aorta, be inhibited by
adenosine At receptors. However, it is unclear whether
activation of PLC fully accounts for mAChR-mediated
depolarization and reductions in spike frequency adaptation
in the hippocampus (Muller & Misgeld, 1986; Dutar & Nicoll,
1988; Colino & Halliwoll, 1993). Whatever the case, the
inability of CADO to abolish carbachol-induced responses
would suggest that this mechanism or a membrane-delimited
interaction between the adenosine A, receptor-mediated
signal transduction mechanism(s) and the mAChR-coupled
K conductances is unlikely to account for the depressant
effects of adenosine At receptors on the EPSPm and
reduction in spike frequency adaptation in response to
subthreshold stimulation (see Fig. 10B). However, adenosine,
by activating postsynaptic K+ conductances, will restrict the
magnitude of the EPSPm recorded at the soma, to some
extent, by the shunting of membrane currents as well as
hyperpolarization towards the reversal potential of the
EPSPm (Cole & Nicoll, 1984).
Implications for adenosine receptor-mediated
inhibition of the EPSPm
The established role of adenosine in regulating glutamate
but not GABA-mediated synaptic transmission has
implicated this neuromodulator as a neuroprotective agent
(Thompson et al. 1993). The present study identifies another
dimension of adenosine-mediated regulation of synaptic
excitability in the hippocampal CAl region, viz. inhibition
of mAChR-mediated synaptic responses. This regulation is
likely to be of relatively minor importance under normal
physiological conditions as the septohippocampal cholinergic
synaptic input is important in learning and memory
formation in vivo (Decker & McGaugh, 1991; Hasselmo &
Bower, 1993). However, during seizures or hypoxic and
ischaemic episodes, when extracellular adenosine levels are
raised, adenosine Aj receptors may restrict cholinergic
synaptic transmission to levels that are below that which is
damaging to neurones.
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